Clinical and experimental studies of hereditary and acquired forms of amyloidosis by Tan, S.Y.
Clinical and experimental studies of hereditary and acquired forms of
amyloidosis
DECLARATION
This thesis has been composed entirely by myself unless otherwise stated. The work
contained in the thesis has not been submitted in candidature for any other degree,
diploma, or professional qualification.
20 October 1996 S Y Tan
Consultant Nephrologist
The Renal Unit
King's College Hospital (Dulwich)
East Dulwich Grove
London SE22 8PT
Clinical and experimental studies of hereditary
and acquired forms of amyloidosis
S Y TAN
Doctor of Medicine
The University of Edinburgh
Immunological Medicine Unit







Although the proteinaceous nature of amyloid deposits was first recognised
more than 100 years ago, characterisation of amyloid fibril precursor proteins was made
possible only recently following the development of a method of amyloid fibril protein
extraction. Since then, 15 different amyloid proteins have been identified. In this thesis
the development of a novel "mini-fibril" extraction technique, allowing for the first time
the isolation of amyloid fibril proteins from tiny milligram quantities of biopsy tissue, is
described. This led directly to the identification of a novel amyloid fibril precursor
protein in a case of primary localised orbital amyloidosis and enabled the identification
and full characterisation of a novel apolipoprotein AI variant in an Australian family
with hereditary renal amyloidosis (HRA). In a large Spanish family with HRA, a novel
apolipoprotein AI deletion variant was identified as the precursor protein. In both these
families, simple dsDNA sequencing confirmed complete concordance between mutation
and the exclusive presence of variant protein sequence in the fibril proteins. Two other
families with previously described apolipoprotein AI and fibrinogen a-chain variants,
together with an Italian family and a Colombian family with novel transthyretin variants
associated with familial amyloid polyneuropathy were also studied. Clinical,
biochemical, histological and scintigraphic studies using radio-labelled serum amyloid P
(SAP) component, an in vivo technique for the diagnosis of systemic amyloidosis
provided unique information on the pattern of distribution of amyloid and the natural
history of the disease in addition to demonstrating the virtually complete penetrance of
these autosomal dominantly inherited mutations.
Dialysis-related amyloid (DRA) is an invariable complication of long term
haemodialysis (HD). The long term outcome of successful renal transplantation and the
prevalence of this disease in patients dialysed predominantly by continuous ambulatory
peritoneal dialysis (CAPD) compared to long term HD populations were studied for the
first time using radiolabeled SAP scintigraphy and radiology. These studies provide
unique evidence for regression of DRA deposits following successful renal
transplantation in contrast to relentless progression of DRA in patients maintained on
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HD. Intriguingly, prevalence of the disease appears to be comparable in long term
CAPD populations, but clinical expression of the disease may be different, suggesting
that the modality of HD itself may be important in modulating symptoms associated
with the deposits. In both HD and CAPD patients, CTS was the commonest presenting
feature of DRA, the wrists were invariably affected scintigraphically, age and duration
of dialysis were confirmed as the most important risk factors and the prevalence of
DRA was found to be frequently underestimated clinically and radiologically.
Histological and scintigraphic studies demonstrated that in both hereditary and acquired
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Chapter 1 - Introduction
Amyloidosis
Definition
Amyloidosis is a disorder of protein metabolism characterised by the
extracellular deposition of abnormal protein fibrils [1-3], It may either be localised, or
systemically distributed throughout the body (Table 1.1 & Table 1.2), causing organ
damage and serious morbidity. Major organ involvement, especially of the kidneys and
heart is usually fatal.
Protein fibrils form the bulk of amyloid deposits and are derived from a
remarkably heterogeneous variety of precursor proteins. The remaining specific
amyloid constituents are largely sulphated GAGs and SAP.
Amyloid is defined by its pathognomonic tinctorial properties with the dye
Congo red [4], and by its characteristic ultrastructural morphology. The term
"amyloid" (Greek for starch-like) was introduced by Virchow in 1854 on observing that
the waxy infiltrated organs of patients who had died with chronic inflammatory diseases
such as tuberculosis and osteomyelitis, reacted with iodine in the same manner as starch
and cellulose [5], That these deposits were of a protein nature was demonstrated in
1859 by Fredereich and Kekule and despite this the term "amyloid" was retained [6],
In the past 25 years, much has been learned of the biochemistry and
pathogenesis of amyloid, though it has as yet had only a limited impact on therapy. The
fibrillar nature of amyloid was first observed in 1959 by Cohen and Calkins, and by
Spiro [7], A major breakthrough came in 1968 when Pras et al described the first
satisfactory method for isolating amyloid fibrils from tissue in a sufficiently pure form
for chemical analysis [8], This permitted the precise identification of amyloid fibril
proteins which was first achieved for immunoglobulin light chains (AL) by Glenner et al
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and subsequently for amyloid A protein (AA), prealbumin and for many other proteins
[9]-
Classification and Nomenclature
The development of a method of fibril extraction [8] and its recent modification,
[10] means that amyloid fibril proteins can now be extracted from tiny milligram
quantities of biopsy tissue for full biochemical characterisation. This have led to a new
method of classification of amyloid [11] according to the nature of the fibril proteins of
which 15 have so far been identified (Table 1.1 & Table 1.2), replacing earlier
classifications based on clinico-pathological features. In many cases related or identical
proteins, which are clearly the precursors of the fibril proteins, are produced locally or
are present in the circulation. In other cases the precursor-product relationship is not




Diseases complicated by AA amyloidosis are characterised by their ability to
provoke a sustained acute phase response and can be divided into 3 main types of
chronic disease: chronic inflammatory disorders, chronic local or systemic microbial
infections, and malignant neoplasms (Table 1.3). Amongst the connective tissue
diseases, systemic lupus erythematosus (SLE) is unique in that it is only very
exceptionally complicated by AA amyloidosis and a similar contrast exists between
Crohn's disease in which amyloid occurs in 1 to 8% of cases and ulcerative colitis in
which it is extremely rare.
Table1.1Acquiredmyloidosissyndrom CLINICALSYNDROME SystemicALamyloidosis,a sociatedwithimmun ydyscrasia, myeloma,onoclonalgammop thy,occultdyscrasia LocalnodularALamyloidosis(sk n,resp ratoryt curogenit l tract,et )associatedwi hfoc limmunocytedyscr si ReactivesystemicAAamylo dosis,a sociatedwi hchr nicactive diseases Senilesystemicamyloidos s Focalsenileamyloidosis:trifthhe rt brain joints seminalv sicles prostate Non-familialAlzheimer'sdis se,D wn'syndrome Sporadiccerebralamyloidngiopathy SporadicCreutzfeldt-Jakobdisease,k u(transmissiblep ngiform encephalopathies,priondiseases)
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FIBRILPROTEIN
ALfibrilsderivedrommonoclonalimmunogl bulinlightchains ALfibrilsderivedrommonoclonalimmunoglobulinlightchains AAfibrilsderivedromserumamyloiprot in(SAA) Transthyretin( TR)derivedfromplasmaTTR Atrialnatr ureticpeptide P-protein Notknown Seminalvesicleexocrinepr tein P2-microglobulin P-proteinderiv dfromP-amyloiteinprecursor(APP) P-proteinderiv dfromP-amyloirecursorp otein(APP) Prionprotein( rP)de ivedfromp iot iprecursor
TypeIIdiabetesm llitu Endocrineamyloidosis,associatedwithAPUD mas Dialysis-relatedamyloidosis;loc listoosteoa ticulart s u s systemic Primarylocalisedcutaneousmyloi(macul r,p pula ) Ocularamyloid(cornea,onjunctiva) Orbitalamyloid
26
Isletamyloidpolypeptide( APP),ylinderiv dfroit precursorp otein Peptidehormonesorfrag e tthereof(e.g.pr calcitoninin medullarycarcinomaofthyr id) (32-microglobulinderivedfromhighplasmaleve s ?Keratin-derived Notknown AHfibrilsderivedromimmunoglobulinh avychainnas (seeChapt r7)
Table1.2Hereditarymyloidosissyndromes CLINICALSYNDROME Predominantperipheraln rveinvolvem t,familialamyloid polyneuropathy(FAP).Autosomaldominant Predominantperipheraln rveinvolvem nt,familialamyloid polyneuropathy(FAP).Autosomaldominant Predominantcrani lnerveinvolve entwithlatticco neal dystrophy.Autosomaldominant Hereditaryrenal(non-n uropathic)amyl idwithpromi envisce al involvement(Ostertag-type).Aut so aldominant Hereditaryrenal(non-n uropathic)amyl idwithpromi envisc al involvement(Ostertag-type).Aut so aldominant Hereditaryrenal(non-n uropathic)amyl idwithp omi envisc al involvement(Ostertag-type).Au so aldominant Predominantcardi cinvolveme t,noclinicalneuropathy. Autosomaldominant
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FIBRILPROTE N
Transthyretin(TTR)geneticvariantsmoscommo lyMet30,but over40thersdescribed) ApolipoproteinJ(a oAI)N-terminalfr gme tfen ticvaria t Arg26 Gelsolin,fragmentofgen ticvaria tAsnl87rTyrl ApoAI,N-terminalfragmentofen ticvariantsAr 26,r 50, Arg60,ordeletion/insertionvariant. LysozymegeneticvariantThr56rHi 67 Fibrinogena-chain,fragmentofen ticv ria s,Leu554r Val526 TTRgeneticvarian sh 45,Ala60Ser84,Metl11,Ilel22
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AA amyloid deposition has a predilection for parenchymal organs and may be
widely distributed without causing symptoms [12], The spleen is always affected but
the common involvement of the kidneys is most closely associated with an adverse
prognosis and it usually presents with non-selective proteinuria due to deposition in the
renal glomeruli. This may lead to nephrotic syndrome before terminating in end stage
renal failure. The second most common presentation is with organomegaly.
Involvement of the heart and gastrointestinal tract is frequent though it rarely causes
functional impairment [1, 13],
AL (Monoclonal Immunoglobulin) Amyloidosis
AL amyloid may be associated with almost any dyscrasia of the B lymphocyte
lineage ranging from frank malignancy of plasma cells (multiple myeloma) to "benign"
monoclonal gammopathy in which the only demonstrable abnormality may be the
overproduction ofmonoclonal light chains. In some cases AL amyloid may be the only
evidence of an underlying plasma cell dyscrasia. AL amyloid occurs in up to 15% of
cases ofmyeloma and in a lower proportion of other plasma cell disorders [14, 15],
AL amyloid affects principally the mesenchymal tissues causing peripheral and
autonomic neuropathy, carpal tunnel syndrome, macroglossia, restrictive
cardiomyopathy and arthropathy of the large joints although visceral organs or indeed
any tissue may be involved. It has a poor prognosis especially when the heart is
involved (6-18 months) when the usual presentation is of a restrictive cardiomyopathy
[16].
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There are many forms of hereditary systemic amyloidosis and most of them are
rare. However autosomal dominant inheritance and the adult onset of symptoms have
ensured persistence of the trait which causes this devastating disorder. All the various
syndromes are characterised by point mutations leading to the production of variant
amyloidogenic proteins. Variant transthyretin which causes familial amyloid
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polyneuropathy (FAP) was the first of these proteins to be identified [17] and more than
40 mutations in the transthyretin gene have since been described [14, 15], Mutations in
the apolipoprotein AI [18, 19] and gelsolin [20] gene may also be involved and more
recently mutations in the lysozyme [21 ] and a fibrinogen [22] gene leading to
expression of amyloidogenic variants in patients with Ostertag-type, non-neuropathic
amyloidosis have been discovered.
Familial Mediterranean Fever (FMF) is an autosomal recessive inflammatory
disease that may be complicated by AA amyloidosis especially in some ethnic groups.
Senile Systemic Amyloidosis
Some amyloid is present in all autopsies on aged individuals. It may be systemic
(usually due to normal wild type transthyretin) with deposits predominantly found in the
heart and none in the brain, or it may be focal, involving the brain (p protein), corpora
amylacea of the prostate (P2-M), joints and seminal vesicles (precursor protein(s)
unknown) [1],
Dialysis related amyloid
This form of amyloid in which fibrils consist of P2-M [23] affects a large
proportion of patients receiving long term haemodialysis and has also been reported in
patients on CAPD [24] and even in a patient with chronic renal failure but not requiring
dialysis [25], Initially thought to be confined to joints, bones and periarticular tissues
deposits of P2-M have now been reported in many other tissues and several cases of
fatal extensive disease have been reported. It causes carpal tunnel syndrome,
arthralgias of the large joints and bone cysts often leading to pathological fractures.
Renal transplantation is the only effective treatment with rapid normalisation of blood
P2-M levels and resolution of symptoms [13, 26],
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Localised amyloidosis
Deposits of amyloid localised to particular organs or tissues occur in a wide
variety of different forms and are presumably consequent on either the local production
of fibril precursors (nodular AL amyloid, cutaneous amyloid, endocrine amyloid) or the
properties of a particular microenvironment that predisposes to localisation and fibril
formation of systemically distributed circulating precursor proteins (e.g.
bony/periarticular P2-M in DRA. Many local forms of amyloid are common
accompaniments of ageing and rarely of clinical significance. Protein precursors of
tumour related amyloid remain unidentified [27] but are probably derived from tumour
related or locally produced proteins such as keratin.
Cerebral amyloid
The brain and intracerebral blood vessels are rarely affected in the systemic
amyloidoses but are common and important sites for the local deposition of amyloid in
the absence of amyloid elsewhere in the body. The most frequent and important type of
amyloid in the brain is that related to Alzheimer's disease, which is the commonest
cause of dementia. The vast majority of cases of Alzheimer's disease are sporadic but
there are also families with an autosomal dominant pattern of inheritance [28, 29], The
triad of cerebral amyloid angiopathy, neurofibrillary tangles and neuritic plaques seen in
Alzheimer's disease (AD) is also seen in dementia that universally occurs in Down's
syndrome patients over the age of 40 years [30], These intracerebral and
cerebrovascular amyloid deposits are hallmarks of the neuropathological diagnosis and
are derived from the amyloidogenic P-protein fragment of the amyloid precursor
protein (APP).
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Fibril proteins and their precursors
AA
Amyloid A (AA) which has a molecular weight around 8000 daltons is derived
from the circulating precursor serum amyloid A (SAA) by proteolytic cleavage. SAA,
an apolipoprotein of HDL particles, is an acute phase reactant. Synthesis of SAA by
hepatocytes is regulated by cytokines especially IL-1, EL-6 and TNF and its
concentration may increase by up to several thousand fold during the acute phase
response but its function is not known. SAA is polymorphic but there is no evidence
that any particular form is either more or exclusively amyloidogenic.
AL
AL proteins consist of either the whole molecule or fragments of monoclonal
immunoglobulin light chains, and in any individual case there may be a mixture of these.
The fragments are derived from the N-terminal region and consist of whole or part of
the variable (VL) domain. The L chain of the circulating or urinary monoclonal
paraprotein is either identical to, or clearly the precursor of, AL isolated from the
amyloid deposits. AL is more commonly derived from X chains than from k chains
despite the fact that k chains predominate among normal immunoglobulins and the
paraprotein products of immunocyte dyscrasias.
Transthyretin
Transthyretin (TTR), formerly known as prealbumin, is produced by the liver
and choroid plexus and is involved in the transport of thyroid hormones and vitamin A.
Genetic variants of the TTR molecule, all involving a single amino acid substitution, are
the most common cause of hereditary amyloidosis (Table 1.4). TTR which has a
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notably high content of beta sheet structure, is an inherently amyloidogenic molecule,
and little change is required in its structure for this property to be greatly enhanced.














































The wild type sequence of transthyretin is shown above. Amino acid substitutions
shown in bold italics below are associated with transthyretin amyloidosis; others shown
in normal type are not.
P-protein
The protein in the intracerebral and cerebrovascular amyloid of Alzheimer's
disease, Down's syndrome and hereditary amyloid angiopathy of Dutch-type is P
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protein, a 39-43 residue sequence derived by proteolysis from APP, a high molecular
weight protein encoded on the long arm of chromosome 21. There is controversy over
whether or how the P-protein fragment per se, or the amyloid fibrils which it forms,
contribute to the neuronal dysfunction damage which underlie the dementia. However,
the fact that APP mutations may cause Alzheimer's disease [28, 29] and produce the
same neuropathology as sporadic cases, including tangles, argues strongly that the APP
and P-protein pathway can be of primary pathogenetic significance. Further support for
this concept comes from the fact that all individuals with Down's syndrome (trisomy 21)
over the age of 40 years develop typical Alzheimer's disease [30], Since APP is coded
by a gene on chromosome 21 it seems that excessive gene dose with wild-type APP can
have the same effect as the APP variants in familial Alzheimer's disease.
p2-microglobulin (P2-M)
P2-M is the amyloid fibril protein of dialysis-related amyloidosis [23], It is a
non-polymorphic single chain polypeptide with a molecular weight of 11,800 daltons,
and is the light chain of Class I MHC antigens present on all nucleated cells. It is
continually shed from cell membranes and is normally filtered by the kidney and
catabolised in the proximal tubule. The failure of haemodialysis membranes to clear
P2-M efficiently leads to persistently raised plasma levels and this presumably
predisposes to its deposition as amyloid fibrils. The strong affinity of P2-M for
collagen in vitro may explain the striking predisposition for P2-M amyloid to deposit in
the collagen rich tissues of the joints [31],
Cystatin C
Cystatin C is an inhibitor of cysteine proteinases and a 110 variant residue of
this protein, with an amino acid substitution (glutamine for leucine) at position 58, is
the subunit of amyloid fibrils in Icelandic patients with hereditary cerebral haemorrhage
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with amyloidosis [32], These cerebrovascular amyloid deposits lead to haemorrhagic
and thrombotic strokes, usually causing death before the age of 40 years.
Polypeptide hormones
Amyloid often occurs in endocrine organs in connection with ageing and in
some polypeptide hormone secreting tumours. The localised amyloid deposits
occurring in certain polypeptide hormone secreting tissues consist mainly of hormone or
pro-hormone. Examples are calcitonin related amyloid in medullary carcinoma of the
thyroid, islet amyloid polypeptide derived amyloid which occurs in 95% of patients with
Type II diabetes [33] and atrial natriuretic peptide in isolated atrial amyloidosis.
Nature of amyloid deposits
Fibrillar components
Amyloid is defined histologically by its binding of the dye Congo Red and the
subsequent green birefringence when viewed under polarised light [4], This unique
property resides in the fibrils themselves and is retained in isolated fibril preparations.
Most though not all, proteins which are precursors of amyloid fibrils are rich in [3-sheet
secondary structure. This, together with the apparent resistance of amyloid fibrils to
proteolysis, led to the concept that amyloid fibrils consist exclusively of a stack of anti-
parallel [3-pleated sheets arranged with their long axis perpendicular to the long axis of
the fibril, resembling the structure proposed for silk, which is also highly proteinase
resistant. However, fibrillar morphology per se does not require (3-pleated sheet
structure, and X-ray fibril diffraction studies suggest that a shared repeating structure in
different amyloid fibrils may derive from similar intermolecular packing motifs rather
than a shared secondary structure.
Another constant feature of all amyloid deposits is the universal presence of
sulphated glycosaminoglycans (GAGs) which are probably laid down simultaneously
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with the fibrils. These fibril associated GAGs are heparan sulphate and dermatan
sulphate in all forms of amyloid which have been investigated [34], Fibrils isolated by
water extraction contain 1-2% by weight of GAG carbohydrate, none of which is
covalently associated with the protein. The significance of GAGs remains unclear but
there is strong presumptive evidence that they may be the ligands to which SAP,
another universal constituent of amyloid deposits, binds.
Non-fibrillar components
Human SAP, a decameric plasma glycoprotein, binds in a calcium dependent
manner to all forms of amyloid fibril and is universally present in amyloid deposits [35],
including the cerebral amyloid of Alzheimer's disease. SAP which is produced only by
the liver is also a normal constituent of glomerular basement membrane and elastic fibre
microfibrils.
SAP is remarkably resistant to proteolytic degradation in the presence of
calcium. This resistance to proteinase digestion is likely to be an important aspect of
the normal function of SAP, and may also contribute to the persistence of amyloid
deposits by protecting them against digestion. Protection could result simply from
coating of the abnormal amyloid fibrils by SAP, which is completely unaltered with
respect to its normal circulating form, and which would therefore not be expected to
trigger macrophage activation and phagocytosis. However, the proteinase resistance of
SAP itselfmay be a significant factor.
The three dimensional structure of SAP has recently been solved to atomic
resolution [36], Availability of the complete structure to 2A resolution of SAP and
determination of its ligand binding sites now offer the opportunity of direct modelling of
competitive inhibitors of SAP binding and for producing binding site homologues,
either of which could be used as drugs to displace SAP from amyloid deposits in vivo.
This would open up new avenues for treatment of amyloidosis, enabling the body to





A necessary condition for the formation and deposition of amyloid fibrils is the
presence of an autologous protein precursor, which is either circulating or produced
locally, and which is abnormal either in structure, concentration or both. Until recently,
it was generally accepted that the pathogenesis of amyloid fibril deposits involved the
partial proteolytic cleavage of qualitatively or quantitatively abnormal precursor
proteins into fragments with a propensity for aggregating into anti-parallel beta pleated
sheets [2, 3], There is however now evidence that intact undegraded variant
transthyretin [37] and (32-M [38] molecules can aggregate to form fibrils in FAP and
DRA respectively.
Although the pathogenesis of amyloid fibril formation is not known, the primary
structure of precursor proteins is crucial in determining their amyloidogenicity. The
evidence is provided by the genetic variants of transthyretin [39-41], apolipoprotein AI
[42-44] and lysozyme [21] in which a single amino acid substitution converts the non-
amyloidogenic wild type proteins into highly amyloidogenic variants.
The presence of precursor proteins is obviously necessary for fibril formation
but the factors that determine the deposition of precursor proteins as amyloid fibrils in
some individuals but not others, and the variation in the time and anatomical
distribution of deposits are not known. Mice given repeated inflammatory stimuli over
a period of 3 weeks or more eventually develop AA amyloidosis but the latent period
can be reduced to 1-2 days in mice which have previously received a single intravenous
injection of an extract of amyloidotic tissue. The nature and mode of action of this so
called "amyloid enhancing factor" [45] is not known, but may be responsible for the
marked individual variation in susceptibility to fibril formation and elucidation of the
processes involved will clearly be of considerable clinical relevance.
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Fibril Degradation
The natural history of amyloid deposits is to persist and accumulate. This
apparent resistance to proteolytic degradation has been ascribed to the silk-like
antiparallel p-pleated sheet structure of the native protein and it is also possible that the
universal presence of SAP, in an apparently native unaltered state, may be involved in
some way.
However, amyloid deposits can and do regress once supply of the precursor
proteins is reduced. Evidence for this was previously provided only histologically by
isolated case reports [46], However, there is now collective data from serial studies
with 123I-SAP scans demonstrating regression of amyloid deposits following treatment
to reduce precursor protein levels in patients with AA, AL p2-M amyloidosis and in
FAP due to TTR mutations [12, 47-50],
Diagnosis
Clinical features of amyloidosis are extremely varied and non-specific and it's
diagnosis which often requires a high index of suspicion, is confirmed by demonstration
of tissue amyloid deposits which when stained with the dye Congo red [4] and viewed
under cross polarised light produces characteristic apple-green birefringence. This
universal congophilic property of amyloid remains the gold standard by which other
diagnostic techniques are judged in amyloidosis. Typing of amyloid fibril protein can
usually be determined, most simply, by immunohistochemical staining and this have
rendered obsolete previous attempts at classification of amyloid on the basis of
differences in Congo red staining following pre-treatment of tissue sections with
potassium permanganate, alkaline guanidine or autoclaving [14]. Finally, amyloid fibrils
may be demonstrated directly by electron microscopy of tissue sections but a negative
result does not exclude the diagnosis.
Histological confirmation of the diagnosis requires a biopsy which can be
potentially hazardous in a patient with systemic amyloidosis because there is an
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increased risk of bleeding since amyloid deposits are usually present in the walls of
small blood vessels throughout the body. In addition, deficiency of clotting factors IX
and X which occurs occasionally in AL amyloid must be sought. Biopsy of a major
affected organ such as the kidney or heart is most likely to give a positive result but is
invasive. It may therefore be preferable to biopsy a more accessible site especially in
patients in whom the index of suspicion is low. Commonly used procedures include
fine needle aspiration of fat [51] and biopsy of the rectum or labial salivary glands [52]
which in experienced hands should provide positive results in at least 80% of patients
with systemic amyloidosis [53], However, a negative result does not exclude the
diagnosis and the positive yield in any of the above procedures may be substantially
reduced in non-specialist centres.
Histological
Congo red staining
The unique optical property of Congo red stained amyloid has been shown to be
dependent on the [3-pleated sheet configuration in the native protein [54], allowing
planar dye molecules to fit edgewise into the face of the pleated sheets with their long
axes in the axis of the filament. Under cross polarised light, the birefringent Congo red
crystals show colours that vary from red in thick crystals through orange and yellow to
green in thinner crystals. Since the original method of Congo red staining was first
described [55], it has undergone several modifications to improve its sensitivity,
specificity, and reliability [4],
Other methods of detection of amyloid include fluorescent stains, e.g., thioflavin
T or S, and metachromatic stains such as crystal violet. The fluorescent dyes, because
of their high sensitivity, may be helpful in screening tissues for amyloid deposits but
positive results should be confirmed by more specific methods.
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Sensitivity and specificity
The optical properties of Congo red stained amyloid may be affected with loss
of green birefringence in very thin or very thick sections. A thickness of 5-10 pm is
optimal. Congo red staining of amyloid is more intense in tissues fixed in alcohol or
Carnoy's than those fixed in formalin but this may lead to a higher incidence of false
positive results. Staining of non-amyloid components may be removed by alcohol and
this effect is enhanced by the addition ofNaOH. False positive staining may occur with
collagen and this may be avoided by saturation of staining solution with NaCl. Congo
red solutions are unstable and should be freshly prepared every 2 months. Good
microscopic technique, knowledge of the variables involved in Congo red staining and
inclusion of positive and negative controls in every staining run is therefore critical to
the sensitivity and specificity of the technique.
Classification of amyloid proteins on the basis of Congo red staining
Congo red staining after autoclaving or treating the tissue with potassium
permanganate or alkaline guanidine has been used to subclassify amyloidosis [56],
Autoclaving the tissues at 120°C for 30 minutes causes protein AA to lose its affinity
for Congo red. Prolongation of autoclaving to 120 minutes abolishes the congophilia of
protein AL, but prealbumin-related amyloid show little or no change Treatment of the
tissue with potassium permanganate causes protein AA and 02-M to lose their affinity
for Congo red. Protein AA fails to stain with Congo red after treatment with alkaline
guanidine for 1 min and protein AL and senile systemic amyloid after 2 hours.
However, the general availability of immunohistologic methods which can be used to
identify and classify amyloid proteins in tissues with great precision renders obsolete
attempts at differentiating amyloid proteins by differential staining through the
demonstration of temperature and permanganate sensitivity.
42
Immunohistologic methodsfor detection and classification ofamyloid
The development of antibodies against amyloid proteins has helped in the
identification and classification of amyloid fibrils in tissue sections. Both
immunofluorescence (Figure 1.1) and immunoperoxidase techniques are used. The
immunofluorescence method requires the use of frozen sections. The
immunoperoxidase technique is more sensitive and has the advantage of being able to
detect amyloid in formalin fixed paraffin embedded tissues. However, formalin fixation
may mask the epitopes of amyloid proteins especially in AL and TTR-related amyloid.
Pre-treatment of sections with trypsin may be necessary to break down the cross-linking
bridges and "unmask" the epitopes although the process itselfmay damage and alter the
antigenic determinants of the proteins [57], Antigenicity is much better preserved with
frozen sections although tissue architecture is more likely to be disrupted than with
fixed sections. In AL amyloid, only about half of the cases are stainable with standard
antisera to k or X light chains probably because the light chain fragment is usually
derived from the variable domain and may contain unique epitopes that are not
recognised by the antibodies. Although fibril proteins can be identified
immunohistochemically and enable the amyloid to be classified, the demonstration of
amyloidogenic proteins in tissues does not on its own establish the presence of amyloid
and Congo red staining with green birefringence is always required.
Whilst immunohistochemical staining allows the majority of cases of
amyloidosis to be typed, the development of fibril extraction methods means that fibrils
can now be extracted from amyloidotic organs or biopsy tissue and fully characterised
by protein sequencing and electrospray mass spectrometry.
Under the EM, fibrils are rigid, non-branching and 10-15 nm in diameter. Each
fibril is in turn composed of aggregates of 2 to 5 filaments, arranged in a twisted ribbon
pattern. However amyloid fibrils cannot always be convincingly identified
ultrastructurally, and EM alone is not sufficient to confirm the diagnosis of amyloidosis.
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Figure 1.1 Renal glomerular amyloid deposits in a case of AA amyloidosis
complicating renal adenocarcinoma, a. Immunofluorescence staining with rhodamine-
labelled rabbit anti-human AA antibodies, b. Same field stained with fluorescein-
labelled sheep anti-human SAP antibodies. (x400)
Non-Histological
,2SI-SAPScintigraphy
A recent and major development is the use of radiolabeled SAP as a targeting
molecule for the in vivo diagnosis of amyloid [58-60], This is based on the principle
that SAP is a universal constituent of all amyloid deposits [35] and once injected into
the circulation, radiolabeled SAP will localise and bind to amyloid deposits in a specific
manner and in proportion to the quantity of amyloid present. SAP is labelled with I23I,
a medium energy short half-life pure y emitter for whole body scintigraphic imaging and
with 12SI for metabolic turnover studies. 123I-SAP scintigraphy is sensitive and specific
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for the in vivo diagnosis of amyloid with positive images obtained in over 90% of
patients with systemic amyloidosis [61]. In addition, scintigraphy provides information
on the tissue distribution of amyloid especially in sites not normally available for biopsy
(Figure 1.2) and this is particularly important in determining prognosis and assessing
patients for organ transplantation which is relatively contraindicated in patients with a
large total body amyloid load. It may be used for the monitoring of amyloidosis,
providing unique information on the natural history of amyloidosis and the effects of
treatment (Table 1.5). SAP scans have now been performed on over 800 patients
without adverse effects but is currently restricted in availability to no more than 20
centres worldwide because of the cost and preparations involved in producing clinical
grade pure SAP and the isotope, 123I. However, SAP scintigraphy may become more
widely available in the near future with the development of genetically engineered SAP
and the use of alternative isotopes such as "Tc which is cheaper and widely available.
The chemistry for labelling proteins with a metal nuclide is challenging but the
technique have recently been successfully developed and used in SAP scintigraphy [62],
Attempts have been made to develop other specific tracers for imaging amyloid
deposits, the most successful of which are studies involving 13'i labelled P2-M [63] as a
scanning agent in DRA in which the deposits are derived from P2-M. However, the
radioactivity involved is high and the technique is suitable only for anuric patients.
Table 1.5 Applications of SAP scintigraphy
Diagnosis and quantification of systemic and some local forms of amyloidosis
Identifying tissue distribution of amyloid deposits - may indicate type
Screening at-risk individuals for sub-clinical amyloid
Monitoring clinical and sub-clinical disease, i.e. natural history
Evaluating effects of therapy
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Figure 1.2 Whole body scintigraphs 24 h after intravenous injection of 123I-labelled
human SAP. a, anterior view of normal control subject showing distribution of residual
tracer in the blood pool and radioactive breakdown products in urine in the bladder;
note the absence of localisation or retention of tracer anywhere in the body, b, anterior
(left) and posterior (right) views of patient with juvenile chronic arthritis complicated by
AA amyloidosis. There is uptake of tracer in the spleen, kidneys and adrenal glands, a
typical distribution of AA amyloid in which the spleen is involved in 100% of cases,
kidneys in 75% and adrenals in 40%. c, posterior (left) and anterior (right) views of
patient with monoclonal gammopathy complicated by extensive AL amyloidosis. There
is uptake and retention of tracer in the liver, spleen, kidneys, bone marrow and soft
tissues around the shoulder. Note the complete absence of blood pool or bladder signal
compared to a. This pattern of amyloid distribution revealed by scintigraphy is
pathognomonic for AL amyloidosis, bone marrow uptake never having been seen in any
other type.
Echocardiography, radiology and gene studies
Echocardiography is the most sensitive non-invasive means of diagnosing
cardiac amyloid [64], Small, concentrically hypertrophied ventricles with generally
impaired contraction, dilated atria, homogeneously thickened valves, and 'sparkling'
echodensity of ventricular walls are characteristic echocardiographic findings of cardiac
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amyloid whilst ECG classically shows low voltage complexes.
Bony involvement by amyloid deposits occurs occasionally in AL amyloid but
characteristically and invariably in [32-M amyloid which typically produces multiple
periarticular cystic bone lesions on X-ray examination which grow in size and number
with increasing duration of dialysis. Commonly affected sites include the carpal bones,
femoral and humoral heads, acetabulum, tibial plateau and distal radius, and may result
in pathological fractures especially in weight bearing bones [65], Extraosseous
radiologic findings which include swelling of articular and periarticular soft tissue
mainly involving joint capsules, synovia and tendons, can be visualised and quantified by
ultrasonography [66],
In some patients, AL amyloid is the only feature of an underlying plasma cell
dyscrasia with no demonstrable morphological evidence of the clonal population on
bone marrow aspiration and trephine biopsy nor of its products such as a paraprotein
band or Bence Jones proteins. These tiny populations of plasma cells can now be
identified with immunoglobulin gene rearrangement studies by Southern blotting [67,
68] but only if they represent at least 1% of the total cells [67], Hence, whilst serum or
urine protein electrophoresis is used to detect products of the plasma cell clone,
immunoglobulin gene rearrangement studies are now available to detect the clone itself.
In hereditary systemic amyloidosis and familial AD, DNA sequencing has
identified the gene mutations responsible for the disease and is also used together with
other methods such as allele specific oligonucleotide hybridisation to screen relatives
who may be carriers of the mutation and therefore at risk of developing the disease.
Clinical Features
Amyloid deposits exert their pathological effects largely through their physical
presence, which distorts tissue architecture and hence disrupts normal function
Continued accumulation ultimately leads to organ failure, or the consequences of a
space occupying mass lesion. In addition there may be secondary effects due to the
presence of amyloid, such as renal interstitial fibrosis.
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The spectrum of clinical features resulting from systemic amyloidosis is
therefore enormous (Table 1.6). Clinical presentation, distribution and the amount of
amyloid varies greatly in different forms of amyloid and even among patients with the
same form. However, the features of any particular organ involvement generally follow
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Chapter 2 - Materials and Methods
General Reagents
Buffers
EDTA Equimolar mixture pH 7.5 of disodium salt, pH 4.0 of
tetrasodium salt, pH 11.0 of ethylene diamine tetra-acetate.
PBS Phosphate buffered saline, pH 7.3 (Oxoid Ltd, Basingstoke,
Hants)
PBS-serum-EDTA Sterile isotonic PBS, pH 7.4, containing NasEDTA 2 mg/ml
(Limclair, Sinclair Pharmaceuticals Limited, Godalming,
Surrey) and 5% v/v heat treated (560C, 30 min) accredited
serum (National Blood Transfusion Service, Edgware)
TBS Tris buffered saline, pH 7.6, 50 mM Tris, 0.85% w/v sodium
chloride, pH adjusted with HC1
TC 0.01 M Tris, 0.138 M NaCl, 0.002 M CaCl2, 0.1% w/v
NaN3, pH 8.0
TCB TC containing 1% w/v BSA (Sigma)




Pure human SAP for clinical scintigrahic studies was provided by Professor
M B Pepys, having been isolated to more than 99% purity by affinity
chromatography as described [69], HSA and BSA were obtained from Sigma.
Antisera
Rabbit antisera against human SAP and SAA were raised by immunisation
with pure isolated proteins emulsified in Freund's complete adjuvant (CFA; Difco
Labs, Surrey) followed by booster injections in incomplete Freund's adjuvant
(ICFA, Difco) and provided by Professor M B Pepys. The following polyclonal










Sample preparation for histological analysis
Frozen sections
Fresh material for histology were snap frozen with dicholorodifluoromethane
(Arcton 12 I.C.I., Cheshire, U.K.) and then mounted on cork disks in OCT.
(Tissue-Tek, Raymond Lamb, London, U.K.) embedding medium. Frozen blocks
were stored at -80°C. Frozen sections of 6 pm thickness were cut on a cryostat
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microtome (-20°C) and air dried for 60 min prior to staining or stored at -80°C until
required.
Paraffin sections
Tissue was fixed for 24 hours in 10% buffered formalin, embedded in
paraffin and 6 pm sections were kindly cut on to PLL coated slides by the
Department of Pathology, Hammersmith Hospital, for staining and
immunohistochemical studies.
Amyloid fibril preparations
A 20 pi drop of the solution was placed on a poly-L-lysine coated
microscope slide, air dried, then fixed with 95% ethanol v/v for 3 min.
Histologicalmethods
Congo red staining
For histological frozen sections Congo red staining was done by the method
of Puchtler et al [4], The slides were rehydrated with TBS for 5 min and
counterstained with Coles Haematoxylin for 10 min which was then "blued" with
tap water. Freshly filtered Congo red (Raymond Lamb) prepared in alcoholic
saturated salt was made alkaline with 1% w/v sodium hydroxide and the slides
immersed in this for 30 min. After 3 rinses with 100% ethanol they were placed in
Histoclear® (National Diagnostics, New Jersey, U.S.A.) for 5 min and then
mounted under Histomount® (Natural Diagnostics). Following drying for at least 1
hr the mounts were examined under a Leitz dialux 20 EB microscope (Wetzlar,
Germany). Paraffin sections were dewaxed with Histoclear® and ethanol and
rehydrated with water before Congo red staining was performed. Fibril preparations
were stained only with Congo red but were otherwise processed similarly, with
positive control material always processed in parallel.
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Typing of amyloid by immunohistochemistry
Peroxidase-anti-peroxidase method
Immunohistochemical staining by the PAP method was performed on
paraffin fixed sections which was first deparaffinised and rehydrated in the usual
manner [57], Sections were then incubated overnight at 4°C with the 1° anti-serum
at established dilution (usually 1:500 to 1:10 000) in 1% TBS containing normal
serum from host of 2° antibody. Slides were then washed on a rotating platform,
twice with TBS containing Triton X-100 (BDH Chemicals Limited, Poole, U.K.)
0.005% (v/v) (TBS-T) for 5 min followed by TBS alone for a further 5 min.
Sections were then incubated for 60 min at room temperature with 2° antibody at
established dilution (usually 1:50) in TBS with 5% normal serum from tissue host.
After washing as above to remove unbound antibody, sections were incubated for
30 min at room temperature with peroxidase anti-peroxidase antibody complexes at
established dilution (usually 1:100) in TBS with 1% normal serum from host of 2°
antibody. After another wash cycle, bound enzyme was detected using 3,3'-
diaminobenzidine tetrahydrochloride (DAB, Sigma 5637) (Sigma Chemical
Company Limited, St. Louis, Missouri, U.S.A.) 0.05% w/v in TBS containing 10
mM imidazole (BDH), pH 7.4 to 7.6 and 0.02% v/v H202 (Taab Laboratory
Equipment Limited, Reading, U.K.) as substrate. Sections were immersed for 5 to
10 min, rinsed with dH20, then counterstained lightly with Coles Haematoxylin for
30 seconds. After blueing in running tap water and rinsing with dH20, sections
were dehydrated and mounted in the usual manner.
Indirect immunofluorescence
Typing of amyloid protein by IIF was performed only on frozen sections
which were first rehydrated with TBS and the background blocked for 15 min at
room temperature with 10% normal serum from the species donating the 2°
antibody. Sections were then incubated for 30 to 60 min at room temperature with
1° antibody at established dilution in buffer containing 1% normal serum from host
of 2° antibody. After washing as above to remove unbound antibody and to reduce
non-specific binding due to ionic or electrostatic forces, sections were incubated for
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30 min at room temperature with 2° antibody (anti-Ig of the species providing the 1°
antibody - conjugated with FITC or RITC) at established dilution (usually 1:50) in
buffer containing 5% normal serum from the tissue host to negate any reaction
between 2° antibody and tissue Ig. The sections were then washed and mounted in
Citifluor (Citifluor Limited, London, U.K.) under coverslips sealed with varnish, and
examined immediately with a Leitz Orthoplan microscope with water immersion
lenses. Photography was performed with a Leitz Orthomat system on Kodak
ASA400 slide film.
Antisera and controls
Antibodies directed against a range of known amyloid proteins which were
all commercially available were used. The following controls were also included:
• Control tissue known to be positive.
• Replacing first antiserum with 1% of normal serum of the species of the second
antibody.
• Replacing first antiserum with normal rabbit serum diluted as much as the
antiserum.
• Replacing the first antibody with antibody absorbed with specific antigen.
Interpretation of results
Tissue structures stained with Congo red in an alcoholic alkaline salt
solution were regarded as showing positive staining if they showed apple green
birefringence when viewed under cross polarised light (Figure 4.1, Figure 4.3).
SAP is normally present in the GBM and as a mantle on the elastic fibres throughout
the body, SAP in other sites is abnormal. To be of diagnostic significance the
fluorescence of the other stains, e.g. anti-SAA should be titratable: positive in the
known control tissue, and negative in the replacement controls.
The type of amyloid fibril is readily determined by immunohistochemical
methods. The widely used potassium permanganate method [56, 70] in which some
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types of amyloid, notably AA, lose their capacity to bind Congo red when pre-
treated with this agent is not specific [14], Antisera to SAP/AP, AA, P2-M,
transthyretin, apoAI, lysozyme, fibrinogen, kappa and lambda light chains are all
commercially available and may be used to stain fixed or snap frozen tissue.
Variable and poor results are obtained in AL amyloid [71, 72] as the light chains are
derived predominantly from the variable (Vl) domain and hence differ from case to
case. Anti-transthyretin rarely stains the deposits of senile systemic amyloid though
good results may be achieved with hereditary transthyretin amyloid.
Isolation ofamyloid fibrils from gram quantities of tissue
Organs from patients with amyloidosis obtained at post-mortem or during an
operation were stored at -20°C and used for fibril extraction by the method of Pras
et al [8], Approximately 30 gms of tissue were homogenised in 300 ml of 0.14 M
NaCl and 0.01 M EDTA with 0.1% w/v NaN3 using an Ultraturrax homogeniser
(Sartorius Instruments Ltd, Surrey, UK) and then centrifuged at 15 000 g for 30
min. The process was repeated 8 to 15 times, discarding the supernatant each time,
until the A28o of the supernatant stabilised at < 0.05. The pellet was then
homogenised with pure distilled water, centrifuged at 20 000 g for 30 min and the
process repeated a further 3 to 4 times.
A28o, corrected by subtraction of A320 (for light scattering), was measured on
each salt and water supernatant. Material from the DW washes with the greatest
A28o, (usually the second wash with A2go of 1.5 to 3) was dried on a microscope
slide and stained with Congo red to confirm the presence of amyloid fibrils. Fibrils
extracted by this method were either lyophilised using an Edwards E F4 Modulyo
freeze dryer (Edwards High Vacuum, Crawley, Sussex, UK) or kept in DW at 4°C,
where they remained in solution for periods of at least 3 months.
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Isolation of amyloid fibrils from milligram quantities of tissue
The standard water extraction method [8] for isolation of amyloid fibrils
from tissue involves numerous preliminary homogenisations in saline, during which,
in our experience, significant losses of fibrils may occur. In order to maximise
recovery from tiny milligram quantities (1 to 2 mg) of tissue obtained at biopsy, the
tissue was initially homogenised in 0.5 ml of distilled water to extract the fibrils
immediately [10], After centrifugation at 15,000 g for 10 min and separation of the
supernatant, the process was repeated twice more and the supernatants were pooled
together. The amyloid fibrils were then selectively precipitated by adding sodium
chloride to a final concentration of 0.2 mol/l, leaving essentially all other
components of the water extract in solution in the saline. The suspension was
centrifiaged at 15,000 g for 10 min and the presence of amyloid fibrils was
confirmed by drying 10 pi of resuspended material on a poly-L-lysine coated slide,
fixing with 10% formalin/90% ethanol and staining with Congo red [4], The protein
composition of the fibril pellet was analysed by SDS 8-18% gradient PAGE.
Polyacrylamide gel electrophoresis
Gradient PAGE analysis of reduced SDS treated proteins was performed in
8-18% gradient gels (Pharmacia ExcelGel™) run in accordance with manufacturer's
instructions. Standard globular proteins used as high molecular weight markers
were myosin 205 kDa and P-galactosidase 116.5 kDa. Low molecular weight
marker polypeptides were phosphorylase B 106 kDa, bovine serum albumin 80 kDa,
ovalbumin 49.5 kDa, carbonic anhydrase 32.5 kDa, soybean trypsin inhibitor 27.5
kDa and lysozyme 18.5 kDa (Bio-Rad Laboratories, Richmond, U.S.A.). Gels were
stained with Coomassie Blue according to the manufacturer's instructions.
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Immunoblotting
Immunodetection of fibril subunit proteins was performed by Western
blotting. Isolated amyloid fibrils or fragments of delipidated amyloid laden
subcutaneous tissue were solubilised by boiling in 10 mM Tris, pH 8.0 containing
10% v/v glycerol, 5% v/v 2-mercaptoethanol, 2.5%w/vSDS and 1 mM EDTA.
Amyloid fibril subunit peptides were separated by SDS 8-18% gradient PAGE
(Excelgel™, Pharmacia) and transferred to pure 0.2 pm nitrocellulose membrane
(Scleicher and Schull A/G, Anderman and Co. Ltd., Kingston-upon-Thames,
Surrey, UK) by electroblotting at 0.8 mA/cm2 for 30 minutes using the Pharmacia
Novablot™ semidry blotting apparatus with continuous buffer system according to
the manufacturer's instructions. Immunostaining was performed with rabbit anti-
human immunoglobulin (Dako), horseradish peroxidase-labelled affinity purified
goat anti-rabbit IgG (Dako) and 3,3'-diaminobenzidine tetrahydrochloride (Sigma
Chemical Company, St Louis, MO, USA) according to the Bio-Rad immunoblot
protocol (Bio-Rad Labs Ltd., Hemel-Hempstead, Herts, UK).
Isolation of DNA andAmplification and Sequencing of TTR Gene
DNA was extracted from whole blood [73] and TTR exons were amplified
by the polymerase chain reaction (PCR) using taq polymerase (Amplitaq, Perkin
Elmer Cetus, Norwalk, CT) with the following cycling conditions: 1 cycle of 94°C,
5 minutes; 35 cycles of 94°C for 1 minute, 60°C for 1 minute, and 72°C for
1 minute; and a final step of 72°C for 10 minutes. For exon 1 intron sequences, (5'
to 3'), CAGCAGGTTTGCAGTCAGAT and GGTACCCTTGCCCTAGTAAT
were used, for exon 2, CAATTTTGTTAACTTCTCACG and
CAGATGATGTGAGCCTCTCTC; exon 3, CCTCCATGCGTAACTTAATCC and
TAGGACATTTCTGTGGTACAC; exon 4, TGGTGGAAATGGATCTGTCTG
and TGGAAGGGACAATAAGGGAAT.
PCR products (100 pL) were purified by size fractionation on a Nusieve
agarose gel (FMC, Rockland, ME). The band was extracted using Magiprep
58
columns (Promega, Madison, WI), recovered by ethanol precipitation and dissolved
in 12 pL of distilled water. Six pL was then used in the sequencing reaction for
each primer.
The sequencing reaction was modified from Casanova et al [74], A reaction
mix containing 2 pL of sequencing buffer, 2 pL of primer (100 ng/pL) and 6 pL of
template was boiled for 2 minutes, before freezing in a dry ice/methanol bath for
15 seconds, and then adding 5 pL ofMastermix. Just after the mixture thawed, 3 p
L was added to 2.5 pL of each of the four dideoxynucleotides and the termination
reaction was then incubated at 37°C for 2 minutes before addition of 4 pL of stop
solution. The same primers were used for PCR and sequencing, except that for
exon 4 the primer (5 -3'), CTCGTCCTTCAGGTCCACTG, was used since, for
unknown reasons, poor sequence was obtained with the exon 4 PCR downstream
primer.
Isolation and radiolabelling of SAP
SAP, isolated from the serum of a single accredited blood donor provided by
the National Blood Transfusion Service (Edgware, London) was purified to greater
than 99% purity under strictly sterile conditions and was stored sterile and frozen at
-70°C. For each study 1 mg of pure SAP was oxidatively labelled with 1000 Mbq of
Na123I (Amersham International), N-bromosuccinimide being used to achieve 85-
95% incorporation. Free 123I was removed by gel filtration on Sephadex G25
column (PD10, Pharmacia, Milton Keynes, U.K.) which was equilibrated with 5%
v/v heat treated (56°C, 30 min) accredited serum in phosphate buffered saline
(PBS), pH 7.4, containing Na3EDTA 2 mg/ml (PBS serum-EDTA). The column
was then promptly eluted with 5 ml PBS serum-EDTA which served to quench the
reaction and to separate iodinated protein from free radioiodine. After this gel
filtration step more than 95% of the radioactivity was precipitable by 10% w/v
tricholoroacetic acid. The labelled protein was then passed through a sterile 0.22
pm filter into a sterile vial to provide sufficient material for 5 patient studies.
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Imaging
Each subject received by intravenous injection approximately 200 pg of SAP
bearing approximately 190 Mbq of 123I, corresponding to an effective dose
equivalent of 3.8 mSv and comparable with that from an intravenous pyelogram or
barium meal study. Thyroid uptake was blocked by administration of potassium
iodide 60 mg twice daily for 2 days before the study and for the subsequent 5 days.
Anterior and posterior whole body and abdominal imaging was performed in each
individual 24 hours after injection of 123I-SAP by means of an IGE-Starcam y-
camera (IGE Medical Systems, Slough, U.K.). In dialysis patients, static images of
the wrists, shoulders and knees were also taken.
Metabolic studies
Venous blood samples were taken at intervals (10, 20, 30 min, 6 and 24 hrs)
after I23I-SAP injection. Radioactivity precipitable by trichloroacetic acid was
determined in each serum sample as a proportion of the injected dose.
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Chapter 3 - Hereditary Renal Amyloidosis
Hereditary renal amyloidosis due to a new apolipoprotein Al
TrpSOArg variant in an Australian family
Introduction
Hereditary non-neuropathic systemic amyloidosis, first described in a kindred
reported by Ostertag [75, 76] is a rare autosomal dominant condition in which
amyloid deposition in the viscera, especially the kidneys, leads inexorably to organ
failure. It can present at any age from the second to the sixth decade and there is
considerable variation both within and between families in the presentation, pattern
of organ involvement and rate of progression. Single residue substitution variants
of three different proteins, apolipoprotein AI (apoAI) [19, 77], lysozyme [21] and
fibrinogen a-chain [22, 78], encoded by point mutations in the respective genes,
have been identified as the causes of this syndrome in different families. However
there is little relationship between the amyloid fibril protein or its particular variant
and the clinical manifestations. Whilst inheritance of an amyloidogenic mutation is
necessary for development of the disease in each case, other factors evidently play
an important role in determining the distribution and clinical effects of the amyloid
deposits.
A previously undescribed kindred with hereditary non-neuropathic systemic
amyloidosis in which the amyloid fibrils from the proband consisted of ,/V-terminal
fragments of a variant of mature apoAI with arginine in place of tryptophan at
position 50 is described here. The two previously reported amyloidogenic variants
of apoAI also contained arginine substitutions for uncharged residues, Gly26Arg,
which also causes neuropathic amyloid in one family [18, 42], and Leu60Arg [19]
respectively. There is no such pattern of residue substitutions among the known
amyloidogenic variants of other proteins [1, 14], There may thus be a common
mechanism of apoAI amyloidogenesis resulting from acquisition of the extra




The proband was an only child born in 1947 to Ashkenazi Jewish parents. His
mother is alive and well in her seventies. His father died in 1968, aged 45, with
massive hepatic and renal amyloidosis confirmed histologically. The father's parents
and all his siblings were murdered in the Nazi holocaust and no further previous
family history of amyloid is available. The proband's children are well and have not
been investigated.
The proband presented in 1981, aged 34, with microscopic haematuria
detected on routine urinalysis. He also had slight hepatomegaly and raised serum
alkaline phosphatase, 272 U/l (upper limit of normal 260). There was trace
proteinuria and his renal function was moderately impaired, creatinine 129 mmol/1
(normal 30-120). At routine health screening in 1973 his urinalysis and serum
biochemistry had been normal. The microscopic haematuria persisted, renal
function and liver function tests slowly deteriorated, and he developed intermittent
explosive diarrhoea. Renal and small and large bowel biopsies in 1983 all contained
extensive amyloidosis. In 1989 in vivo scintigraphy with 123I-labelled serum amyloid
P component [59, 79] demonstrated massive hepatic and splenic amyloidosis (Figure
3.1). Although he continued to work full-time, renal and hepatic function
deteriorated slowly but progressively until 1991 when he commenced peritoneal
dialysis. Proteinuria had increased to 2.47 g/day at that time but he was never
hypoalbuminaemic or nephrotic. Hepatomegaly had increased, splenomegaly had
appeared and he suffered chronic diarrhoea and malabsorption. However, there was
no clinical evidence of peripheral or autonomic neuropathy and nerve conduction
was normal until late in the course, when the changes were compatible with
advanced renal failure. There was also no clinical cardiac involvement and
echocardiography was normal. Two months after successful renal transplantation in
March 1992, he died with an overwhelming cytomegalovirus infection and liver
failure.
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Figure 3.1 Anterior scintigram of abdomen in the proband 24 h after
intravenous injection of 123I-SAP. There is massive uptake in the liver and spleen
and no blood pool background, indicating a heavy whole body amyloid load.
Identification of the amyloidfibril protein
Immunohistochemical staining, SDS-PAGE analysis, isoelectric focusing and
immunoblotting were all performed exactly as described in our report of the apoAI
Leu60Arg variant [19], The only amyloidotic tissue available was a needle biopsy
of liver and amyloid fibrils were therefore isolated from 50 mg of tissue, using the
modified water extraction procedure recently reported [10],
Identification of the mutation in the apoAI gene
DNA was extracted from the proband's muscle tissue [80] and three
fragments comprising the coding region of the apoAI gene were amplified by PCR
and subjected to nucleotide sequencing [19], or cloned into pGEM.T (Promega,
Madison, WI, USA) and sequenced [81], The PCR product of exon 4 was also
digested with Mspl and the fragments analysed by polyacrylamide gel
electrophoresis [82],
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Characterisation of the amyloidfibril subunitprotein
Isolated amyloid fibrils were dissolved in 6 M guanidine
hydrochloride/0.5 Tris, pH 8.5 and fractionated by FPLC gel filtration on Superose
12HR (Pharmacia) in 4 M guanidine hydrochloride/0.05 Tris, pH 8.5. The single
major eluted peak was dialysed against water and lyophilised before analysis by
electrospray mass spectrometry [19]. For polypeptide analysis the whole amyloid
fibril isolate was run in SDS-PAGE, transferred to a Problott membrane (Applied
Biosystems) and the single main band at -10 kDa was sequenced using fast cycle
chemistry in a modified Applied Biosystems 477A system [83], The band was also
excised from the gel, digested with lysyl endopeptidase and the products analysed by
matrix assisted laser desorption ionisation time of flight (MALDI-TOF) mass
spectrometry [19], The digest was then fractionated on HPLC, the main peaks were
characterised by MALDI-TOF, and the variant peptide was subjected to automated
sequencing [83],
Results
Identification of the amyloidfibrilprotein as apoAI
The amyloid deposits in a liver biopsy taken during the proband's final illness
stained immunospecifically with antibodies to apoAI. Amyloid fibrils isolated from
the liver tissue gave a single major protein band, running at about lOkDa in
SDS-PAGE (Figure 3.2), that stained specifically on immunoblotting with
antibodies to apoAI. The first 28 amino acid residues of this band were determined
by automated Edman degradation after blotting from SDS-PAGE and comprised the
A-terminal sequence of mature wild type apoAI. However immunoblotting after
isoelectric focusing of the proband's delipidated plasma proteins demonstrated a
variant apoAI species with a single extra positive charge, in addition to wild type
apoAI (Figure 3.3).
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Figure 3.2 SDS 8-18%
PAGE analysis of amyloid fibrils
isolated from the proband's liver
(lane 1). The major band at
about lOkDa migrates to the
same position as the purified
subunit of the amyloid fibrils
from the spleen of a patient with
Leu60Arg variant apoAI
amyloidosis [19] (lane 2).
Molecular weight markers were











focusing and immunoblotting of
plasma apoAI showing the
variants with one extra positive
charge. Lane 1, proband; lane 2,
known case of Leu60Arg apoAI
amyloidosis [19]; lane 3, normal
control.




Identification of the apoAl gene mutation
The exons of the proband's apoAI gene were amplified by PCR, cloned and
sequenced, demonstrating that he was a heterozygote for a T-»C transition changing
the codon for residue 50 in the mature protein from TGG (Trp) to CGG (Arg)
(Figure 3.4), compatible with the observed charge variant in the plasma. The
mutation creates a new restriction site and this was confirmed by analysis of the
fragments after digestion of the PCR product with Mspl (Figure 3 .4).
Characterisation of the amyloidfibril subunitprotein
Electrospray mass spectrometric analysis of the purified amyloid fibril subunit
protein, apparent mass about lOkDa, demonstrated three species (Figure 3.5)
corresponding to the TV-terminal 86, 92 and 93 residues of mature apoAI variant
with a single Arg for Trp substitution (Table 3.1). In each case the measured mass
exceeded the predicted value by -16 Da, compatible with oxidation of Met86 to
methionine sulphoxide as we have previously observed in fibrils formed from the
apoAI Leu60Arg variant [19], There was no evidence of material corresponding to
the wild type apoAI sequence.
After incubation of the fibril subunit protein with lysyl endopeptidase the
whole digest was analysed by MALDI-TOF mass spectrometry and all peptides
resolved from the matrix with mass greater than about 1 kDa were detected. Their
masses corresponded to those predicted from the variant apoAI sequence (Table
3.2). In particular the peptide of measured mass 1582 Da, corresponding to the
fragment of predicted mass 1582.7 Da containing the Arg for Trp substitution at
residue 50, was clearly seen, whilst there was no sign of a peptide of mass
1612.8 Da expected from the wild type sequence. The peptide of expected mass
1307.4 Da was detected at 1325 Da, the increment of 17.6 Da being compatible
with the oxygen atom involved in sulphoxidation of Met86, given the lower
precision of TOF compared to electrospray mass spectrometry.
Finally the lysyl endopeptidase digest was fractionated by HPLC and the
fractions were screened by uncalibrated MALDI-TOF mass analysis to identify the
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variant peptide for Edman sequencing, and only Arg was detected at the position





Figure 3.4 a, Nucleotide sequence of plasmid clones of part of exon 4 of the
apoAI gene of the proband. Partial sequence of the normal and variant alleles
demonstrates the T->C transition in codon 50 that encodes Arg in place of Trp. b,
Restriction fragment analysis. The mutation introduces anMspl restriction site and
digestion of the PCR products of exon 4 in the proband (lane 1) yielded an
uncleaved 391 base pair band, corresponding to the normal allele, and cleaved
products of 339 base pairs (lane 1) and 52 base pairs (not seen). Digestion of a
normal control (lane 3) gave a single band running in the same position as the
undigested material from either the patient (lane 2) or the control (lane 4).
Table 3 .1 Amyloid fibril subunit analysis by electrospray mass spectrometry
Peak Measured mass Predicted apoAI Trp50Arg *Calculated mass
(Da) fragment (Da)
A 9,903.1 Residues 1-86 9,905.0
B 10,606.6 Residues 1-92 10,606.7
C 10,706.2 Residues 1-93 10,705.9





Figure 3.5 Electrospray mass spectrum of the purified 10 kDa amyloid fibril
subunit protein. The precise masses and assignments of the three species, A, B and
C are shown in Table 3.1.
Variation in clinical expression
Table 3.3 summarises information on all currently known kindreds with
hereditary apoAI amyloidosis, including two families under our care who have not
previously been reported, as well as the present case. Although all patients have had
extensive visceral deposits, there are striking variations in presentation,
manifestations and course between different kindreds, even those with the same
causative mutation and even between members of the same family (Table 3.3). For
example the initial clinical presentation ranges from the second to the sixth decade,
and only the original Iowa family suffered from peripheral neuropathy. Renal failure
is almost universal though the rate of progression varies greatly, as does the
occurrence and severity of cardiac involvement. On the other hand some individuals
from families with different mutations have followed a very similar course.
68




















































Themainsubunitbandrunningtabo t10kDinSDS-PAGEofisol tedamyl ifi i swad gesithly lendopeptida eanthwhole digestanaly edbMALDI-TOF.Thdigestwth nfract onatedHPLCa duncalibratem ssly i(*)wustide tifyhv rian peptideforsequencing.Thpr dictedseque eithafmat ra oAITrp50 g,sindic t dbytg nsequ n ;tv ri nte idi shownbyt eoldfaceRinpeptid5. ND,notdetected;d,to e.
69























































































The proband's father died of systemic amyloidosis for which no primary cause
was identified. The proband similarly had no evidence of any other disease known
to be complicated by amyloidosis, strongly suggesting that he suffered from
hereditary amyloidosis. Furthermore the proband's amyloid fibrils were composed
exclusively of a variant apoAI protein, Trp50Arg, encoded by a mutant allele of the
apoAI gene for which he was a heterozygote. This variant has not been found
previously, even in very extensive population studies [86], Analogous findings in
patients with the Gly26Arg [18, 42] and Leu60Arg apoAI mutations [19], and
concordance in these more extensive kindreds with development of amyloidosis,
identify the mutant genes as the cause of the disease.
The mechanism by which single residue substitutions cause a normally soluble
protein to be deposited in an insoluble, abnormal, form as amyloid fibrils that cause
devastating disease in vivo is obscure. However it is notable that the three known
amyloidogenic variants of apoAI all contain the cationic amino acid arginine in place
of non-charged residues. In contrast the pathogenic variants of other amyloidogenic
proteins involved in hereditary or acquired amyloidosis, including transthyretin,
cystatin C, gelsolin, P-amyloid precursor protein, prion protein, lysozyme,
fibrinogen a-chain, serum amyloid A protein, and immunoglobulin light or heavy
chains, show no discernible pattern of residue substitutions [1, 14], No three
dimensional structure of any amyloid fibril is yet available. However all amyloid
fibrils and many of their precursor molecules have a rich content of P-sheet
secondary structure [2] and partial unfolding of precursor molecules, favoured by
destabilising single residue substitutions in the case of hereditary amyloid, may
expose aggregation-prone sequences, possibly P-strands or sheets, that promote
stacking of globular subunits into amyloid fibrils [87, 88], The three dimensional
structure of apoAI is not known but the Af-terminal region that comprises the fibril
subunit in apoAI amyloidosis is predicted to adopt a predominantly p-sheet
conformation [89], It is therefore possible that the additional arginine residue in this
domain, and/or the extra positive charge it confers may mediate a
pro-amyloidogenic destabilisation or unfolding of the variant apoAI. The presence
in the amyloid fibril subunit of methionine sulphoxide at residue 86 may be evidence
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of such unfolding since it has been reported that Met86 in wild type apoAI is not
oxidised following chromatographic purification, and may even be resistant to
artificial oxidation, compared to Metll2 and Metl48 that are always oxidised to
some extent [90],
Alternatively the processing and proteolytic degradation of the Arg variant
apoAI molecules may differ from those ofwild type apoAI, leading to production of
an abnormal, amyloidogenic, TV-terminal fragment. The physiological cleavage
pathway of apoAI is not known so it is not clear whether the TV-terminal fragments,
from residues 1-86 up to 1-94, that are found in the amyloid fibrils, are normally
generated from wild type apoAI in vivo. However it is of interest that similar
fragments have been identified in all apoAI fibrils that have been adequately
characterised, regardless of the Arg substitution position, 26, 50 or 60. In the
original Gly26Arg variant, the sequence up to residue 83 was obtained but the intact
fibril subunit was not studied, nor was the precise C-terminal determined [42], In
the Leu60Arg variant [19] we demonstrated fragments corresponding to residues
1-88, 92, 93 and 94, compared to 1-86, 92 and 93 in the present case.
The isolated splenic amyloid fibrils from the Leu60Arg patient [19] also
contained traces of apoAI migrating in SDS-PAGE at about 28 kDa, the same
position as whole intact mature apoAI. Insufficient material was available to
identify this as wild type or variant apoAI, but its presence raises the question of
whether cleavage of the TV-terminal fragment is a pre- or post-fibrillogenic event.
Although proteolytic cleavage has been considered a necessary precondition for
deposition of precursor molecules as amyloid fibrils, and this may be true for some
proteins, others such as human (I2-M [38], human transthyretin [37] human
lysozyme [21] and duck serum amyloid A protein [91] form fibrils without any
cleavage. Furthermore recent work indicates that mouse serum amyloid A protein,
which like apoAI is an apolipoprotein of high density lipoprotein, undergoes
cleavage to amyloid A protein (AA) the fibril subunit of reactive amyloidosis, after
rather than before accumulation at sites of AA amyloid deposition [92, 93], It is
thus of interest, firstly, that the plasma clearance rate of apoAI Gly26Arg,
reconstituted into high density lipoprotein particles, was found to be more rapid
than that of wild type apoAI both in normals and in individual Gly26Arg
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heterozygotes, and secondly, that there was extravascular sequestration and delayed
catabolism of the variant apoAI compared to normal [94],
Only variant apoAI molecules have been associated with amyloidosis in man,
but the pulmonary vascular amyloid deposits that occur commonly in aged dogs
consist of the N-terminal 71-80 residues ofwild type canine apoAI [89], There are
11 amino acid differences between human and dog apoAI up to residue 80, and 8 of
these are either moderately or extremely conservative substitutions. The only 2
major changes are insertion of an extra proline residue in the human protein at
position 3, and replacement of the polar serine residue at position 30 in human
apoAI by hydrophobic alanine in dog apoAI.
Whatever the mechanism by which arginine substitutions, or the other
differences between dog and human apoAI, are amyloidogenic in vivo, the present
observations enhance the potential value of this system as a model for investigation
by protein engineering. Studies are currently in progress of the effects of arginine
substitutions at different positions, and of other mutations causing charge changes,
on the properties of the A-terminal domain of human apoAI expressed in vitro. In
addition to effects on fibrillogenesis, these substitutions may modulate interactions
with other molecules that are universally associated with amyloid fibrils in vivo [1,
14], including anionic glycosaminoglycans, serum amyloid P component and
apolipoprotein E.
Nothing is known of the factors other than the amyloidogenic protein itself
that determine where, when and how much amyloid is deposited in vivo in any form
of amyloidosis. Inheritance of the apoE4 genotype is associated with an increased
risk of Alzheimer's disease [95] and with increased cerebral deposition of amyloid
(3-protein [96], but is not related to the development or age of onset of either
acquired amyloid A protein amyloidosis or familial amyloidotic polyneuropathy
caused by Met30 variant transthyretin (unpublished observations). Intriguingly,
apoE4 contains two arginine residues at positions 112 and 158, and the only
sequence difference from the two other common apoE isoforms, apoE2 and apoE3,
is that they contain Cys/Cys and Cys/Arg respectively at these positions [97],
However, apoE is only a trace non-fibrillar constituent of amyloid deposits [98] and
since nothing definite is yet known of its pathogenic role, if any, in amyloidosis, it is
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premature to speculate on aspects in common between apoE4 and the
amyloidogenic apoAI variants.
The mechanisms by which amyloid deposits cause disease are also quite
obscure. There is usually no significant inflammation or necrosis around amyloid
in vivo and it has generally been assumed that the deposits are not inherently toxic
but merely cause damage by physically disrupting the structure and function of
affected tissues [1], However, the recent finding that amyloid fibrils formed in vitro
from pure synthetic peptides can cause cell death in tissue culture by inducing
apoptosis, may help to elucidate this issue, especially as fibrils composed of different
proteins were found to have differential toxicity for different target cell types [99,
100], If this is indeed a general mechanism by which amyloid fibrils are pathogenic
in vivo, and if the various tissues of different individuals had varying susceptibility to
the action of the same and different amyloid fibrils, then it could explain the clinical
observations.
The mainstay of treatment of hereditary apoAI amyloidosis is supportive
management, including organ replacement if necessary. An affected relative of our
first patient with Leu60Arg apoAI disease [19] underwent successful renal
transplantation 7 years ago and remains well. The Leu60Arg proband himself had
his grossly amyloidotic spleen removed four years ago and remains well with little
progression of organ dysfunction despite extensive visceral amyloid deposits.
Another patient from a different kindred with the same Leu60Arg mutation
underwent combined heart and kidney transplantation in September 1992 for end
stage cardiac and renal failure, and also remains well leading a normal life [101],
More specific approaches to treatment include measures to reduce production or
availability of the amyloidogenic variant apoAI protein. Liver transplantation has
been extremely successful in hereditary transthyretin amyloidosis, leading to rapid
disappearance of the amyloidogenic variant from the plasma, its replacement by wild
type donor transthyretin, and clinical improvement in most cases [50, 102],
Although, unlike transthyretin, apoAI is produced in the intestine and elsewhere as
well as in the liver [103], even partial reduction in circulating levels of the
pathogenic variant should slow progression of amyloidosis. However, given the
variable rate of progression of organ dysfunction in hereditary apoAI amyloidosis,
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timing elective liver transplantation correctly will be almost insuperably difficult. A
more realistic prospect may be the use of probucol which reliably reduces high
density lipoprotein levels by up to 25% without major side effects.
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Hereditary renal and systemic amyloidosis caused by a new
deletion/insertion apolipoprotein Al variant in a Spanish family
Introduction
Hereditary amyloidosis is an autosomal dominant condition caused by point
mutations in the genes encoding a variety of different proteins [1, 14], These mutations
produce single residue substitutions in the mature protein that lead to the whole
molecule, or a proteolytic cleavage fragment, being deposited extracellularly in the
tissues as insoluble amyloid fibrils that accumulate and cause organ dysfunction
presenting in adult life. Mutations in the gene for (3-amyloid precursor protein cause
amyloid deposition that is confined to the brain, in familial Alzheimer's disease [104,
105] and in hereditary cerebral haemorrhage with amyloidosis (Dutch type) [106],
However in all other forms of hereditary amyloidosis the deposits are systemic even
though the clinical presentation is usually dominated by manifestations in particular
organ systems. Mutations in some genes cause very specific patterns of disease, such as
hereditary cerebral haemorrhage with amyloidosis (Icelandic type), associated with
variant cystatin C [107], and Finnish familial amyloidosis, associated with variants of
gelsolin [108, 109], Mutations in the genes for other amyloidogenic proteins cause
varied and overlapping clinical syndromes unrelated to the protein involved, and the
same mutation can produce a different phenotype in different families and even between
members of the same family. This is the case in familial amyloid polyneuropathy, the
commonest form of hereditary amyloidosis, which can be caused by more than 50
different point mutations in the transthyretin gene [41, 110], and in hereditary
non-neuropathic amyloidosis which can be caused by mutations in the genes for
apolipoprotein AI (apoAI) [19, 77, 85, 111], lysozyme [21] and fibrinogen a-chain [22,
78], Although the most common amyloidogenic transthyretin variant, Met30Val, does
not always cause disease, all the amyloidogenic mutations in other genes seem to be
completely penetrant. Nevertheless there are evidently other genetic and/or
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environmental factors, unrelated to the amyloid fibril protein itself, that contribute to
deposition of amyloid and its clinical effects.
Apart from their intrinsic interest and clinical significance for the rare affected
kindreds, the hereditary amyloidoses provide valuable models for analysing the
pathogenesis of the common acquired forms of amyloidosis. The most important of
these is Alzheimer's disease, the fourth most common cause of death in the Western
world, and the discovery that mutations in the gene encoding P-amyloid precursor
protein can cause early onset familial Alzheimer's has already revolutionised work on
this condition [104, 105], Furthermore, elucidation of the molecular basis of amyloid
fibril formation, which should be facilitated by study of the amyloidogenic variant
proteins, may permit rational approaches to therapy. The lysozyme mutations that
cause non-neuropathic amyloidosis [21] are particularly promising because all aspects
of the structure and folding of this protein are so well characterised. However apoAI
offers a different but very intriguing challenge because, although its wild type crystal
structure has not yet been determined, all three amyloidogenic variants contain arginine
substitutions for neutral residues within the A-terminal region of the molecule, and it is
this fragment that forms the amyloid fibrils [18, 19, 42, 111], None of the other known
apoAI variants are amyloidogenic [112], We report here a family with hereditary
non-neuropathic amyloidosis caused by a new apoAI variant, in which 12 residues in
the amyloidogenic A-terminal fragment have been deleted and 2 residues inserted. This
is the first deletion mutation in any gene associated with hereditary amyloidosis, but
most importantly it produces an extra positive charge, suggesting that acquisition of
such a charge in this part of the apoAI molecule, rather than substitution by any specific
residue, may be the key amyloidogenic change.
Methods
Patients.
An extended kindred from Cerdanya, Catalonia, Spain, was identified with a
high incidence of systemic amyloidosis presenting with slowly progressive and
uniformly fatal liver involvement. The diagnosis of amyloidosis was first made in two
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asymptomatic female first cousins (Figure 3.6) with abnormal liver function tests
detected during routine screening at ages 60 and 55 yrs respectively, and in whom liver
biopsies were then undertaken. Subsequently the male proband for the present study
(Figure 3.6), in whom chronic liver disease had been diagnosed at age 40, presented at
age 61 yrs with bleeding oesophageal varices and rapidly developed fatal hepatic
encephalopathy.
Clinical investigations.
All clinical chemistry, plasma lipid and lipoprotein analyses and histological
examinations were performed by standard procedures. Amyloid deposits were
identified histologically by green birefringence in polarised light after Congo red
staining [4],
Identification, isolation and characterisation ofamyloidfibrils.
Fresh frozen, unfixed tissue obtained at autopsy of the proband was examined
by immunohistochemical staining precisely as described previously [85, 113], Amyloid
fibrils were isolated from fragments of spleen, liver, kidney and heart by the water
extraction method [8] as lately modified for very small tissue samples [10], Their
protein subunits were separated in reduced SDS-PAGE, and subjected to automated
amino acid sequence analysis, as previously described [19, 83], The subunits were also
excised from the gel and digested with endopeptidase lys-C. The resulting peptides
were separated by reverse phase HPLC with on-line diode array detection
(Hewlett-Packard 1090M). Fractions containing aromatic residues were identified by
their absorbance spectra and characterised by matrix-assisted, laser desorption, time of
flight (MALDI-TOF) mass spectrometry (Lasermat, Finnigan MAT, Hemel Hempstead,
Herts, UK) as described before [19], Selected peptides were then sequenced. Amyloid
fibrils isolated from the spleen were also dissolved in guanidine hydrochloride,
fractionated by gel filtration, and the single main subunit peak analysed by electrospray
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ApoAI gene studies.
DNA was extracted from the proband's blood and two fragments of the apoAI
gene, comprising the region encoding the A-terminal region of apoAI, were amplified
by PCR and the nucleotide sequence determined, all as reported elsewhere [19]. The 5'
end of exon 4 was abnormal, producing a PCR product of 361 base pairs as well as the
normal 391 base pair fragment. These were clearly distinguishable in a 3% gel of low
melting point agarose and this procedure was used to screen the family for other
carriers. The fragments were also excised from the gel, purified by Magiprep
(Promega) and sequenced [19],
Plasma apoAI analysis.
Charge variant apoAI was sought by isoelectric focusing in urea-agarose gel of
delipidated whole plasma followed by pressure blotting and immunostaining with
anti-apoAI antiserum, as described previously [19, 114],
Serum amyloid P component scintigraphy.
Scintigraphy after intravenous injection of radioiodinated pure human serum
amyloid P component (SAP) was performed exactly as described previously [58, 59]
except that the isotope 13'i was used instead of 123I. Although the image quality is less
good the longer isotope half life was necessary because the SAP had to be labelled in
London and flown to Barcelona for the patient studies.
Results
Clinicalfeatures.
Affected individuals in generations A and B of the family (Figure 3.6) died with
liver failure between 48-66 yrs of age. Apart from their abnormal liver function tests no
other clinical or pathological information is available but it is likely that the female case
in generation A was the source of the disease. Cases in generation C were found to
have abnormal liver function tests at about 35-45 yrs of age but the patients all
remained asymptomatic for the next 15-20 yrs. During this phase serum concentrations
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of alkaline phosphatase, transaminases and y-glutamyl transpeptidase were raised but
bilirubin was normal. There were no symptoms or signs of involvement of the kidneys,
peripheral or autonomic nervous system, or any other tissues or organs. Liver function
slowly deteriorated in all affected cases and in the proband there was unusually rapid
progression over about one year to frank cholestasis, portal hypertension, hepatic
encephalopathy and death. Renal failure and proteinuria occurred during the terminal
liver disease.
Percutaneous liver biopsies from four affected family members in generation C
showed similar histology, with some preservation of overall structure but most of the
portal tracts replaced by large amyloid nodules with some compressed arterioles and
ductules at the periphery and a few foamy macrophages. Central veins and hepatic
trabeculae appeared normal. A transjugular liver biopsy, from the patient who
subsequently died and underwent post mortem examination, consisted of fragments of
heavily amyloid laden tissue with conspicuous venous structures but no identifiable
hepatocytes or ductules.
At autopsy his liver was markedly enlarged (weight 6000 gm) with a granular
capsule and small focal parenchymal areas of calcification. The right lobe was
completely replaced by massive amyloid deposition and the left contained large
confluent amyloid nodules among areas of cholestatic hepatic tissue (Figure 3 .7). The
spleen was also large (1300 gm) with massive subcapsular amyloid and multiple nodular
deposits within the parenchyma, unrelated to the white pulp (Figure 3.8). The kidneys
were small with hard yellow nodular masses in the papillae, corresponding
microscopically to diffuse interstitial amyloid deposition (Figure 3.9) limited to the
medulla and associated with tubular atrophy. The renal cortex contained no amyloid;
there was moderate atherosclerosis in the glomeruli and vessels. The heart was slightly
enlarged and contained extensive interstitial amyloid (Figure 3.10) but myocardial fibres
were preserved. The adrenals were enlarged, right 60 gm and left 35 gm, and massively
infiltrated with amyloid leaving only minimal islands of cortical cells. Both testes were
also massively replaced with amyloid and showed marked atrophy of seminiferous
tubules. There were perivenular amyloid deposits in the pituitary gland and its capsule
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and focal deposits were present in the thyroid, prostate, periprostatic sympathetic
ganglia, bone and articular cartilage. The lamina propria of the tongue contained a
band-like amyloid deposit but the rest of the gut was spared as were the lungs, bronchi,
pancreas, lymph nodes, skin and subcutaneous fat.
Identification ofthe amyloidfibrilprotein.
Immunohistochemical staining of all the amyloidotic tissues obtained at autopsy
was strongly and specifically positive with antibodies to apoAI (Figure 3.8, Figure 3.9,
Figure 3.10) and to SAP, but was completely negative with antibodies to amyloid A
protein, k and X immunoglobulin light chains, transthyretin, (32-M and lysozyme.
Figure 3.7 Cryostat section of unfixed liver from the autopsy of the proband,
stained with Congo red and viewed in bright light, showing massive amyloid nodules
among areas of cholestatic hepatic tissue. XI00.
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Figure 3.8 Sections of fixed spleen from the autopsy of the proband, stained by the
immunoperoxidase technique with antiserum to apoAI. Top. Strong positive staining of
the massive amyloid deposits with unabsorbed antiserum; Bottom. Complete absence of
staining with antiserum to apoAI that had been absorbed with pure human HDL. XI00.
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Figure 3.9 Sections of fixed kidney from the autopsy of the proband, stained by the
immunoperoxidase technique with antiserum to apoAI. Top. Strong positive staining of
the massive interstitial amyloid deposits with unabsorbed antiserum, Bottom. Complete
absence of staining with antiserum to apoAI that had been absorbed with pure human
HDL. Renal deposits were confined exclusively to the interstitium with sparing of the
glomeruli. XI00.
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Figure 3.10 Sections of fixed heart from the autopsy of the proband, stained by the
immunoperoxidase technique with antiserum to apoAI. Top. Strong positive staining of
the massive amyloid deposits with unabsorbed antiserum; Bottom. Complete absence of
staining with antiserum to apoAI that had been absorbed with pure human HDL. XI00.
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Characterisation of the apoAI gene mutation.
Sequencing of the apoAI gene from the deceased patient revealed that he was
heterozygous for a mutation in exon 4 in which 35 nucleotides had been deleted from
the wild type sequence and 5 nucleotides inserted, maintaining the reading frame
(Figure 3.11). The mutation was readily demonstrable by gel analysis of the exon 4
PCR product (Figure 3.12), and this test was used to screen all members of the family
from whom samples could be obtained. The observed DNA changes encoded deletion
of residues 60-71 of the mature wild type amino acid sequence and their replacement by
two new residues, ValThr. This predicted acquisition by the variant apoAI molecule of
one additional positive charge, compared to wild type apoAI.
Plasma lipid and lipoprotein studies.
Among the family members from whom results were available the plasma levels
of apoAI and HDL were significantly lower in carriers of the mutation than in
unaffected individuals (Table 3.4), and were also lower than the normal range. There
was a trend towards higher levels of LDL among the cases, although this did not
achieve statistical significance, but the values for apoB, total cholesterol and
triglycerides were the same in the two groups. Subsequent measurements of plasma
lipids and lipoproteins in other laboratories showed exactly the same pattern in further
carriers and unaffected family members (data not shown).
Variant apoAI with one extra positive charge was detected in the plasma of
carriers of the mutation, but was significantly less abundant than wild type apoAI,
especially in one individual with massive amyloidosis and a particularly low
concentration of HDL and total apoAI (approximately 50% of the lower limit of
















Figure 3.11 Nucleotide sequence of part of exon 4 of the apoAI gene from the
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Figure 3.12 Agarose gel electrophoresis of the PCR product from the 5' end of
exon4 of the apoAI gene. Affected individuals (lanes 4-7) yielded a product of 361
base pairs in addition to the normal 391 base pair fragment seen in unaffected family
members (lanes 1-3). Markers of known length were run in lane M.
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Table 3.4 Plasma Lipid and Lipoprotein Levels in Relation to the ApoAI Gene
Mutation
HDL LDL Total Total

























































The carriers tested comprised 3 females and 10 males, mean age 41.9 yrs, SD 17.6,
range 18-67; the controls were 8 female and 6 male family members, mean age 36.1 yrs,
SD 12.2, range 23-60. The P values denote significant differences between carriers and
controls; NS, not significant.
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Characterisation of the amyloidfibril protein.
Amyloid fibrils isolated from spleen, liver and kidney tissue consisted
predominantly of protein subunits running with apparent mass of approximately
8-9 kDa in SDS-PAGE, just ahead of the 10 kD subunit of amyloid fibrils from a case
of apoAI Arg60 hereditary amyloidosis [19] (Figure 3.13). Immunoblotting (not
shown) identified the subunits in the present case as fragments of apoAI and this was
confirmed by automated amino acid sequencing demonstrating the amino terminal
sequence ofmature human apoAI.
Electrospray mass spectrometric analysis of the purified spleen amyloid fibril
subunits, separated by gel filtration, identified two dominant major species and a
number of trace peaks (Table 3.5). The main peaks corresponded precisely to the
masses calculated for TV-terminal fragments of mature variant apoAI encoded by the
observed mutation, encompassing residues 1-83 and 1-92 respectively. The residues
are numbered according to the wild type sequence but the masses are calculated to
include deletion of wild type positions 60-71 and insertion of ValThr at this point.
Almost all the minor peaks could be assigned to other TV-terminal fragments of the
variant sequence, and no species corresponding to fragments from wild type apoAI
were seen (Table 3.5).
After endoproteinase lys-C digestion, no species corresponding to the peptide
expected from wild type apoAI, LREQLGPVTQEFWDNLEK, was found by HPLC
and MALDI-TOF analysis. However a species with mass 1004 D, corresponding to the
peptide VTWDNLEK predicted from the sequence of the variant apoAI, was identified
in each of four separate digests. This material yielded a single amino acid sequence of
VTW in each case. It is not clear why sequencing was blocked after three residues, but
cyclisation of the adjacent aspartic acid and asparagine residues during the Edman
chemistry cycles may have been responsible.
Radioiodinated SAP scintigraphyfor amyloidosis.
Scans were performed in 13 family members. Four individuals from generation
C and 3 from generation D, none ofwhom carried the apoAI gene mutation, showed no
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localisation or retention of tracer. However, all carriers of the mutation, including 4
cases with amyloid confirmed histologically on liver biopsy, had abnormal scans with
uptake of tracer in the liver in each case (Figure 3.14), although there was considerable
variation between patients. The weakest signal was observed in a biopsy positive 67 yr
old woman who remains asymptomatic 6 yrs after discovery of abnormal liver function
tests. This suggests that her amyloid load may be small and not increasing rapidly. In
contrast other patients, all of whom are also asymptomatic, had much more intense
uptake in the liver and occasionally also the spleen, indicating a heavy visceral amyloid
load, even at the much younger ages of 29 and 36 yrs, and possibly predicting a more
aggressive pattern of disease. No positive images of the kidneys, adrenals or any other
organs were observed in any case, possibly because of overwhelming uptake of tracer in
the massive hepatic deposits.
94 kDa —»
67 kDa ->




14.4 kDa -> —
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Arg60
Figure 3.13 SDS 8-18% PAGE analysis of amyloid fibrils extracted from various
tissues of the proband. The main band in the fibrils from heart (lane 2), liver (lane 3),
spleen (lane 4) and kidney (lane 5) ran ahead of the apoAI Arg60 fibril subunit (lane 6)
[19], Marker proteins of known mass were run in lane 1 and isolated human serum
amyloid P component, mass 25462 D [115], in lane 7.
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Figure 3.14 Anterior (left) and posterior (right) views of whole body scintigrams
taken 24 h after intravenous injection of 13^-labelled human SAP in the individual
marked 4* in Figure 3.6. There is massive uptake of tracer in the liver with no
significant retention elsewhere and very low blood pool background, compatible with
massive hepatic amyloidosis.
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Table 3.5 Electrospray Mass Spectrometry ofPurified Subunits from Splenic
ApoAI Amyloid Fibrils. Measured and Calculated Molecular Masses ofPredicted
Fragments
Measured




A 8332.7 1-83 8332.2
B 9438.8 1-92 including methionine sulfoxide 9438.3
Related
minor peaks
BK 8353.7 1-83 +Na+ 8355.2
BW 8373.2 1-83 +K+ 8372.2
BX 8377.4 1-83 +2Na+ 8378.2
BJ 9420.1 1-92 9422.2




CA 9471.1 1-92 + 2Na+ 9468.3
BV 9478.5 1-92 including methionine sulfoxide + K+ 9478.3
Other minor
peaks
BD 8063.7 1-81 8062.8
BT 8196.2 1-82+ Na+ 8199.0
BQ 8590.7 1-85 8589.4
BL 8638.9 1-85 + 2Na+ 8635.4




mass (Da) Predicted apoAI fragment mass (Da)
BY 9306.5 1-91 including methionine sulfoxide 9309.2
BG 9538.4 1-93 including methionine sulfoxide 9537.4
BP 9559.4 1-93 including methionine sulfoxide + Na+ 9560.4
CC 9581.9 1-93 including methionine sulfoxide + 2Na+ 9583.4
BO 9601.8 1-93+ 2K+ (or 1-93 including methionine
sulfoxide + Na+ + K+)
9601.4
(9600.4)
BZ 9642.7 1-93+ 3K+ (or 1-93 including methionine
sulfoxide + Na+ + 2K+)
9641.4
(9640.4)
BI 10608.6 1-102 + 2Na+ 10610.7
BE 10706.3 1-103 +Na+ 10702.7
BU' 10953.5 1-105 10955.0
CD 11582.6 1-110 including methionine sulfoxide + K7 11582.7
BS 11965.5 1-113 +2Na+ 11962.2
Residues numbered according to the wild type sequence but masses calculated to
include the deletion of residues 60-71 and insertion of new residues ValThr at this
position. Peaks A and B were overwhelmingly dominant. The other peaks were only
traces by comparison but all were assigned, as shown here, except two with masses
7644.7 and 12128.1 D respectively.
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Discussion
Affected members of the family described here had a unique phenotype of
hereditary, non-neuropathic systemic amyloidosis that has not been reported previously
and that was caused by the first deletion mutation to be associated with amyloidosis.
Although at autopsy amyloid deposits were extremely widespread, the clinical
presentation, ensuing illness and death were all exclusively related to the massive
hepatic involvement. In common with most other forms of systemic amyloidosis there
was an asymptomatic prodromal phase, lasting for many years, with only biochemical
evidence of disease. Nevertheless, liver biopsy or SAP scintigraphy demonstrated
amyloid long before advent of clinical symptoms. Interestingly SAP scintigraphy
suggested anticipation, at least with respect to amyloid deposition, with 3 individuals in
generation D aged 29 and 36 having substantially more amyloid than 4 individuals in
generation C aged between 54 and 67 yrs. Also 6 of the 7 generation D cases carrying
the causative apoAI gene mutation already had abnormal liver function tests at ages
between 18 and 36, whereas there was one 57 yr old carrier in generation C with no
biochemical abnormality.
It remains to be seen whether clinical disease will also develop earlier and/or
progress more rapidly in the youngest generation, and, if it does, they may be
candidates for orthotopic liver transplantation. This would both replace organ function
and reduce, though not eliminate, production of the amyloidogenic apoAI variant
protein. Liver transplantation has been successful in hereditary transthyretin
amyloidosis, eliminating the source of the variant amyloidogenic protein from the
plasma and leading to clinical benefit in most patients and regression of amyloid
deposits [50, 102, 116], Although apoAI is produced not only by the liver but also in
the intestine and elsewhere [103, 117], a significant reduction in availability of the
pathogenic variant might favourably reduce the rate of amyloid deposition in a disorder
that already has a very long presymptomatic phase.
The concordance between the apoAI gene mutation discovered here, the
presence of the corresponding charge variant apoAI protein in the plasma, the presence
of amyloid in the tissues, the identification of apoAI as the amyloid fibril protein, and
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the clinical and/or biochemical signs, established the mutation as the cause of the
disease. It is highly penetrant and among the 31 family members whose DNA we have
been able to study, only 2 of the 13 carriers, aged 27 and 57 respectively, do not yet
have any disturbance of liver function. Neither of these subjects has undergone either
liver biopsy or SAP scintigraphy so the presence of amyloid deposits is not excluded.
The mechanisms by which any of the amyloidogenic variants of apoAI, including
the present one, form amyloid fibrils are not known but it is unlikely to be a coincidence
that they all carry one extra positive charge on the A-terminal part of the molecule and
that the fibrils in all cases which have been analysed are composed of this fragment. In
amyloid fibrils of all types the protein subunits are arranged in anti-parallel P-sheets
lying with their long axes perpendicular to the fibril long axis [3, 118], Some intact
native globular proteins, some fragments of larger proteins, and some synthetic peptides
have a high propensity to aggregate and adopt this conformation, that is they are
amyloidogenic in vivo or in vitro [1], The point mutations that are responsible for the
autosomal dominant hereditary amyloidoses evidently increase the amyloidogenicity of
the affected proteins. In the case of lysozyme, gelsolin, fibrinogen and cystatin C, the
wild type molecule is not known to be amyloidogenic and either the whole or a
fragment of the variant forms the fibrils. In the case of transthyretin and P-amyloid
precursor protein the wild type molecule can be amyloidogenic in elderly individuals but
this is greatly enhanced for the variants. Following the finding that wild type apoAI
causes senile pulmonary vascular amyloidosis in dogs [89, 119] it has lately been
discovered that the frequent small amyloid deposits in the aortic wall of elderly human
subjects, associated with atheromatous plaques, are also derived from wild type apoAI
[120],
ApoAI is thus an inherently amyloidogenic protein and this has been confirmed
by the formation of amyloid fibrils from whole isolated apoAI in vitro [121], although
in vivo the apoAI fibril subunits consist of A-terminal fragments. The variants may
have enhanced amyloidogenicity because the substitutions destabilise the native
structure, promoting fibrillogenic aggregation with proteolytic cleavage as a secondary
phenomenon, or they may facilitate proteolytic cleavage of the native molecule to yield
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fibrillogenic fragments. Also all amyloid fibrils are tightly associated with polyanionic
sulphated glycosaminoglycans in vivo [34, 122], that are thought to contribute to
formation and/or stabilisation of fibrils, and these interactions could be enhanced by the
cationic nature of the amyloidogenic apoAI variants. Interestingly a synthetic peptide
corresponding to residues 9-20 of the wild type apoAI sequence was amyloidogenic in
vitro [120], although this does not necessarily relate to fibrillogenesis by the much
larger fragments found in vivo. In the original case of Arg26 variant apoAi (Iowa) the
main fragment consisted of residues 1-83 [42], whilst in human senile aortic amyloid it
was 1-69 [120] and in senile dogs 1-71 and 1-80 [89, 119], all determined only by
amino acid sequencing. In our electrospray mass spectrometry study of the Arg60
variant we found fragments 1-88, 92, 93 and 94 [19]. In the present case
overwhelmingly the most abundant fragments were from position 1 to the residues
corresponding to positions 83 and 92 in the wild type but including the
deletion/insertion substitution that we have described here. In addition we detected
traces of fragments 1-81, 82, 85, 88, 91, 93 102, 103, 105, 110 and 113. This level of
precision cannot be achieved by sequencing without mass spectrometry, and it is likely
that similar C-terminal raggedness and heterogeneity is present in all cases. Either there
is no particular, specifically amyloidogenic, cleavage point or else the initial cleavage
and/or subsequent C-terminal clipping proceed as post-fibrillogenic events [92],
Mass spectrometry also identified the frequent presence of sulfoxidation of
Met86 in apoAI fibril subunits, both in the present case and in the Arg60 individual
[19], Whilst this might be an in vitro artefact generated during fibril isolation and
protein purification, there is evidence that Met86 is relatively much more resistant to
oxidation in vivo and in vitro than Metl 12 and Met 148 in wild type apoAI [90], The
amyloidogenic substitutions, or in the present case deletion/insertion, Wterminal to
Met86 might affect this property and thereby influence cleavage of apoAI and/or its
association with HDL [123], Oxidation of apoAI can also enhance its polymerisation
[124],
In affected members of the present family, as in both the original Arg26 cases
[18, 94] and the first Arg60 kindred [19], the plasma contained the expected charge
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variant form of apoAI but at a significantly lower abundance than the wild type protein
in all individuals tested. This is compatible with the accelerated plasma clearance of the
variant directly documented for apoAI Arg26 by Rader et al [94], who also showed that
clearance of normal apoAI was accelerated in carriers of this mutation who had
subnormal plasma apoAI and HDL levels. However after plasma clearance, the
extravascular catabolism of variant apoAI was significantly slower than that of the wild
type, indicating sequestration, possibly in the amyloid deposits [94], Carriers in the
Spanish family studied here also had subnormal plasma levels of both total HDL and of
apoAI, and the individual with the lowest plasma concentration of variant compared to
wild type apoAI had massive hepatic and other amyloid deposits.
Identification of this new amyloidogenic variant extends the potential value of
the apoAI model for studies of amyloidogenesis and enables informed testing and
genetic counselling to be conducted in the affected family. Work on in vitro
fibrillogenesis by apoAI is in progress and in future the effects of liver transplantation
on survival, plasma apoAI levels and metabolism, and the natural history of
extra'hepatic amyloid deposits will be of considerable interest.
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Hereditary renal amyloidosis due to variant apolipoprotein Al Gly26Arg
in an Irish family
Case Report
The proband who originates from Ireland, was 38 years old when he presented
with hypertension and renal failure. He remained well until 6 years later when
investigations for abnormal liver function tests (LFTs) demonstrated hepatic amyloid.
There was no glomerular amyloid in his tiny renal biopsy but interstitial involvement
could not be excluded. Enquiries revealed a strong family history of amyloid and renal
failure. His brother died aged 47 years from colonic carcinoma but prior to that had
hypertension, renal failure and abnormal LFTs with amyloid identified on liver biopsy.
Their father had died also aged 47 years of unknown cause and one of his brothers had
died in his early fifties of renal failure. Thirteen years after presentation, peritoneal
dialysis was commenced for his renal failure and two years later, he remains alive and




Nodular amyloid deposits clustered around portal tracts of the proband's liver
biopsy was identified on Congo red staining [4] and characterised by
immunohistochemical studies using antibodies directed against serum amyloid A,
immunoglobulin light chains, transthyretin, apoAI, lysozyme and (32-M as previously
described [19]. Specific staining of nodular deposits were seen only with rabbit anti-
human anti-apoAI antibodies and absorption control was negative (Figure 3.15),
indicating staining to be specific. A subcutaneous cube of fat was taken from the
proband but was not sufficiently amyloid-laden for successful fibril extraction.
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Direct dsDNA sequencing of PCR amplified fragments ofDNA extracted from
proband's white blood cells [19] demonstrated that he was heterozygous for a single
base substitution in exon 3 of the apoAI gene (Figure 3.16), changing the codon for
residue 26 of the mature protein from GGC (Gly) to CGC (Arg). The rest of the
sequence was normal. This mutation had previously been reported in three other
families, one of whom had familial amyloid polyneuropathy with extensive visceral
involvement [18, 42, 84] whilst in the other two, phenotype was of Ostertag-type with
visceral amyloidosis without neuropathy [77, 85],
123I-labelled SAP component scintigraphy [58-60] demonstrated a moderately
large total body amyloid load with deposits in spleen and especially in the liver (Figure
3 .17). Follow-up scans over the next two years remained essentially unchanged with no
significant extra-renal disease progression. Abnormal LFTs, consisting of raised
alkaline phosphatase also remained unchanged at follow-up.
Conclusion
The clinical phenotype, strong family history of renal failure and systemic
amyloidosis in this Irish family was broadly similar to two other families with HRA [77,
85] due to apoAI Arg26 mutation. That this family has a similar genotype-phenotype
relationship was supported by the demonstration of a similar mutation and apoAI in
amyloid deposits. This is therefore the third family to have HRA due to variant apoAI
Arg26, but the fourth family with this mutation. The original apoAI Arg26 family [18,
42, 84] had a mixed neuropathic-nephropathic presentation with disease confirmed in 8
cases on post-mortem studies. No further families with such mixed neuropathic-
nephropathic disease due to any protein variants has since been reported.
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Figure 3.16 Nucleic acid sequence of part of exon 3 of the apoAI gene. The
proband is a heterozygote for a single base change ofG to C in codon 26.
Figure 3.17 123I-labelled SAP scan of proband 24 hours after injection of tracer.
Anterior (left) and posterior (right) views demonstrating splenic and massive liver
deposits.
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Hereditary renal amyloidosis due to fibrinogen a-chain Glu526Val
variant in a German family
Hereditary systemic amyloidosis often presents with renal disease but is rare and
its significance is easily missed. Precise characterisation of the underlying metabolic
defect in each kindred may have important therapeutic implications and also provides
models for studying the pathogenesis of amyloidosis generally. The clinical findings
and molecular basis of autosomal dominant renal amyloidosis in a large German family
is described here.
Ten first degree family members (Figure 3.18) aged 23-70 years were evaluated
clinically and by quantitative 123I-labelled SAP scintigraphy after renal amyloid had been
identified routinely in 2 cases. Scans (Figure 3.19) demonstrated systemic amyloidosis
in 7 patients, affecting the spleen in all cases and, variably, the kidneys, adrenals and
liver. Clinical features (Table 4.1) were hypertension, proteinuria, nephrotic syndrome
and renal failure, but the age of presentation, mode of renal disturbance and outcome
were remarkably inconsistent. Furthermore, correlation with the underlying quantity of
amyloid was poor. DNA sequencing (Figure 3.20), confirmed by 2 RFLP analyses,
identified a missense point mutation in the fibrinogen a chain gene, coding for a
previously described Glu526Val variant protein. There was complete concordance
between the mutation and presence of amyloid on SAP scanning.
Since fibrinogen is produced only by hepatocytes, liver transplantation as used
in hereditary transthyretin amyloidosis ("surgical gene therapy") may also be potentially
curative in this disease. However in this family, progression of amyloid was slow,
evidence of significant extra-renal disease was minimal and long term survival on
dialysis was uncomplicated. Moreover, in one case there was no evidence of new
amyloid in a renal allograft after 4 years.
This study illustrates the role of SAP scanning and molecular techniques for
characterising phenotype-genotype relationships in hereditary amyloidosis. Late onset,
slow evolution and modest whole-body amyloid deposition, along with results in one
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ANT UB POS LIB Figure 3.19 123I-labelled
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renal and splenic deposits.
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G A T C
Figure 3.20 Autoradiogram of DNA sequencing gel of an affected individual
demonstrating both adenine (A) and thymine (T) at position 4909 of fibrinogen a-
chain indicating heterozygosity for Val526.
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Chapter 4 - Clinical, scintigraphic, histological, biochemical
and genetic characteristics of families with hereditary renal
amyloidosis
Introduction
In 1932, Ostertag, a German pathologist, reported the first kindred with
hereditary systemic amyloidosis [75], Post-mortem examination on two brothers
who died in their 30's with renal failure revealed extensive amyloid deposits in
heart, kidney, spleen and liver. Since then, several kindreds have been reported to
have similar extensive visceral amyloid deposits [125-128], Pattern and severity of
organ involvement may vary but these families were identifiable by the invariable
involvement of the kidneys and absence of neurological disease, distinguishing them
from the more common hereditary neuropathic amyloidoses, subsequently described
by Andrade in 1952 [129], Therefore the term hereditary renal amyloid (HRA) is
sometimes used to describe Ostertag type families with hereditary systemic (non-
neuropathic) amyloidosis. The molecular basis of this disease was first characterised
only in the 1990s, and since then eight amyloidogenic variants of three circulating
plasma proteins which are not normally amyloidogenic have been described [19, 21,
22, 44, 77, 78, 85, 111, 130], The clinical, scintigraphic, histological, biochemical,
and genetic characteristics of families with HRA where the disease has been fully
characterised is reviewed here.
Proteins associated with hereditary renal amyloidosis
Variant apolipoprotein AI
The incidence of electrophoretic variants of apoAJ is 1:1000 [86] and
although more than 20 amino acid substitutions together with 2 frame shift
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mutations and one inversion have now been identified, only a few are pathogenic
causing abnormal cholesterol metabolism, premature coronary artery disease
(especially in homozygotes where apoAI may be completely absent from the plasma
compartment) or, hereditary systemic amyloidosis [112], In heterozygotes with
variant amyloidogenic apoAI, the circulating levels of both variant and wild-type
apoAI [19, 44, 85, 111] are low and could be due to accelerated catabolism of
variant and to a lesser extent wild-type apoAI [43], Interestingly, all 3
amyloidogenic apoAI point mutations result in the substitution of a neutral residue
by the positively charged arginine, and the more complex deletion mutation, also
results in the acquisition of an extra positive charge in variant apoAI, suggesting
that this structural change rather than a specific residue substitution plays an
important role in amyloidogenesis, perhaps by mediating a pro-amyloidogenic
destabilisation or unfolding of the aorta. The presence in the amyloid fibril subunit
may be evidence of such unfolding, since it has been reported that Met86 in wild-
type apoAI is not oxidised following chromatographic purification, and may even be
resistant to artificial oxidation, compared to Metll2 and Met 148 that are always
oxidised to some extent [90],
Kindreds with amyloidogenic apoAI variants typically have extensive
visceral amyloid load affecting heart, adrenals, gut and especially liver, spleen and
kidneys. Most present with hypertension, proteinuria, haematuria, chronic renal
failure, and hepatosplenomegaly. The disease has an autosomal dominant pattern of
inheritance and penetrance appears to be complete in all cases studied so far.
However, the disease which may present as early as the third decade may vary in its
course even amongst members of the same kindred, although it always terminate in
end-stage renal failure, necessitating renal replacement therapy with dialysis or renal
transplantation. Clinical features are therefore very similar to the original
description of the disease by Ostertag in 1932. The exception is the Spanish family
with the apoAI deletion mutation where affected individuals presented with liver
disease and death was from liver failure whilst renal function remained well
preserved despite extensive interstitial amyloid [44],
Histologically, the variants may be divided into 2 smaller groups according
to the pattern of distribution of renal involvement by amyloid. In kindreds with the
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deletion mutation (Figure 3.8) and Arg26 variant, only renal interstitium was
infiltrated with amyloid and in contrast, with the Arg60 (Figure 4.1) and especially
Arg50 variant, only the glomeruli were severely affected, similar to that reported in
the Ostertag brothers. The reasons for localisation of deposits to glomeruli or
interstitium are not obvious although it is interesting that other forms of systemic
amyloidosis also usually affect only the glomeruli (Figure 4.2) [131, 132],
Variant lysozyme
Lysozyme is a ubiquitous bacteriolytic enzyme present in external secretions,
polymorphs and macrophages [133], but its physiological role has not been fully
defined [134], The first lysozyme variants known to cause disease in man, Thr56
and His67, were reported recently in two unrelated English families with hereditary
amyloidosis [21], Amyloid fibrils extracted from the kidney of the proband with
lysozyme Thr56 mutation were composed of the full length variant lysozyme
molecules. As with other families with hereditary renal amyloidosis due to other
variant proteins, the disease has an autosomal dominant pattern of inheritance and
the mutation appears to be highly penetrant. Phenotype in the Thr56 family was
characterised by unique presentation with petechiae, which may be obvious even in
childhood [135], In addition, two members also presented with abdominal pain
resulting in laparotomy and splenectomy. Liver in both cases were grossly enlarged
and almost completely replaced by amyloid but the heart does not appear to be
affected in all 3 cases where post-mortem examination was performed. In the His67
family [126], hepatic involvement was not prominent with no gross hepatomegaly
and amyloid deposits were confined to the portal vessels in at least 2 of 3 cases on
post-mortem examination. In the kidneys, glomeruli and interstitium were infiltrated
with amyloid in both families (Figure 4.3), although progression to renal failure
appears to be more rapid in individuals with lysozyme His67 variant.
Whilst the role of lysozyme is not entirely clear, there is evidence that
impairment of its function increases the risk of bacterial infection [136], Preliminary
results of functional studies on serum and saliva of an affected individual using the
lysoplate assay as previously described [137] suggest that its physiological actions
are not impaired (Pepys et al, unpublished observations), consistent with the absence
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of a clinical history of increased susceptibility to bacterial infections in both kindreds
where the commonest cause of death was renal failure.
Evaluation of the possible effects of variant residues on the crystal structure
of wild-type lysozyme which has been resolved to 1.5A [138] suggest that both
amino acid substitutions which occur in highly conserved regions of the protein have
a destabilising effect on the structure of lysozyme [21], As wild-type lysozyme is
not normally amyloidogenic, structural analysis of the present variants and lysozyme
fibrils may yield novel information on the general mechanisms of amyloid
fibrillogenesis.
Variant fibrinogen a-chain
Fibrinogen, a major plasma protein involved in the final phase of blood
coagulation is composed of two sets of three different polypeptide chains (a, [3, and
y) [139], Several fibrinogen a-chain variants have been determined for inherited
dysfibrinogenaemias and most are single amino acid substitutions affecting the 19 N-
terminal residues of the mature protein [139], None are known to be
amyloidogenic. The first amyloidogenic fibrinogen variant [22], involving the a-
chain (Leu554), was described in 1993 in a Peruvian-American family. Fibrils
extracted from the kidney of the proband were derived exclusively from the C-
terminal fragment of the variant protein. Since then, a second amyloidogenic
fibrinogen variant which also affect the C-terminus of a-chain, Val526, have been
identified in two unrelated Irish-American families [78] and one German family
[130], Immunohistochemical studies confirmed fibrinogen to be the precursor
protein but full fibril protein characterisation was not possible in these families.
As with other families with the disease, there was variation in phenotype
although individuals with Leu554 variant tend to present much earlier and with
more severe organ involvement, causing end-stage renal failure in three affected
members aged 24 to 36 years. All have died despite replacement of renal function
with haemodialysis or cadaveric renal transplantation. In contrast, none of the
current generation of affected members of the three Val526 families have died from
the disease or from renal failure. After more than 8 years of haemodialysis, there
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was no evidence for significant extra-renal disease progression in one, and in
another transplanted 4 years ago, graft function remains preserved with no
recurrence of amyloid [130], A feature common to both Leu554 and Val526
families is the lack of significant liver involvement clinically, biochemically and
histologically. In only one out of 4 cases where tissue was available, small amyloid
deposits were identified within vessel walls but not liver parenchyma.
Scintigraphically, deposits were confined mainly to kidneys and spleen, with minor
deposits in the liver demonstrated in only 2 of the 5 cases with abnormal scans.
Another common feature was the absence of significant cardiac involvement
clinically, echocardiographically and histologically. In both cases where heart tissue
was available, no amyloid was demonstrated. Finally in all 5 cases where the pattern
of renal distribution of amyloid was described, deposits were confined to the
glomeruli.
The fibrin forming potential of variant amyloidogenic fibrinogen remains
intact on functional studies [78] although thrombolysis of formed clots, which is
impaired resulting in recurrent thrombosis in other non-amyloidogenic fibrinogen
variants, was not studied. However, in none of the four families was there a history
ofbleeding or clotting disorders.
Histological, scintigraphic and fibril protein characteristics
associated with hereditary renal amyloidosis
Renal histology
Heterogeneity in distribution of amyloid was also apparent within the
kidneys (Table 4.1, Figure 3.8, Figure 4.1, & Figure 4.3). Even within the
glomeruli, deposits may be diffusely distributed with preservation of glomerular
architecture or, may be nodular resulting in disruption and in some cases
replacement of glomerular structure by amyloid. In other kindreds amyloid was
confined to the interstitium (identifiable only on electron microscopy in one
individual) [85] or, less commonly, amyloid may distributed between glomeruli and
interstitium. However, within an individual, distribution was consistent although it
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may conceivably change with disease progression. Similarly, the pattern of
distribution tend to be consistent within the same family but may vary especially
between families and the reasons for such heterogeneity are not obvious. It is
tempting to speculate for example, that nodular forms of glomerular amyloid may be
due to slow accumulation of amyloid around a nidus of amyloid fibrils, whilst rapid
deposition of variant proteins result in diffuse distribution of amyloid. Localisation
of amyloid to the interstitium is distinctly uncommon in systemic amyloidosis [131,
132] and may be due to abnormal processing of precursor protein [132], In
addition, the function of glomerulus as a filter suggest that charge and size of
precursor protein may be important determinants of the pattern of distribution of
amyloid between glomerulus and interstitium. Individuals with glomerular amyloid
tend to have heavier proteinuria and although interstitial diseases in general are
more likely to cause renal failure, it is interesting that renal function in the Spanish
family with apoAI deletion mutation for example, remained well preserved despite
extensive interstitial amyloid [44], confirming our previous observations that
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Radiolabeled SAP scintigraphy [58-60] has been an indispensable tool in our
studies on families with HRA. The visceral pattern of distribution of amyloid first
determined by Ostertag on post-mortem studies can now be studied for the first time in
vivo by scintigraphy (Figure 3.1, Figure 3.14, Figure 3.17, Figure 3.19). In addition to
demonstrating variation in pattern of visceral amyloid distribution most obvious in
disease caused by different amyloidogenic proteins, subclinical amyloid deposits may
also be detected in asymptomatic carriers of mutant genes [19, 44, 130], providing
evidence for its use as a screening procedure and for determining concordance between
mutation and disease that could previously only be confirmed in such cases on biopsy.
In one kindred, only 4 out of 9 biopsies was diagnostic in 8 cases where systemic
amyloidosis was subsequently confirmed on post-mortem studies [84], suggesting that
scintigraphy may be a more sensitive technique in the diagnosis of systemic amyloidosis.
Scans may also be used to follow rate of disease progression. We have for example,
recently confirmed clinical suspicion that disease progression may be slow in individuals
with fibrinogen a-chain Val526 variant, with scintigraphic studies demonstrating lack of
extra-renal disease progression in an individual who have been dialysed for more than 8
years and in another individual with no amyloid recurrence in a graft 4 years post-
transplant [130], We have now studied seven different families [19, 21, 44, 85, 111,
130] with six different amyloidogenic protein variants and in all cases where tissue was
available, there was complete concordance between mutation and disease. Therefore
radiolabeled SAP scans may be used in the diagnosis, screening and follow-up of
families with HRA.
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Figure 4.1 Renal section of a patient (NP) with HRA due to apoAI Arg60 [19]
stained with Congo red and viewed in bright light (top), and polarised light (bottom),
demonstrating nodular amyloid deposits (arrow) confined to the glomeruli. X40.
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Figure 4.2 Sections of kidney stained by immunoperoxidase technique with
antiserum to SAA in a case of AA amyloidosis. Strong positive staining
demonstrating diffuse amyloid deposits confined to the glomeruli with sparing of the
interstitium. Bottom. Complete absence of staining with antiserum to SAA that had
been absorbed with pure human acute phase serum. X40.
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Figure 4.3 Renal section of a patient (SD) with HRA due to lysozyme His67 [21]
stained with Congo red and viewed in bright light (top), and polarised light (bottom),




The lack of affinity of fibril precursor protein for neural tissue is both diagnostic
and striking, a unique property that is evidently preserved even in affected individuals
where disease progression whilst maintained on long term dialysis might be expected to
occur and involve other tissues such as nerves. The observation that this does not
happen [130] will need to be confirmed and could be due to preferential localisation of
circulating variant proteins into existing amyloid deposits.
In all cases where the disease has been fully characterised, the fibril precursor
proteins in HRA were exclusively derived from variant molecules (Table 4.2).
Characterisation of these precursor proteins may identify a common property that can
provide crucial information on the mechanisms of fibrillogenesis, and may also help to
explain the variation in phenotypic expression, especially between kindreds. So far, all
fibril proteins are of 8 to 14 kDa in size, and in the case apoAI variants, the fibril
proteins extracted from spleen, liver and heart of different kindreds are homogeneous in
both size and charge. All have an extra positive charge as a result of the substitution or
deletion and all are derived from the N-terminal 84 to 94 residues. Although these
properties are unique and evidently critical in apoAI amyloidogenesis, it does not
however lead to uniformity in phenotypic expression. Indeed, in the original apoAI
Arg26 family [84], the disease had an unusual mixed neuropathic-nephropathic
presentation although fibril proteins extracted from spleen and liver (sequenced up to
the N-terminal 77 and 83 residues respectively) [42] were of similar size and charge.
Whilst variant apoAI and variant fibrinogen a-chain are cleaved either before or
after the fibrillogenic event, this is not a necessary requirement for amyloidogenesis in
general. Both wild type and variant transthyretin, wild-type (32-M and variant lysozyme
may be deposited as whole intact molecules into amyloid fibrils [1, 14], Finally, as none
of the wild type proteins associated with HRA are known to be amyloidogenic, the high
degree of, if not complete penetrance of the associated mutations suggest that their




The main clinical consequence of HRA is renal failure and indeed, the disease
was usually fatal within 10 years of diagnosis, death being due to or related to renal
failure. Supportive therapy therefore consists of replacement of renal function by
dialysis or renal transplantation and this has improved the prognosis considerably [13],
For example, none of the affected members of the current generation of our German
family with fibrinogen Val526 variant has died from the disease or from renal failure in
contrast to earlier pre-dialysis generations where some have succumbed to renal failure
in their fifth decade. Transplantation of other organs terminally affected by disease
should also be considered. In December 1992, we performed a double heart and kidney
transplant on a 35 year old girl with organ failure due to variant apoAI Arg60
amyloidosis and she remains alive and well 3 years later with no significant extra-renal
disease progression or amyloid recurrence in her grafts (Pepys et al, unpublished
observations).
Specific treatment aimed at reduction of fibril precursor protein may be
accompanied by halt in disease progression and in some cases, disease regression [12,
13, 50], Since fibrinogen is produced exclusively by hepatocytes [140], liver
transplantation is potentially curative. Such surgical forms of genetic therapy have been
used successfully in hereditary neuropathic amyloidosis due to variant transthyretin [50,
102], a protein that is produced almost exclusively by the liver. The synthesis of apoAI
is divided approximately equally between liver and small intestine [103, 117] and
therefore liver transplantation may reduce circulating variant apoAI levels sufficiently to
slow down or even halt disease progression. Similar options are not available in disease
due to variant lysozyme, a ubiquitous component of external secretions, polymorphs
and macrophages.
As with all hereditary diseases, genetic counselling and screening form an
important part of their management. Individuals who present in their early years and
wish to have children may be reassured that disease progression can be slow and in
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those affected prognosis may be considerably improved especially with renal supportive
therapy and organ transplantation.
Discussion
Most cases of hereditary systemic amyloid either have mainly neuropathic
disease which is frequently accompanied by a lesser degree of visceral organ
involvement or, less commonly, it affects exclusively the visceral organs and
characteristically spares the nerves [1, 14J. Since the original description of this
visceral disease by Ostertag in 1932, 12 different families with amyloid due to 4
different amyloidogenic variants of apoAI [19, 44, 77, 85, 111], 2 variants of lysozyme
[21] and 2 variants of fibrinogen a-chain [22, 78, 130] have been reported. Wild-type
molecules of these 3 proteins are not normally amyloidogenic although wild-type apoAI
may cause pulmonary amyloidosis in aged dogs [89], The mechanisms by which these
normally soluble circulating proteins are rendered amyloidogenic by single residue
substitutions are obscure. All amyloid fibrils and many of the precursor molecules have
a rich content of P-sheet secondary structure [2], There is in vitro evidence that single
residue substitutions in structurally critical positions may have a destabilising effect on
protein structure, causing precursor molecules to unfold, exposing aggregation prone
sequences possibly P-strands or sheets that promote the deposition of variant molecules
as insoluble amyloid fibrils [87, 88], This may be the case with variant lysozyme, where
structural analysis suggest that both amino acid substitutions occur in highly conserved
regions of the protein and are likely to have a destabilising effect on domain structure
and stability [21],
In apoAI amyloidosis, a discernible pattern has emerged, with all variants
including the deletion variant, resulting in the mature protein acquiring an extra positive
charge in the N-terminal part of the molecule which is the fragment actually deposited
in the tissues as amyloid (Table 4.2). The mechanism by which this renders the protein
pro-amyloidogenic remains to be determined. Whilst the extra positive charge may
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have a destabilising effect on protein structure, it may also possibly result in abnormal
processing and proteolytic degradation of the variant molecules, leading to the
production of an abnormal N-terminal fragment. Evidence for abnormal handling of
variant apoAI is provided by in vivo studies demonstrating that plasma clearance rate of
apoAI Arg26, reconstituted into high density lipoprotein particles, was found to be
more rapid than that of wild type apoAI both in normals and individual Arg26
heterozygotes, and secondly, that there was extravascular sequestration and delayed
catabolism of the variant apoAI compared to normal [43], No discernible pattern has
yet emerged from variant fibrinogen a-chain, the three dimensional structure of which,
like apoAI, has yet to be determined. It is however significant that the Leu554 variant
is amyloidogenic but not Cys554 [141] which is due to a codon change from CGT
(Arg) to TGT (Cys) resulting in functional abnormalities causing thrombophilia and,
although there are associated structural anomalies with abnormal fibrin formation, this
variant does not appear to be amyloidogenic. Conversely, Leu554 (and Val526)
variants appear to be functionally normal on clotting studies and functional assays [78],
Clearly, in addition to the site of residue substitution, the type of amino acid with
changes in charges or hydrophobicity may be critical in determining phenotype.
Comparison of the subtle but clearly crucial changes in biochemical and structural
properties of these two variants may provide important information on the mechanisms
of fibrillogenesis.
Heterogeneity was also evident in clinical phenotype with diversity in timing and
distribution of amyloid, corroborated by scintigraphic and histological studies where
variation of involvement was observed even within an organ, with for example
predilection of amyloid deposition in glomeruli in most, whilst exclusively localised to
the interstitium in some kindreds (Table 4.1). Identification of factors responsible for
such diversity will clearly be of considerable clinical relevance and may improve our
understanding of the pathogenesis of amyloidosis, leading perhaps to new therapeutic
strategies aimed at the abnormal kinetics leading to fibril deposition.
In his follow-up paper in 1950 [76], Ostertag reported 3 other members of the
family who died aged 18, 36 and 43 years, with a clinical diagnosis of amyloid, in
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addition to the 2 brothers whom he previously reported their post-mortem findings. In
this paper, he speculated that the amyloid, which by that time was known to be derived
from proteins, was likely to be caused by a mutation associated with the protein.
Descendants of this family, if any, have not yet been identified and the nature of the
disease remain uncharacterised. Phenotype in the Ostertag family was distinguished by
presentation with early development of hypertension and renal failure, and at autopsy,
there was massive infiltration of amyloid in the clinically enlarged liver and spleen.
Renal amyloid was confined to the glomeruli and the heart was not affected. This
description is most closely resembled by the apoAI families, especially the Arg50
family, who originated from Poland and therefore also geographically closet to
Ostertag, apart from the German fibrinogen Val526 variant family whose phenotype
was however very different with minimal liver involvement and late-onset disease. The
phenotype-genotype relationship in the Ostertag family may never be determined, but it
is clear from the 12 families where the disease has been fully characterised that within a
family, this is a monogenic disease with an autosomal dominant pattern of inheritance.
The aberrant genes of which carriers are all heterozygotes, was in all families due to a
point mutation encoding single residue substitutions, except for one family with the
apoAI deletion mutation. The mutant genes appear to have a high degree of penetrance
and phenotypically, they are identified by exclusive visceral organ involvement with
invariable renal amyloid deposition but marked absence of nerve involvement. Timing,
severity and distribution of other organ involvement may however, vary. Frequently
fatal within 10 years of diagnosis, the prognosis has been considerably improved with
renal supportive therapy, and in some, liver transplantation as a surgical form of genetic
therapy may be potentially curative [1, 13],
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Chapter 5 - Hereditary Transthyretin Amyloidosis
Familial amyloid polyneuropathy with predominant cardiac involvement
associated with a novel variant of transthyretin, Thr59Lys, in an Italian
family
Introduction
Cardiac amyloidosis is a distinct form of cardiomyopathy which usually carries a
grave prognosis [142], Amyloid deposits are largely composed of protein fibrils, the
precursors of which differ in different forms of the disease, and clinical amyloidosis
syndromes are classified according to the identity of these proteins and whether the
disorder is acquired or hereditary [1, 11], It is essential to characterise the underlying
process in all cases since this may have major implications for prognosis and treatment.
Hereditary forms of amyloidosis are rare but are extremely serious for the affected
families and are also valuable models for understanding the pathogenesis of amyloid
deposition in general. This is important because clinically significant amyloidosis is not
rare [1]: localised amyloid deposits in the brain are a hallmark pathological feature in
Alzheimer's disease and amyloid is present in the islets of Langerhans of the pancreas in
most patients with Type II diabetes mellitus. Systemic forms of amyloidosis are less
frequently encountered but their management is a major challenge.
Clinically significant acquired cardiac amyloidosis is usually of AL (formerly
known as primary) type, in which the amyloid fibril protein is derived from monoclonal
immunoglobulin light chains [1, 142], Although so-called senile cardiac amyloid, in
which normal wild-type transthyretin (TTR) is the fibril protein, is very common in the
elderly, it is rarely symptomatic [142, 143], Hereditary cardiac amyloidosis presents
from the third decade onwards and usually occurs in the context of familial amyloid
polyneuropathy (FAP) [142, 144], associated with peripheral and autonomic
neuropathy which dominate the clinical picture, although there are families in which
cardiac involvement has been the major or only clinical feature. The amyloid fibril
protein in most kindreds with FAP is derived from variant TTR. In each family the
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variant contains a single amino acid substitution encoded by a point mutation in the
TTR gene, and more than 40 such mutations, inherited in an autosomal dominant
pattern, have been identified [1, 110],
Here we report an Italian family with a new variant of TTR associated with
hereditary amyloidosis and a predominantly cardiac presentation. Interestingly the
clinical features in several of the affected individuals strongly suggested ischaemic heart
disease. This family illustrates the diverse phenotypic expression of amyloidogenic
mutations and underscores the importance of early diagnosis in cardiac amyloidosis.
Methods
Clinical Evaluation ofPatients
Clinical details and the results of routine investigations were available on 7
members of an Italian family who all presented with cardiac disease. Cardiac
investigation included 12-lead electrocardiography, 24 hour Holter rhythm monitoring
and detailed echocardiography with Doppler analysis. Cardiac catheterisation,
endomyocardial biopsies and electrophysiological studies were performed in some
cases. Limited autopsies were obtained in 3 cases.
Histology
Tissue was available from each case, obtained during life in four, and at autopsy
in the remainder. Myocardial tissue was studied in 6 cases, rectum in 2, and small
intestine and sural nerve biopsies in 1 case each. Amyloid was identified by Congo red
staining with pathognomonic green birefringence when viewed under crossed polarised
light [4],
Immunohistochemical Staining
For detection of TTR, sections were first incubated overnight with 1% w/v
sodium-m-periodate for 10 minutes, 0.1% w/v sodium borohydride for 10 minutes and
6 mol/L guanidine hydrochloride in 0.9% w/v NaCl, to enhance immunoreactivity.
After washing with saline non-specific binding was blocked by incubation with
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10% (v/v) normal non-immune goat serum in 10 mmol/L Tris-buffered saline (TBS) for
60 minutes at room temperature. Sections were then incubated overnight at 4°C with
specific polyclonal rabbit anti-human TTR antibodies (Dako Ltd, High Wycombe,
Bucks, UK) diluted 1:400 in TBS containing 1% (v/v) normal goat serum. Specificity
of staining was established by reacting adjacent serial sections with the same dilution of
antiserum previously absorbed with pure human TTR to remove all anti-TTR activity.
After these primary reagents, the slides were washed on a rotating platform, twice with
TBS containing Triton X-100 (BDH Laboratory Supplies, Lutterworth, Leics, UK)
0.005% (v/v) and once with TBS alone prior to incubation for 60 minutes at room
temperature with polyclonal goat anti-rabbit antiserum (ICN Biochemicals Ltd, Thame,
Oxon, UK) 1:50 in 5% (v/v) normal human serum. The washing as above was repeated
and sections were then incubated at room temperature for 60 minutes with rabbit
peroxidase-anti-peroxidase complexes (PAP) (Serotec Ltd, Kidlington, Oxon, UK)
1:50 with 1% (v/v) normal goat serum in TBS. After another wash cycle to remove
unbound rabbit PAP, bound enzyme was detected using 3,3'-diaminobenzidine
tetrahydrochloride (Sigma Chemical Co Ltd, Poole, Dorset, UK) 0.05% (w/v) in TBS
containing 10 mmol/L imidazole (BDH Laboratory Supplies, Lutterworth, Leics, UK),
and 0.002% (v/v) H202 (Taab Laboratory Equipment Ltd, Reading, Berks, UK) as
substrate. Separate sections were stained using antisera against other known amyloid
fibril proteins: k and A. immunoglobulin light chains, amyloid A protein,
apolipoprotein AI and lysozyme.
Radiolabeled SAP Scintigraphy and Turnover Studies
Whole body scintigraphic imaging and a 24 hour plasma turnover study were
performed in one patient (III.4) using 123I-labelled serum amyloid P component (SAP),
as previously described [58, 59], Briefly, anterior and posterior whole body scans and
regional images were obtained with an IGE Starcam gamma camera 24 hours after i.v.
injection of 123I-labelled SAP (200 MBq of activity associated with 100 pg of pure
protein). The decline of radioactivity was measured in the plasma over 24 hours and
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activity was also estimated in the complete collection of urine obtained for 24 hours
after isotope administration.
Isolation ofDNA andAmplification and Sequencing of TTR Gene
DNA was extracted from whole blood [73] and TTR exons were amplified by
the polymerase chain reaction (PCR) using taq polymerase (Amplitaq, Perkin Elmer
Cetus, Norwalk, CT) with the following cycling conditions: One cycle of 94°C,
5 minutes; 35 cycles of 94°C for 1 minute, 60°C for 1 minute, and 72°C for 1 minute;
and a final step of 72°C for 10 minutes. For exon 1 intron sequences, (5' to 3'),
CAGCAGGTTTGCAGTCAGAT and GGTACCCTTGCCCTAGTAAT were used, for
exon 2, CAATTTTGTTAACTTCTCACG and CAGATGATGTGAGCCTCTCTC;
exon 3, CCTCCATGCGTAACTTAATCC and TAGGACATTTCTGTGGTACAC;
exon 4, TGGTGGAAATGGATCTGTCTG and TGGAAGGGACAATAAGGGAAT.
PCR products (100 pL) were purified by size fractionation on a Nusieve
agarose gel (FMC, Rockland, ME). The band was extracted using Magiprep columns
(Promega, Madison, WI), recovered by ethanol precipitation and dissolved in 12 pL of
distilled water. Six pL was then used in the sequencing reaction for each primer.
The sequencing reaction was modified from Casanova et al [74], A reaction
mix containing 2 pL of sequencing buffer, 2 pL of primer (100 ng/pL) and 6 pL of
template was boiled for 2 minutes, before freezing in a dry ice/methanol bath for
15 seconds, and then adding 5 pL of Mastermix. Just after the mixture thawed, 3 pL
was added to 2.5 pL of each of the four dideoxynucleotides and the termination
reaction was then incubated at 37°C for 2 minutes before addition of 4 pL of stop
solution. The same primers were used for PCR and sequencing, except that for exon 4
the primer (5'-3'), CTCGTCCTTCAGGTCCACTG, was used since, for unknown




The 7 patients presented with chest pain typical of angina pectoris (n=4), with
exertional dyspnoea (n=l), or with sudden cardiac death (n=2) (Figure 5.1, Table 5.1).
Two patients died suddenly shortly after presenting with chest pain.
Electrocardiography, obtained in 6 cases, demonstrated reduction in standard lead
voltages and a pseudo-infarct pattern (characterised by deep Q waves in the inferior and
septal leads) in each patient (Figure 5.2). First degree atrio-ventricular block was
present in one case. Echocardiography, performed in 3 cases, demonstrated massive
concentric thickening of the left ventricular wall, mean approximately 18 mm, with
small internal left ventricular dimensions and good systolic function; Doppler studies
showed a restrictive filling defect in each case. There was no evidence of atheromatous
coronary artery disease at angiography or at autopsy (3 cases each). Ventriculography
showed normal contractility in each of 3 cases and mild mitral regurgitation in 2
patients. LVEDP was elevated to about 25 mmHg in each case, and pressure tracings
showed a restrictive (deep-plateau) pattern. Pulmonary artery pressure was elevated to
approximately 45/25 in the 3 patients studied and the cardiac index was within normal
limits. Twenty-four hour ambulatory ECG monitoring was performed in 2 patients, and
in each demonstrated frequent ventricular extrasystoles; ventricular tachycardia was
induced during electrophysiological studies in one patient and abolished following oral
amiodarone therapy, 800 mg daily, for one week.
Evidence of clinically significant amyloid deposition outside the heart was
apparent at presentation in only one case (Table 5.1, patient III.5), in whom there were
neuropathic features typical of FAP. Autonomic and peripheral neuropathy developed
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Figure 5.1 Family tree of the Italian kindred with hereditary cardiac amyloidosis.
Individual 1.2 (hatched symbol) is suspected of having had amyloidosis. The only
clinically affected living member of the family, individual III.4, is aged 62.
Figure 5.2 Electrocardiogram of individual III.3, showing the low voltage in the
standard leads and the infero-septal pseudo infarct pattern which characterised the
electrocardiograms of all cases in whom they were available.
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Histology and Immunohistochemistry
Congo red stains confirmed the presence of abundant amyloid deposits in all
biopsy specimens from each of the 7 cases. Cardiac histology was similar in each case
and showed regularly arranged muscle fibres exhibiting hypertrophy or atrophy. There
was some interstitial fibrosis and very extensive amyloid deposition. The
intramyocardial arteries were also heavily infiltrated with amyloid, causing significant
luminal narrowing in some areas. The abundant Congophilic amyloid deposits in
myocardial and rectal biopsy tissue from patient III.5 all reacted strongly with an
antiserum to TTR (Figure 5.3), but not with antisera to other known amyloid fibril
proteins. The TTR immunoreactivity was completely abolished by prior absorption of
the antiserum with pure TTR (Figure 5.3).
RadiolabelledSAP Studies
!23I-SAP scintigraphy in patient III.4 demonstrated the presence of unsuspected
amyloid deposits in the spleen and both kidneys. Plasma and whole body turnover of
the tracer fell within our reference range for normal subjects [60], indicating that less
than 10% of the activity had localised to amyloid, consistent with a relatively modest
whole body amyloid load.
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Figure 5.3 TTR amyloid in tissues of patient III.5. A, Myocardium stained with
Congo red and viewed in crossed polarised light, showing massive infiltration with
brightly birefringent amyloid deposits. B, Myocardium stained with monospecific
antiserum to TTR, showing extensive dark peroxidase reaction product. C,
Myocardium stained with antiserum to TTR which had been absorbed with isolated
pure TTR, showing complete absence of reactivity. D, Rectal submucosa stained with
monospecific antiserum to TTR, showing extensive dark peroxidase reaction product.
E, Rectal submucosa stained with antiserum to TTR which had been absorbed with
isolated pure TTR, showing complete absence of reactivity. All illustrations are at the
same magnification; the magnification bars correspond to 100 pm.
Characterisation of the TTR Gene
Amplification and direct sequencing of all four exons of the TTR gene [145] in
patients III.3 and III.4 showed that they were heterozygotes with a single base change
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in one allele, altering the codon for residue 59 of the native protein from ACA (Thr) to










Figure 5.4 Nucleotide sequence of part of exon 3 of the TTR gene from patient
III.3 (right), compared to a healthy subject (left). The patient was a heterozygote for a
single base change in one allele altering the codon for residue 59 from the wild type
ACA encoding Thr to AAA encoding Lys. An identical result was obtained in patient
III.4, the only other family member from whom DNA was available.
Discussion
Members of two, and probably at least three, generations in this family have
been affected by amyloid heart disease apparently transmitted as an autosomal dominant
trait. The presence of the TTR Lys59 gene mutation, TTR in the amyloid deposits and
the absence of any other TTR variant provide compelling evidence that this mutation,
which has not been reported previously, is causative. Normal wild-type TTR is
inherently amyloidogenic, being deposited in acquired senile amyloidosis [143], and
more than 40 different point mutations in the TTR gene have been associated with
hereditary amyloidosis [41, 110], The structure of TTR has been defined to atomic
resolution and each protomer consists of an a-helix, 8 (3-strands forming two
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face-to-face sheets, and their connecting loops [146], Mutations in (3-strand C, the CD
loop, and (3-strand D region are particularly likely to be amyloidogenic [147], 59^ is
situated in this part of the molecule and is highly conserved in mammalian and avian
TTR sequences [148], suggesting that it is important for the molecular structure and/or
function of TTR. Indeed displacement within the CD loop and D strand, which may be
induced even by quite distant substitutions, has been proposed as the final common
pathway for TTR fibrillogenesis via aggregation of edge P-strands [147],
Hereditary TTR amyloidosis usually presents as FAP with peripheral and
autonomic neuropathy dominating the clinical picture, although the amyloid is always
systemic and symptomatic involvement of the heart and kidneys is common. However,
six TTR variants (45Thr, 60^, 60Leu, 89Gln, 11 lMet and 122De) have been reported in
association with predominantly cardiac amyloid and minimal signs elsewhere [149],
The clinical features of affected members of the present family were very diverse (Table
5.1), with amyloid involvement of different organ systems and at ages between the fifth
and the seventh decade. One subject, III. 5, presented with severe neuropathic features
identical to those typically seen in FAP, and similar features developed in her brother,
subject III.3, 2 years after he had presented with cardiac disease. The factors, other
than the TTR mutation itself, which govern the penetrance, age of onset and tissue
distribution of amyloidosis associated with variant TTR are unknown.
A prominent feature among patients in this family was chest pain, with the
characteristic quality of angina pectoris. This is an unusual symptom of cardiac
amyloidosis, although it has been described before, and its basis is probably
multi-factorial. Increased ventricular wall tension during diastole, infiltration of the
interstitial space between myocardial cells and reduced blood flow through small distal
coronary arterioles, the lumens of which were partially obliterated by amyloid in this
family, may all contribute. Three family members had sudden cardiac deaths suggesting
a dysrhythmic aetiology. Potentially life-threatening ventricular arrhythmias were
detected in electrophysiological studies of 2 surviving individuals which, notably,
responded to conventional therapy with amiodarone. The rhythm disturbances may
have been precipitated directly by amyloid deposits and/or by ischaemia.
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This family study highlights some of the common difficulties faced by the
clinician when a diagnosis of cardiac amyloid is suspected. The clinical features
masqueraded as those of ischaemic heart disease, and echocardiography suggested
severe left ventricular hypertrophy raising the possibility of hypertrophic
cardiomyopathy. Endomyocardial biopsy is essential to confirm the presence of cardiac
amyloid, but unless immunohistochemical studies are performed in addition to Congo
red histology, the type of amyloid cannot be defined. The clinical features of amyloid
neuropathy and heart disease in patient III. 5 were originally presumed to be those of
AL amyloidosis which frequently presents in this manner. A family history should
routinely be sought, and if more than one first degree relative has cardiac amyloidosis
or if the amyloid is found to be of TTR type in a non-elderly patient, analysis of the
TTR gene should be undertaken.
Restriction fragment length polymorphism and single strand conformational
polymorphism analyses have been widely used to seek TTR gene mutations, and even
more sophisticated indirect approaches, such as PCR-primer-introduced restriction
analysis, have been reported [150], Restriction fragment length polymorphism analysis
is not applicable for the present mutation because it neither creates nor abolishes a
restriction enzyme site. However, the most precise and unambiguous method for
detecting mutations, with the least potential for erroneous results, is direct sequencing,
as reported here [151], This can be undertaken in any routine molecular genetic
laboratory.
Characterisation of the molecular defect causing hereditary cardiac amyloidosis
in our family has implications for treatment. The circulating TTR is produced almost
exclusively in the liver and we have previously shown that orthotopic liver
transplantation in familial amyloid polyneuropathy due to TTR mutations eliminates
variant TTR from the circulation and is followed by clinical improvement [50, 116],
More than 70 cases of TTR associated FAP have now been treated by liver replacement
and the majority have benefited clinically (Proceedings of the First International
Workshop on Liver Transplantation in FAP, Stockholm, September 1993,
unpublished). SAP scintigraphy, a quantitative method for surveying the whole body
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distribution and extent of amyloid, has shown that the systemic amyloid deposits regress
significantly within 1-2 years after surgery [50], These findings are consistent with
those we have obtained in systemic AA and AL amyloidosis, in which major regression
of amyloid frequently also occurs when the supply of the amyloid fibril precursor
protein is substantially reduced [12, 49],
Another life-saving option in our family is cardiac transplantation, although
without simultaneous liver replacement cardiac amyloid deposition is likely to recur.
Even if the time course of amyloid deposition in the donor heart was slow, and indeed it
may take decades, it is probable that clinically important amyloid in other organ systems
would develop. In July 1992 we performed simultaneous heart and liver transplantation
in a 62 year old man with FAP associated with the 77Tyr variant of TTR. He is alive and
well with increased general well-being, having gained weight, and with subjective and
objective electrophysiological evidence of improved autonomic and peripheral nerve
function. This radical but potentially curative approach is currently under consideration
in the present family.
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Transthyretin Asp18Glu, a new variant associated with familial amyloid
polyneuropathy.
Introduction
Familial amyloid polyneuropathy (FAP) is an adult onset autosomal dominant
disease characterised by systemic amyloid deposition which most frequently involve the
nerves, heart, vitreous and kidneys [1], The disease is most commonly associated with
variant plasma transthyretin (TTR) and more than 40 different variants have now been
identified [41], A novel TTR variant in a woman with TTR amyloidosis is described
here.
Material and Methods
The proband, who was originally from Colombia, first presented age 51 years
with floaters in her right eye which was unsuccessfully treated with laser therapy. The
following year investigations for symptoms of heart failure revealed cardiac amyloidosis
on biopsy. She then developed features of autonomic neuropathy characterised mainly
by postural hypotension and diarrhoea. Although there were no symptoms referable to
the peripheral nervous system, nerve conduction studies demonstrated a degree of small
fibre neuropathy but no evidence for large fibre disease. Her floaters were successfully
treated by excision of the vitreous opacities.
There was a strong family history of heart disease in the proband's family who
remains in Colombia. Her mother died age 61 years of heart disease. Both her siblings
and one maternal uncle also had heart disease. She was married but have no children.
Cardiac biopsy and the excised vitreous mass were examined by Congo red
staining [4] and by immunohistochemical staining using a wide range of antibodies
directed against known amyloid proteins [113], Amyloid fibrils extracted from the
vitreous mass was characterised by immunoblotting with anti-TTR antibodies [37],
DNA extracted and amplified from the proband's white blood cells was subjected to
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direct dsDNA sequencing [113]. A 123I-labelled SAP scan, an in vivo technique for the
identification of systemic amyloid deposits was performed [58, 59],
Results
Amyloid deposits in the cardiac biopsy and vitreous mass were identified by
Congo red staining. Immunohistochemical studies of vitreous amyloid demonstrated
positive staining only with anti-TTR antibodies and the staining was abolished by
absorption with pure human TTR. Immunoblot of fibril proteins extracted from the
vitreous mass confirmed that the fibrils are derived from TTR. Direct dsDNA
sequencing confirmed that the proband was heterozygote for a novel point mutation in
exon two of the TTR gene resulting in a codon change from GAT to GAG, encoding a
single amino acid substitution of aspartic acid by glutamic acid in position 18 of the
mature protein (Figure 5.5). There was no evidence for significant extra-cardiac
systemic amyloid deposits on scintigraphy.
Discussion
Genetic analysis revealed a new TTR variant, Glul8, in a patient with TTR
amyloidosis. The genotype-phenotype relationship between TTR variant and TTR
amyloidosis is well established [1, 14, 41] and this patient's clinical course is consistent
with disease due to FAP. The hereditary nature of the disease is suggested by the
strong family history of heart disease but unfortunately tissue was not available for
analysis to demonstrate the Mendelian inheritance in this kindred.
The TTR subunit is rich in [3-sheet structure [152], a property commonly found
in amyloid precursor proteins and indeed may be an important factor determining the
amyloidogenecity of wild-type TTR associated with senile systemic amyloidosis. Point
mutations encoding single substitutions appear not only to increase the amyloidogenic
potential of the TTR molecule, probably by a destabilising effect on the secondary
structure of the protein, but also results in disease of a different phenotype. Flowever,
1
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not all TTR mutations are amyloidogenic [41] and amongst the 40 amyloidogenic
variants, there is no obvious pattern to the substitutions which are widely distributed
throughout the length of the protein, although there are several mutation hot spots.
There is also considerable heterogeneity in the clinical spectrum of FAP, even amongst
kindreds with the same mutation, suggesting that factors other than the mutations are
important in determining pathogenesis in this apparently monogenic disease. The
importance of these non-genetic factors is further illustrated by the finding that unlike
most autosomal dominant diseases, gene dosage may not adversely influence the age of
onset and severity of symptoms in FAP. Indeed there are individuals homozygous for
TTR Met30 who have remained asymptomatic throughout life [153],
Our description of TTR Glul8 adds to the increasingly heterogeneous mixture
of TTR variants associated with FAP. This is also the first Colombian family reported
to have the disease which most commonly affect populations in Portugal, Sweden, and
Japan. However, with the increasing recognition of this disease and ready availability of
routine molecular biological investigative techniques, the wider population distribution
of the disease will continue to be increasingly recognised and reported.
Glu 18 Heterozygote
G A T C
T G
A A . - - =J .' , w*6
G G
Aspl8 / GIu 18
Figure 5.5 Nucleotide sequence of part
of exon 2 of TTR gene of the patient,
showing that she was heterozygous for a
point mutation resulting in codon change
from GAT to GAG which encodes
substitution of wild type residue (aspartic
acid) by glutamic acid at position 18 of the
mature protein.
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Chapter 6 - Dialysis-related amyloidosis
Long term effect of renal transplantation on dialysis-related amyloid
deposits and disease symptomatology: A prospective 5 year study
Introduction
Dialysis-related amyloid (DRA), a potentially crippling complication of dialysis-
dependent renal failure, is now a major cause of morbidity in long-term dialysis
populations [1, 65], Its major clinical manifestations are related to the accumulation of
amyloid deposits within synovial membranes, resulting in carpal tunnel syndrome (CTS)
and dialysis arthropathy which is characterised by arthralgias of the large and medium
sized joints. Although articular tissue is the main site of deposition, systemic
distribution of DRA is a well described and common but late event that may become
clinically significant [154], The precursor protein ofDRA deposits is P2-M [23], a low
molecular weight protein expressed by all nucleated cells which is normally catabolised
by renal tubules. However, this tubular function of normal kidneys is poorly replaced
by dialysis, causing uraemic retention of P2-M, a process that is evidently necessary for
the pathogenesis of the disease [1, 65],
Specific treatment of DRA is therefore aimed at increasing clearance of P2-M
which is not removed by conventional haemodialysis (HD) with standard cuprophane
membranes. Continuous ambulatory peritoneal dialysis (CAPD) [155], high flux
dialysis [156], immunoadsorption columns [157], and especially haemofiltration [158]
may all reduce but not normalise P2-M levels, a metabolic event that can only be
achieved effectively with a successful renal transplant (Tx). In a recent radiological
study [159], restoration of normal P2-M metabolism following a successful renal Tx
was accompanied by rapid resolution of the clinical features of DRA, and a halt in
disease progression.
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We have recently [160] described a scintigraphic method for the non-invasive in
vivo diagnosis ofDRA which is based on the specific binding of serum amyloid P (SAP)
component, a universal constituent of all amyloid deposits [35], to amyloid fibrils. In
that study [160], we demonstrated that 123I-labelled SAP is sensitive and specific for the
diagnosis of DRA in long-term HD patients. We now report results of a prospective
follow-up study on this original cohort of patients to assess the effect of renal
transplantation on clinical, radiological, and scintigraphic features of DRA deposits,
compared to a control group of patients who remained on HD.
Methods
Patients
Fifteen patients with clinical and histological evidence of DRA, (aged
41-66 years, 10 males, 5 females) who had undergone haemodialysis for a median of
18 years (interquartile range, 14-21 years) were studied prospectively for 5 years. At
completion, 6 patients (Table 6.1) were still receiving dialysis (HD group) whereas 9
(Table 6.2) had successfully undergone renal transplantation (Tx group). Three Tx
patients had been transplanted shortly before recruitment. The median duration post
transplantation was 4.5 years (range, 2-7.5 years). The HD and Tx groups were similar
with respect to follow-up period, age, sex and total duration of dialysis.









































































































































































































Clinical features of dialysis arthropathy were evaluated by a rheumatologist.
At baseline each affected hip, knee, shoulder and wrist, including carpal tunnel
syndrome (CTS), scored one point (maximum 8 points). At completion, each joint
scored 2 ifworse (maximum 16 points), one if unchanged, 0.5 if improved, or zero
if features had resolved. An additional point was given for any joint affected at
follow-up which had been normal at baseline. The relationship between symptoms,
renal transplantation and corticosteroid dosage was recorded.
Radiology
X-rays of the hands, wrists, knees, shoulders and hips were obtained at
approximately yearly intervals. Previous films were available in each case. The
baseline radiologic joint score comprised one point for each amyloid bone cyst
identified using rigorous criteria as summarised in Table 6.3 [161], At completion,
cysts that were larger scored 2, one if unchanged and 0.5 if smaller. No cyst
resolved completely and new cysts scored an additional point. Radiographs were
evaluated "blind" by an experienced skeletal radiologist. In two cases some X-rays
were missing.
1231-labelled SAP scans and metabolic studies
Isolation and radiolabelling of human SAP with 123I and 125I, scintigraphy,
and turnover studies were performed as described [58-60], although the latter were
necessarily limited to plasma clearance measurements in anuric patients.
Scintigraphs were assessed anonymously by two physicians with experience of 1000
such studies. Serial scans were unavailable for the wrists in one patient and knees in
another. Baseline images of the shoulders, wrists, knees and hips were scored one
point for each joint in which there was abnormal uptake of tracer (maximum 8
points). At completion each joint scored 2 points if uptake was greater (maximum
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16 points), one if unchanged, 0.5 if improved, or zero if the images fell within
normal limits; an additional point was given for any joint that became abnormal
during the study.
Table 6.3 Radiological characteristics ofDRA bone cysts *
At least 5 mm diameter in the wrists
At least 10 mm diameter in the shoulders and hips
Multiple
Affect at least 2 joints
Periarticular in distribution
Joint space adjacent to cysts must be normal
(to exclude subchondral bone cysts of osteoarthritic origin)
Grow in size by > 30% per year (to be considered significant)
Located outside areas prone to have "synovial inclusions"
(such as upper third of femoral neck or anatomical humeral neck)
Located outside weight bearing area of the joint
(such as outer third of acetabulum)
*Kidney International 1991;Vol 39:1012-1019
Histology
Biopsies obtained during the study were subjected to routine
examination, staining with Congo red [4] and immunohistochemistry with




Serum concentration of(32-M, SAP and creatinine
(32-M and creatinine levels were measured in venous blood using standard
autoanalyser techniques. SAP concentration was determined by
electroimmunoassay [163],
Statistical analysis
Demographic differences between the patient groups and results of
metabolic measurements were sought using the Mann-Whitney U test. Scores for
symptoms, scans and X-rays were analysed using the Wilcoxon rank tests for paired
samples and unpaired groups. P < 0.05 was deemed significant.
Results
Symptoms
At baseline all patients had symptoms of DRA, with the same median of 4
affected joints in each group. Surgery for CTS had been performed a median of
once per patient in each group.
Four of the 6 HD patients experienced worsening arthralgia, and recurrence
or development of CTS (Table 6.1), 2 of them requiring surgery. The two patients
without progressive symptoms had the shortest follow up.
In the Tx group, 8 of 9 patients reported rapid and substantial relief of
arthralgia following transplantation (P = 0.01 for scores at entry and end of study)
(Figure 6.2). This was sustained despite reduction (N= 5) or complete withdrawal
(N= 4) of corticosteroids, although symptoms recurred transiently in 2 cases whilst
tapering. No Tx patient required surgery for CTS. DRA symptoms remained after
transplantation in one case.
The difference between symptom scores for the HD and Tx groups at
completion was significant, P = 0.018. The difference between the changes in
scores from entry to end of study in the two groups was also significant (P = 0.018).
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Radiology
Amyloid bone cysts were most common in the wrists followed by the hips,
shoulders and knees (Table 6.4). Among patients with baseline radiologic
abnormalities, the median number of affected joints per patient was 3.5 in the HD
group and 3 in the Tx group, whilst the median number of cysts per affected joint
were 2 and one respectively.
Among the HD patients, 18 DRA bone cysts in four cases were identified at
baseline. At follow-up (Table 6.4, Figure 6.3) the cysts were larger and there were
7 new cysts, a significant deterioration (P = 0.018). In contrast, among the 5 Tx
patients with baseline radiographic abnormalities, cyst size decreased and there was
ossification in the cyst walls (Figure 6.7) in 4 affected joints in 4 patients. None of
the 24 cysts resolved (Table 6.4, Figure 6.4), but there was a significant difference
between the HD and Tx scores at completion (P = 0.02). Changes in score during
the study were also significantly different between the groups (P = 0.018).
123I-labelledSAP scintigraphy
Positive scans of at least the wrists were obtained at baseline in all subjects
except one HD patient (Figure 6.5). Amyloid was identified frequently in the knees
and, less often, the shoulders. Images of hips were non-diagnostic because of their
deep location and proximity to the strong masking signal from tracer in the central
blood pool. Amyloid was not identified in any other site.
DRA was progressive in 5 of 6 HD patients (Figure 6.5): 5 additional joints
gave positive images and there was increased tracer uptake in 7 joints that were
positive at baseline (Figure 6.8). Follow-up studies were unchanged in one HD and
one Tx patient. In each of the 8 other Tx patients, amyloid deposits regressed
(Figure 6.9) in at least one site (Figure 6.6) with tracer uptake reduced in 16 of the
41 joints identified as abnormal at baseline, P-O.Ol. Amyloid decreased below
limits of detection (Figure 6.10) in 6 joints in 3 patients, including all 3 affected
joints in one case. Changes in joint score at baseline and completion were
significantly different between the two groups, P = 0.018.
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Histology
During the study tissue was resected at carpal tunnel release in 2 HD
patients, and at spinal surgery in 2 Tx patients, one with a fractured cervical
vertebra, the other during a decompressive procedure. All tissues contained
amyloid that stained specifically for P2-M.
Serum concentration of(12—M, SAP and creatinine
Among Tx recipients serum levels of (32-M and creatinine were significantly
lower at completion (median values 3.2mg/litre and 117 pmol/litre respectively)
than at baseline (45.5 mg/litre and 954 pmol/litre) (P < 0.001), corresponding with
restored renal function. The concentration of SAP, which is raised in renal failure
[164], also fell following Tx, but not significantly. No changes in serum levels of






Figure 6.1 Joint scores for symptoms for individual haemodialysis (N
patients at entry and end of study
study study
Figure 6.2 Joint scores for symptoms for individual renal transplant (N







Figure 6.3 Joint scores for X-rays for individual haemodialysis patients (N = 6)
at entry and end of study
study study
Figure 6.4 Joint scores for X-rays for individual renal transplant (N = 9) patients
at entry and end of study
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Figure 6.5 Joint scores for SAP scintigraphy for individual haemodialysis (N
6) patients at entry and end of study









Figure 6.6 Joint scores for SAP scintigraphy for individual renal transplant (N =
9) patients at entry and end of study
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Entry Completion Entry Completion
Wrists 18 18 14 14
Shoulders 0 0 2 3
Hips 5 5 2 8
Knees 1 1 0 0
Total 24 24 18 25
Metabolic studies
Plasma clearance of 123I-SAP, which reflects whole body amyloid load, was
obtained in 4 HD and 8 Tx patients. The plasma concentration of 123I-SAP after 6
hours, expressed as the mean (SD) percentage of the injected dose, was 75% (8) at
baseline in the HD group and 69% (1) at completion, compared with 75% (4.5) and
76% (7) respectively in the Tx group. These trends were not statistically significant.














Figure 6.8 Serial 123I-SAP scans showing progression ofDRA in the hands of a
67 year old lady who developed symptomatic DRA in both wrists after 6 years on
HD. Images obtained in 1991 (left) show abnormal uptake of tracer into amyloid
deposits in the wrists and some small joints of the hands; uptake was greater in
1994 (right).
Correlation between clinical features, radiology, scintigraphy and histology
The most frequent presenting feature of DRA was CTS followed by
shoulder arthralgia. Scintigraphy and X-rays were positive most often in the wrists.
Positive scintigraphy of at least one joint was seen initially in 14/15 (93%) of
patients whereas radiologic bone cysts occurred in only 9 (60%) of cases. This is
much higher than the 9% of 221 patients found to have positive bone radiology in
another study [161] which adopted a similarly rigorous criteria for radiological
definition of amyloid bone disease. However, in that study, half the patients were
dialysed on high flux membranes which were found to delay the onset of bone
amyloidosis, and, in addition, radiologically affected patients had been dialysed for a
mean period of only 9 years compared to the mean dialysis period of 17.4 years for








Haemodi.iKsis 1971, Renal Tx 1991
Figure 6.9 Serial 123I-SAP scans showing regression of DRA in a 63 year old
man, who was treated with HD for 18 years before undergoing renal transplantation
in 1991. Intense abnormal localisation of tracer to the wrists in 1989 (left),
greatest in the most symptomatic right hand, is substantially reduced in the follow-
up images obtained in 1993, nearly 3 years after transplantation (right).
At completion, among 31 joints affected clinically in HD patients, DRA was
evident radiologically in 11 (35%), and scintigraphically in 17 (55%). Characteristic
symptoms were the sole clinical feature of DRA in 8 (26%) of the joints.
Conversely, among 32 joints with radiological and/or scintigraphic evidence of
amyloid, 9 (28%) were asymptomatic; 2 out of 8 joints with sub-clinical DRA at
baseline became symptomatic subsequently.
All but one Tx patients experienced profound reduction of DRA symptoms
whilst one or both imaging modalities provided evidence of amyloid regression in
every case. Amyloid could not be detected in scans of 8/41 (20%) joints that had
previously been abnormal, although this does not necessarily indicate complete
resolution. Scans showed improvement in a further 16/41 (39%) joints. Radiology
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also showed some improvement, but to lesser extent and among fewer joints (4/13,
31%). Overall, radiology and scintigraphy improved much less than clinical
symptoms.
Baseline wrist radiology and scintigraphy had been positive in both HD
patients who developed CTS requiring surgery, but spinal imaging of the 2 Tx







Haemodialysis 1971, Renal Tx 1991
Figure 6.10 Serial 123I-SAP scans showing regression of DRA in a 63 year old
man, who was treated with HD for 18 years before undergoing renal transplantation
in 1991. There is abnormal uptake of tracer into both knees in 1989 (left) followed




In patients with DRA, a successful renal Tx results in rapid resolution of
symptoms of dialysis arthropathy [65, 159, 165], In addition to confirming these
findings, we have in our study also demonstrated that this early symptomatic relief is
preserved up to 7.5 years post-Tx despite subsequent withdrawal or reduction in
steroid dosage. Until recently, symptomatic relief achieved following a successful
Tx was thought to be due largely to the anti-inflammatory effect of steroids [65,
159], This was supported by a study [166] reporting the beneficial effect of low
dose oral steroids in dialysis patients with DA and the observations [167] that
similar improvement was seen in 2 patients primed with intravenous steroids but not
grafted. However, although steroids may modulate DRA symptomatology in the
short-term, our unique observations suggest that other factors operational
immediately post-Tx and preserved in the longer-term with good graft function are
responsible.
Amyloid fibrils was previously thought to be largely inert, causing organ
damage mainly by its physical presence. However, recent in vitro studies have
shown that amyloid fibrils may be directly toxic to surrounding cells [99, 168], This
toxic effect is seen only in cells in direct physical contact with the fibrils [99] and is
mediated by the induction of apoptosis or programmed cell death. It is therefore
possible that target organ damage and local disease symptomatology are caused by
similar mechanisms or toxic factors induced in vivo by active fibril formation and
deposition, a process that is halted once further fibril formation ceases following a
successful Tx.
It is also possible that DRA symptomatology is dependent on the uraemic
state seen in dialysis-dependent renal failure which contain uraemic toxins or
"middle molecules" which are too large to be dialysed and thought to be responsible
for much of the morbidity seen in patients with renal failure [169], There are several
possible candidates, including (32-M itself, which is biologically active as a bone-
derived growth factor capable of inducing release of fibroblast collagenase [170]
and bone remodelling [171], and these, together with its high affinity for collagen
[172] are properties which may encourage active amyloid deposition in articular
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tissue, a process that may as discussed, be an important local determinant of disease
symptomatology.
Finally, the process of dialysis itself may play an important role in both
disease pathogenesis and symptomatology [65, 165], Development ofDRA may be
delayed by predominant use of high flux dialysis [161, 173, 174] and in patients who
are already affected by DRA, conversion to high flux dialysis may be accompanied
by substantial improvement in symptoms of dialysis arthropathy [175, 176], Our
own preliminary observations with CAPD patients [177] also suggest that clinical
expression ofDRA may be different with this mode of dialysis. In the present study,
the most striking evidence was provided by a patient (BJ) whose symptoms of DA
(which had resolved completely 2 years earlier following a successful Tx), returned
rapidly within a month of recommencing HD although he was still on a small dose
of steroids at that time.
Radiologically and scintigraphically, disease progression was halted in all
cases and in most joints there was evidence for disease regression although this was
not as striking as the clinical improvement seen post-Tx. In the only other
radiological study [159] to have assessed the effect of renal transplantation on
amyloid bone cysts, there was no change in the bone cysts at follow-up. We have,
however, been able to demonstrate healing with either ossification or reduction in
the size of bone cysts in 5 joints of 4 affected patients. There are several possible
reasons for this difference in our findings. Our patients had less severe disease with
25 cysts in 5 patients and secondly, they had a longer mean follow-up period of 5.7
years post-Tx compared to the earlier study with 34 cysts in 5 patients and mean
post-Tx follow-up of 3.9 years. This suggest that mobilisation of amyloid, which
may vary considerably between different patients and different anatomical sites
[165], may be delayed and not obvious radiologically during short-term follow-up.
It is also possible that the absence of changes post-Tx could be due to failure of
bone to heal because of continued treatment with critical doses of steroids which in
our cohort of patients had either been reduced substantially or stopped completely.
The capacity of bone to heal and reabsorb cysts is also evident in other diseases
[178] and in fact regression and even complete resolution of bone cysts due to
multiple myeloma has been described following successful treatment of the
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underlying disease [179], Finally, age, sex, and menopausal status of female
patients may also affect the ability of bone to heal although numbers of patients are
too small for any definitive conclusions to be made.
Scintigraphically, there was complete resolution of the disease in only 1
patient (EW) who was also the least severely affected clinically, radiologically and
scintigraphically. The 2 other patients (BS and BT) with complete resolution of the
disease scintigraphically in some joints had both been transplanted for the longest
period of time. These findings support our radiological observations that once
precursor [32-M levels have been normalised by a successful Tx, disease severity and
duration post-Tx are two important determinants of disease regression. Site of
amyloid deposition may also be an important determinant. The absence of complete
resolution of bone cysts radiologically together with the delay in improvement in
radiological signs suggest that amyloid present in bone cysts cannot be mobilised as
rapidly as amyloid in other articular structures such as the synovium or that bone
cysts, present non-specifically in up to 30% of non-uraemic patients [180], and in
uraemic patients may also be due to secondary hyperparathyroidism [181], are a
relatively crude measure of the spectrum ofDRA.
Histologically, tissue was available for examination from only 1 patient (BT)
post-Tx when he fell and fractured his cervical spine which had to be stabilised
surgically by fusion of C5 and C6 vertebrae. Bone biopsy obtained at operation was
positive for amyloid although there was no radiological evidence for amyloid bone
disease in the cervical spine or other joints. This case illustrates very clearly that
negative radiology does not exclude DRA and equally importantly, it also
demonstrates that in patients with DRA, despite disease regression post-Tx,
complete reabsorption of amyloid and bone healing may be delayed considerably and
may therefore continue to cause problems such as pathological fractures many years
after a successful Tx.
Amongst HD patients, several asymptomatic joints that had scintigraphic
evidence for DRA became clinically affected at follow-up, confirming previous
observations [160] that SAP scintigraphy may detect subclinical or pre-symptomatic
lesions that are well recognised in DRA [182], In fact, in a recent post-mortem
study [183], histological prevalence ofDRA was found to be higher than suggested
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clinically, frequently preceding clinical features of the disease. An unexpected
finding was the common involvement of the knees, which was affected histologically
more frequently than the shoulders, and least frequently in the hips, contrary to what
might be expected from clinical features of the disease. This interesting finding
however, is consistent with our both our present and previous scintigraphic studies
of patients with DRA, where we found that knees were affected more frequently
than the shoulders. In addition to supporting our scintigraphic findings, these
histological observations also suggest that clinical expression of DRA deposits are
delayed and may be obvious only when it reaches a critical size or may be influenced
by factors such as dialysis modality, whilst it is also the first feature of the disease to
improve following a successful Tx.
In both groups of patients, CTS was the earliest and commonest clinical
feature ofDRA, and although all patients reported symptoms related to one or both
wrists, the need for CTD, often used as the most definitive marker of CTS [161,
174] was required in only 10 of 15 patients. In contrast, positive scintigraphy was
obtained in one or both wrists in all patients whilst amyloid bone cysts were seen in
the wrists of 8 out of 14 patients from whom serial radiology was available. These
findings suggest that SAP scintigraphy is the most sensitive non-invasive marker in
detecting both symptomatic and pre-symptomatic DRA deposits, and the prevalence
of the disease is frequently underestimated clinically and radiologically.
The rigorous radiological criteria that we used for X-ray confirmation of
DRA is specific for amyloid bone cysts but lacks sensitivity which can be improved
if interpreted in conjunction with clinical and scintigraphic findings. The need to
demonstrate bone cysts in at least 2 joints as one of the several criteria for
confirmation of the disease obliged us to classify as radiologically "normal", 1
patient (ES) who had a larger than 10 mm cyst in his L shoulder and another patient
(PP) who had several larger than 5 mm cysts in her L wrist, although in both cases
there was clinical and scintigraphic evidence for the disease. Appropriate
modification of this strict radiological criteria may therefore improve sensitivity
without necessarily affecting specificity of the radiological diagnosis for this disease
as have been employed by some specialist units [174] which accept bone cysts of
appropriate size and location in only 1 joint to be consistent with DRA.
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Finally, symptomatic treatment ofDRA with steroids and non-steroidal anti¬
inflammatory drugs are likely to have only a limited short-term benefit in the face of
the progressive nature of the disease as are surgical procedures such as CTD which
often have to be repeated. Immunoadsorption columns and dialysis modalities such
as haemofiltration, high flux dialysis and use of ultrapure dialysis fluid may at best
delay clinical development ofDRA [13], Renal transplantation is therefore the only
effective therapy for DRA, the clinical benefits of which are sustained in long-term
follow-up and accompanied by both scintigraphic and radiological regression of the
disease which may be delayed. These findings add to our observations in other
types of amyloidosis [12, 47-50, 184, 185] that amyloid deposits are constantly
being turned over, and if the supply of precursor proteins is substantially reduced,
the halt in further amyloid deposition or disease progression is frequently
accompanied by disease regression. In addition to patients with AA [12, 49], AL
[47, 48, 185], and hereditary transthyretin amyloidosis [50], this has now been
demonstrated in serial clinical, radiological and scintigraphic studies of patients with
DRA or (32-M amyloidosis.
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Dialysis-related amyloid and treatment with continuous ambulatory
peritoneal dialysis: A clinical radiological and scintigraphic study
Introduction
Although dialysis-related amyloid (DRA) may complicate patients on
continuous ambulatory peritoneal dialysis (CAPD) [1, 186-188], the perfect
biocompatibility of the peritoneal membrane, its permeability to (32-M and, the
lower levels of P2-M in these patients [189, 190] suggest that development of the
disease may be delayed in CAPD compared to patients on haemodialysis (HD).
However, comparison of the prevalence ofDRA in these two patient populations is
hampered by the small number of patients who have been dialysed long-term and
exclusively by CAPD, and by the lack of a sensitive in vivo technique for the
diagnosis of DRA. We have previously described the use of 123I-labelled serum
amyloid P component (SAP) scintigraphy as an in vivo technique for the diagnosis
of systemic amyloidosis [58-60], including DRA [160], and have recently
demonstrated that this scintigraphic technique may also be used for following the
fate of amyloid deposits in patients who remain on HD compared to successfully
transplanted patients [191], We now report a clinical, radiological and scintigraphic
study ofDRA in 13 patients who have been dialysed predominantly by CAPD.
Patients and Methods
Thirteen patients from 5 renal units who have been on continuous dialysis
for at least 5.5 years and spent at least 80% of their total dialysis time on CAPD
were studied (Table 6.5). None of these patients had evidence for systemic diseases
as a cause of their renal failure. Patients were evaluated clinically for features of
carpal tunnel syndrome and for arthralgias of the large and medium sized joints
characteristically seen in dialysis arthropathy [65], Annual X-rays taken of the
wrists, shoulders, hips and knees in all patients were read 'blind' by a skilled skeletal
radiologist for evidence of amyloid bone cysts using a criteria as previously
described (Table 6.3) [161], In vivo assessment of amyloid deposits was performed
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scintigraphically with radio-labelled SAP. Images were taken 24 hours after
injection of tracer and all metabolic studies were performed as previously described
[58-60], Scans were read 'blind' by a specialist with experience with over 800 SAP
scans. Blood was also taken from all patients prior to injection of radio-labelled
SAP for determination of serum [32-M levels which were measured by standard
autoanalyser techniques. All values are expressed as medians with interquartile
ranges and data was compared statistically using the non-parametric Mann Whitney
U test.
Results
Demographic details, clinical, radiological and scintigraphic findings of the
patients are summarised in Table 6.5. The patients, whose median age was 59.8
years, had been on dialysis for a median duration of 6.3 years, with 97.7% of that
dialysis time spent on CAPD. Six patients (46.2%) had no clinical, radiological or
scintigraphic evidence for DRA. Of the remaining 7 patients (53.8%), positive
scintigraphy alone was documented in 3 cases, and clinical features of DRA in the
remaining 4 cases were confirmed scintigraphically (Figure 6.11) in all cases, and
radiologically in only one (Figure 6.12). Carpal tunnel syndrome was the most
common presenting symptom and only one patient (BJ) needed carpal tunnel
decompression. The only patient (AP) to have arthralgia characteristic ofDRA had
also been dialysed longest at 17.3 years, and he was also the only patient to have
radiological features of amyloid bone cysts. Scintigraphically, positive wrist uptake
was seen in all patients with a positive scan, whilst the shoulders and knees were
affected in 2 cases (BJ & AP). In these 2 cases, the asymmetric intensity in tracer
uptake in the wrists corresponded with their clinical symptoms. Total body amyloid
load as determined by metabolic turnover studies was small in all affected cases.
Although the 7 patients with DRA tended to be older (59.8 vs 58.8 years)
and was on dialysis longer than those without DRA (6.4 vs 5.9 years), the difference







































































































































Compared to published figures [156], serum (32-M levels were similar to other CAPD
patients and patients on HD with AN69 membranes but lower than those on HD with
cuprophane membranes.
AMYLOID 24-HRS 18 Mar 1994 at 9:19
Figure 6.11 123I-labelled SAP scans 24 hours after injection of tracer in a patient
(BJ), demonstrating uptake in both wrists (R>L) and shoulders (R>L).
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Our data confirm earlier observations that DRA may also complicate CAPD
[186-188] and, as in HD patients, prevalence of the disease is frequently underestimated
clinically and especially, radiologically [183, 191], Fifty four percent of our patients
had scintigraphic evidence for the disease but only 31% were symptomatic and only 1
(8%) had classical radiological features of the disease. In comparison, a post-mortem
study of 44 HD patients calculated that 50% of 60 year old patients are likely to have
histological evidence for DRA after 5 years of HD [183], This figure is similar to the
scintigraphic findings in our CAPD patients who were broadly matched in age and
duration of dialysis, suggesting that prevalence of DRA is comparable between these
two dialysis populations.
Clinically, the prevalence of CTS as a feature of DRA was also reported to be
similar in the two dialysis dialysis populations in one study [192], Our finding that 31%
of our patients had clinical features of the disease is similar to the 29% of patients in
another study who were found to have CTS and/or arthralgias after 4.7 years of CAPD
[187], Comparison between groups of patients in different studies is however fraught
with difficulties due to the different diagnostic criteria, limited patient homogeneity and
retrospective nature of the studies. One study of HD patients [161] for example, used
the need for carpal tunnel decompression as evidence of CTS due to DRA and found
that only 5% of their HD patients had clinical features of the disease after 5 years of
HD. In contrast, although 31% of our patients had symptoms of CTS, most were only
mildly affected with only 1 needing carpal tunnel decompression and only 1 other
patient had arthralgia suggestive ofDRA after 17 years of dialysis. Therefore, although
the disease may be equally prevalent in CAPD populations, clinical expression of the
disease may be different, with apparently less severe symptoms in affected patients in
our study. This interesting observation suggest that other factors such as dialysis
modality are important in determining disease expression. We [13, 191] have
previously confirmed earlier observations [159, 167] that symptoms of DRA may
resolve rapidly within hours of a successful transplant and these symptoms may also
return rapidly when the patient is put back on HD, even if they remain on steroid
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therapy, suggesting that HD, perhaps through products of bioincompatible membrane
reactions, are important in determining clinical expression of the disease. This is further
supported by reports of improvement and even resolution of symptoms of DRA
following conversion from HD with bioincompatible cellulose membranes to the more
biocompatible synthetic membranes [175, 193] and following a change in dialysis
modality from HD to CAPD [194],
Age and duration of dialysis [13, 161] therefore remain the two most important
risk factors for the development of DRA for which the only effective treatment is
restoration of tubular renal function by renal transplantation [13, 159, 191], The
potentially beneficial effect of HD with more biocompatible membranes in reducing
prevalence ofDRA [161, 173] has not been supported in other studies [195, 196] and is
likely to be evident only if such membranes are used early and exclusively throughout
dialysis [1, 13]. Despite clearance of small molecular weight proteins resulting in lower
serum P2M levels and the perfect biocompatibility of the peritoneal membrane in CAPD
patients [189, 190], the prevalence of the disease is not reduced compared to HD
patients, a finding supported by other studies [192], However, the long term effect of
CAPD on the development and progression of DRA compared to HD remains to be
evaluated by a prospective controlled study which will require a large number of
patients because of the likely high drop-out rate due to renal transplantation and
conversion of dialysis modalities because of technical failure or peritonitis. Finally, the
suggestion from our observations and from other published studies that the likelihood
of developing symptoms in association with the articular amyloid deposits may be
modulated by dialysis modality or the use of biocompatible membranes in HD will need
to be confirmed.
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Chapter 7 - Primary localised orbital amyloidosis due to
deposition of the immunoglobulin gamma heavy chain CH3
domain
INTRODUCTION
Amyloidosis [1-3, 11] is a disorder of protein metabolism in which normally
soluble proteins are deposited in the extracellular space in the form of abnormal fibrils
with characteristic ultrastructural morphology and tinctorial properties. Many different
proteins can form amyloid fibrils in various amyloid syndromes, and 15 different
precursors have been identified to date. The deposits also always contain sulphated
glycosaminoglycans, some of which are tightly bound to the fibrils, and a non-fibrillar
glycoprotein, amyloid P component, which is derived from and identical to the normal
plasma protein, serum amyloid P component. Amyloid deposits can occur in any tissue
and may be widely distributed systemically or localised to specific focal areas. They
cause disease principally by occupying space and disrupting normal structure and
function.
Primary localised orbital amyloid [197-199] is an extremely rare condition in
which the deposits are confined to the orbit and occur in the absence of amyloidosis
elsewhere. There is usually no antecedent orbital disease. Most patients present with a
mass in the anterior orbit or with proptosis. Eye movement may be restricted either by
the mass effect of the amyloid or by involvement of the extraocular muscles.
Inflammatory changes and loss of visual acuity are rare. The condition is usually slowly
progressive.
The eye and orbit may be involved in systemic amyloidosis, for example vitreous
amyloid due to variant transthyretin in familial amyloid polyneuropathy, corneal
deposits due to variant gelsolin in lattice corneal dystrophy, and amyloid deposits in
eyelids and dermal vessels causing periorbital bruising in systemic monoclonal
immunoglobulin light chain (AL) amyloidosis [1], However the fibril protein in primary
168
localised orbital amyloidosis has not been identified, although it is noteworthy that the
deposits are commonly infiltrated with plasma cells, lymphocytes and foreign body giant
cells. The most common form of localised amyloidosis in other tissues, including the
skin, respiratory and urogenital tracts, is immunoglobulin-derived and associated with
non-malignant local clonal B cell/plasma cell proliferation.
Until recently the biochemical identification and characterisation of amyloid
fibril proteins has been hindered by the need for appreciable amounts of material,
usually only obtainable at autopsy. However it is now possible to analyse picomolar
quantities of small proteins and peptides, and we report here such analysis of the traces
of amyloid which were extracted, using a specially modified technique, from a
diagnostic biopsy in a case of primary localised orbital amyloid.
MATERIAL AND METHODS
Patient
R.B., a 73 year old lady, presented in 1992 with a one year history of right
proptosis and more recent difficulty looking to her right. She was blind in her left eye
from a perforating eye injury as a child but was otherwise well with no other relevant
past medical history. On examination her visual acuities were: right 6/9, left not
perceiving light; with her right eye she could see 17/17 with Ishihara colour plates
suggesting that there was no optic nerve compression. There was periorbital oedema
on the right side with 2 mm proptosis, 6 mm medial deviation and 3 mm inferior
deviation of the globe (Figure 7.1). The right eye showed no abduction, minimal
adduction and downward gaze, but only slightly limited upward gaze. The pupil
reacted briskly to direct light and fundoscopy was normal.
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Clinical investigations and results
Computerised tomography showed a mass in the upper outer quadrant of the
right orbit, extending behind the globe (Figure 7.2). Biopsy performed through the
orbital septum yielded connective tissue heavily infiltrated with amyloid, demonstrated
histologically by Congo red staining [4], Some plasma cells and lymphocytes were seen
but immunohistochemical staining with antisera to k and X light chains provided no
evidence for clonal restriction. No other pathology was seen. Full blood count, serum
biochemical profile, erythrocyte sedimentation rate, serum C-reactive protein, and
electrophoresis of serum and urine proteins were all normal. Bone marrow aspirate and
trephine biopsy were both cytologically normal, with no evidence for an abnormal B cell
clone, and no immunoglobulin gene rearrangement was detected in either the bone
marrow aspirate or peripheral blood. Skeletal X-ray survey was normal. Scintigraphy
with 123I-labelled serum amyloid P component [58, 59] was normal with no evidence for
systemic or visceral amyloidosis.
Extraction and isolation of amyloid protein
The biopsy from the orbital lesion, total mass ~ 3 mg, was stored frozen at
-70°C. Since histologically the bulk of the tissue was amyloid a portion (~ 1 mg) was
analysed directly by electrophoresis in SDS 8-18% gradient PAGE (ExcelGel1M
Pharmacia Biotech, St Albans, Herts, U.K.), in the hope that the amyloid fibril protein
would be the major species present and could then be identified by protein sequencing
after electrotransfer to a suitable membrane.
The standard water extraction method [8] for isolation of amyloid fibrils from
tissue involves numerous preliminary homogenisations in saline, during which, in our
experience, significant losses of fibrils may occur. In order to maximise recovery from
the ~ 2 mg of tissue available it was initially homogenised in 0.5 ml of distilled water to
extract the fibrils immediately. After centrifugation at 15,000 g for lOmin and
separation of the supernatant, the process was repeated twice more and the
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supernatants were pooled together. The amyloid fibrils were then selectively
precipitated by adding sodium chloride to a final concentration of 0.2 mol/1, leaving
essentially all other components of the water extract in solution in the saline. The
suspension was centrifiiged at 15,000 g for 10 min and the presence of amyloid fibrils
was confirmed by drying 10 pi of resuspended material on a poly-L-lysine coated slide,
fixing with 10% formalin/90% ethanol and staining with Congo red [4], The protein
composition of the fibril pellet was analysed by SDS 8-18% gradient PAGE.




A fragment of the whole biopsy was run on SDS 8-18% gradient PAGE and the
separated proteins transferred by electroblotting to PVDF membrane. After staining
with Coomassie blue the major band at ~ 14 kDa was excised and sequenced from the
A-terminal on an Applied Biosystems (Foster City, CA, U.S.A.) 477A instrument [83],
The whole purified amyloid fibril preparation was also sequenced directly on the same
instrument, and then repeated with inclusion of proline cleavage cycles [83], Protein
mass of the fibril preparation was determined by time-of-flight laser desorption
spectrometry in a Finnigan-MAT Lasermat (Finnigan-MAT, Hemel Hempstead, Herts,
U.K.), which was calibrated by inclusion of insulin on an a-cyano-4-hydroxycinnamic
acid matrix.
RESULTS
Whole orbital amyloid tissue
SDS PAGE analysis of a whole fragment of the biopsy revealed 14 different
bands (Figure 7.3) the most abundant of which, running at ~ 14 kDa, was expected to
represent the amyloid fibril protein because Congo red staining showed that it was
heavily infiltrated with amyloid. However, partial amino acid sequencing of this band
identified the sequences of haemoglobin a and (3 chains. We have obtained similar
results with other amyloid-containing biopsies (unpublished observations), even when
no blood was visible by naked eye inspection.
Isolation of amyloid fibrils
The modified water extraction procedure yielded amyloid fibrils as shown by
Congo red staining and the pathognomonic apple green birefringence when viewed with
high intensity cross polarised light (Figure 7.4).
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Figure 7.3 SDS 8-18% PAGE analysis of whole orbital amyloid biopsy tissue: Lane
1, molecular weight markers; lanes 2-5, increasing loadings of the reduced denatured
tissue sample.
Figure 7.4 Extracted orbital amyloid fibrils stained with Congo red and viewed in
polarised light, showing the pathognomonic birefringence of amyloid.
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Identification and characterisation of the amyloid fibril protein
SDS PAGE analysis of the extracted amyloid fibrils revealed only one band
migrating at ~ 6 kDa (Figure 7.5); the same band was also present in the SDS PAGE of
the whole biopsy (Figure 7.3, lane 5). Automated amino acid sequencing of this protein
revealed that the 9 TV-terminal residues of the protein corresponded to the known
sequence in the TV-terminal region of the third constant domain (CH3) of the yl heavy
chain of IgGl subclass (positions 278 to 286) and also of the y4 heavy chain of IgG4
subclass (residues 275 to 283) (Figure 7.6). It was not technically possible to obtain
any further sequence from the extremely limited amount of protein available.
The mass of the purified amyloid fibril subunit protein by time-of-flight analysis
was 6125 Da, whilst the predicted mass of the whole yl CH3 domain from residue 278
is 6169.9 Da and that of the y4 CH3 domain from residue 275 is 6214.9 Da.
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Figure 7.5 SDS 8-18% PAGE analysis of extracted amyloid fibrils: Lanes 1 and 6
contain molecular weight markers; lane 2, isolated orbital amyloid fibrils; lane 3,
lysozyme amyloid fibrils [21]; lane 4, purified human transthyretin; lane 5, purified
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Figure 7.6 iV-terminal amino acid sequence of the orbital amyloid fibril protein
aligned with the sequences of the CH3 domains of yl (above) and y4 heavy chains
(below).
DISCUSSION
Monoclonal immunoglobulin light chains were the first amyloid fibril protein to
be identified by protein sequencing [9] and this type of amyloidosis, designated AL, is a
well recognised condition complicating about 15% of cases of multiple myeloma and
also a significant proportion of other monoclonal B cell disorders [1, 200], The actual
amyloid fibril protein in all cases of AL amyloidosis in which it has been sequenced
consists of part or all of the variable domain, together, in some cases, with part or,
rarely, all of the rest of the light chain [1, 200], Since normal polyclonal light chains
and most monoclonal ones do not form amyloid it is generally accepted that unique
individual sequences of the amyloidogenic monoclonal light chains are responsible for
fibril formation [2, 3], This concept is strongly supported by the fact that A, light chains
are more commonly involved in AL amyloid than k chains, although the latter
predominate among both normal immunoglobulins and monoclonals in general [2, 3,
200], Furthermore monoclonal gammopathy in which light chains of the VAVI
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subgroup are involved is almost always complicated by amyloidosis. Finally when
Bence-Jones proteins from myeloma patients with amyloid are injected into mice they
form amyloid deposits whereas Bence-Jones proteins from myeloma patients without
amyloid do not [201],
In contrast immunoglobulin heavy chains and their fragments generally seem to
lack whatever primary and higher structure is required for amyloid fibril formation
in vivo. In 1974 a case of systemic amyloidosis associated with heavy chain disease
was reported in which the y heavy chains formed amyloid-like fibrils in vitro [202], but
only two definite cases of heavy chain-derived amyloidosis have been confirmed by
sequencing. The first such patient had amyloid in the spleen, liver, kidneys and heart, a
pattern of distribution characteristically seen in AL amyloid, but the fibrils consisted of
an intact heavy chain variable domain joined to a complete third constant domain of yl
subclass [203], The second case of heavy chain amyloid also had a typical presentation
for AL amyloid with a monoclonal serum IgGic protein identified by heavy chain
sequence as IgGl subclass, Bence-Jones proteinuria, and amyloid in the spleen and
kidneys [204], The amyloid fibrils contained just the diversity segment of the heavy
chain variable region, VH-D. These cases have been designated as AH type
amyloidosis.
The present patient with primary localised orbital amyloidosis is the third case of
AH, immunoglobulin heavy chain-associated amyloid. The fibril protein is derived from
the CH3 domain of a y heavy chain of either yl or y4 subclass, without any apparent
contribution by the variable domain. This is a unique and exceptional finding since in all
cases of both heavy and light chain amyloid characterised so far the fibril proteins
included at least part of the variable domain [200, 203, 204], Unfortunately insufficient
material was available to permit further sequencing in order to identify either the y
subclass of origin or detect the presence of variant residues which may have been
responsible for amyloidogenicity. Although the mass of the fragment suggests that
virtually the whole domain from the identified TV-terminal residue was present, the
precision of laser desorption mass analysis (-0.5%) was insufficient to support
speculation about the presence of variant residues, C-terminal raggedness or
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glycosylation. However given the rarity of heavy chain amyloidosis it is possible that
some unusual structural feature may be present.
The localised nature of the amyloidosis in this case, the absence of any sign of a
systemic monoclonal gammopathy, and the plasma cell/lymphocyte infiltrate in the
lesion, strongly suggest that these cells were the source of the heavy chain fragment
deposited as amyloid. It is not clear whether the amyloidogenic protein was derived by
proteolysis of a larger precursor or even an intact y chain, or whether it represents an
abnormally spliced product generated by disturbed immunoglobulin gene rearrangement
in an autonomous clone. Unfortunately no tissue was available for immunoglobulin
gene rearrangement studies. Plasma cell infiltration has been reported in all other cases
of primary localised orbital amyloidosis suggesting that these are also
immunoglobulin-related, but it remains to be determined whether they are of light or
heavy chain origin.
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Chapter 8 - Treatment of amyloidosis
Introduction
The past 25 years have seen major advances in our understanding of the
pathogenesis and natural history of amyloidosis. Although specific treatment of
amyloidosis is not yet available, the demonstration that amyloid deposits are derived
from circulating or locally produced precursor proteins that are abnormal in structure or
concentration or both have led to the development of treatment strategies aimed at
reducing the supply of precursor proteins in the hope that disease progression can at
least be halted. The benefit of such therapy have been demonstrated by subsequent
improvement in organ function, histological and scintigraphic evidence for amyloid
regression, and most importantly, improvement in morbidity and survival. At the same
time, major advances have been made in the treatment of renal and heart failure which
are the main causes of death from amyloidosis. The development and availability of
dialysis and latterly, organ transplantation means that prognosis may be considerably
improved in systemic amyloidosis. Major therapeutic advances have therefore been
made over the past 20 years since one of the first attempts at treating amyloidosis was
made with DMSO [205],
Prospective evaluation with 123I-SAP scintigraphy
The effect of treatment of amyloidosis on organ function may be monitored by certain
laboratory markers such creatinine and 24 hour urinary protein excretion in renal
amyloid and liver function tests in hepatic amyloid. However, organ amyloid load
corresponds poorly with organ function, changes of which provide no useful
information on the physical effect of treatment on amyloid deposits. Prospective
evaluation by repeat biopsies have demonstrated regression of amyloid following
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treatment [46, 206, 207] but invasive biopsies are unlikely to have a role in the routine
monitoring of treatment and in any case provide only local qualitative information that
is subject to sampling error (Table 8.1). Serial radiology (Figure 6.7) may be used but
only for following bone cysts due to DRA [26, 159], The only investigation that have
been used effectively and reproducibly in monitoring systemic amyloidosis is serial I23I-
SAP scintigraphy which have confirmed previous suggestions that amyloid deposits are
in a state of dynamic turnover and may be mobilised and redistributed [208] or regress
[46, 206, 207], Response to therapy with scintigraphic evidence for regression have
been demonstrated in AL [47, 48, 185] (Figure 8.1), AA [12, 49] (Figure 8.2), [32-M
[165] (Figure 6.9 & Figure 6.10) and hereditary [50] amyloidosis. In none of these
patients have amyloid progressed despite effective treatment of underlying disease and
neither was there spontaneous regression without treatment.
Table 8.1 Comparison of histology and SAP scintigraphy in amyloidosis
Histology SAP scintigraphy
Microscopic sampling Whole body survey
Permits immunohistochemical Distribution of amyloid may be
typing diagnostic of type
Poorly quantitative Permits quantification
Invasive Serial monitoring
Widely available Restricted availability at present
Management
A feature of the abnormal protein metabolism seen in amyloidosis is the
imbalance between rate of deposition of fibril precursor proteins and the relative but not
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complete resistance of fibrils to degradation and mobilisation. There are, at the
moment, no treatment available that may promote or accelerate degradation of fibrils.
Specific treatment of amyloid is therefore aimed at reducing supply of precursor (Table
8.2) in the hope that fibril deposition and disease progression may be slowed down or
even halted, thereby favouring mobilisation of amyloid. Clinical evidence that this
occurs and may be accompanied by regression of amyloid have been confirmed
scintigraphically [12, 47, 49, 50, 165, 185] and histologically [46, 206, 207],
Reduction in supply of precursor proteins is achieved in AL amyloid by
suppressing plasma cell synthesis of clonal precursor immunoglobulin light chains, and
in AA amyloid by suppressing the stimulus for hepatic synthesis of precursor SAA
proteins. However, in DRA, reduction in supply of precursor [32-M is achieved by
improving dialysis efficacy so that clearance of [32-M is increased. In both DRA and
hereditary transthyretin amyloidosis, organ transplantation restores normal protein
metabolism such that renal transplantation leads to normal (32-M clearance whilst the
source of systemic variant TTR is eliminated following a successful liver transplant.
Until treatment aimed at degradation and mobilisation of amyloid is developed, these
strategies remain the most effective treatment available for amyloidosis.
In patients who are already affected by the disease, supportive therapy remains a
critical component of their management, delaying target organ failure, maintaining
quality of life and prolonging survival whilst specific therapy is instituted. Such
supportive therapy may in some cases 'buy time' and allow patients to live long enough
to see the benefit of chemotherapy which may be delayed [47],
Patients with renal amyloid are acutely sensitive to volume changes because stiff
and poorly reactive amyloid-laden glomerular vessels are unable to respond sufficiently
to changes in blood volume and pressure. Renal failure is often irreversible in amyloid
kidneys and maintenance of volume status and blood pressure especially perioperatively
is therefore critical. Proteinuria and even nephrotic syndrome may respond to
colchicine or treatment of the underlying disease although nephrectomy may rarely be
necessary [209], Clinically significant cardiac amyloid is characteristically manifested
by restrictive cardiomyopathy whereby maintenance of cardiac output is dependent on
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high filling pressures and vasodilators should therefore be avoided and diuretics used
with caution in these patients. There may be increased sensitivity to digoxin because of
binding to amyloid fibrils. Sudden death due to arrythmia is common and prophylactic
pacing may therefore be necessary.
Figure 8.1 Regression of AL amyloidosis. Serial posterior whole body I23I-SAP
scintigraphs of a man with AL amyloidosis presenting with hepatomegaly and massive
elevation of liver alkaline phosphatase. Initially (A) there was extensive uptake in the
spleen, liver (largely obscuring renal deposits) and bone marrow. Remarkably, a second
scan (B) performed 6 months later after 4 cycles of 'VAD' chemotherapy shows major
regression of the liver deposits, associated with near normalisation of alkaline
phosphatase, but little change in the splenic and bone marrow amyloid.
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Figure 8.2 Regression of AA amyloidosis. Serial posterior whole body 123I-SAP
scintigraphs of a young woman with JRA complicated by AA amyloidosis. Scans at
presentation with nephrotic syndrome (A) show intense uptake of labelled SAP into
extensive amyloid deposits in the liver, spleen, kidneys and thyroid gland. Treatment
with chlorambucil induced a complete remission of inflammatory disease activity and
was followed by the disappearance of proteinuria; repeat SAP scan 3 years later (B)
indicates substantial regression of amyloid with only minor splenic adrenal deposits
remaining. The remainder of the image is blood pool background which is increased
when specific uptake into amyloid is reduced, and radioactive breakdown products in
the bladder.
In patients with renal failure, supportive treatment with dialysis [210-213] or
renal transplantation [214-217] may considerably improve prognosis and in patients
with cardiac amyloid, heart transplantation [47, 218] may be life saving but optimal
management of these patients must include specific therapy aimed at reducing supply of
precursor proteins. Parenteral nutrition may be essential in malnourished patients who
present with severe systemic disease and are at risk of pressure sores and infections
because of immobility and impaired bladder and bowel function. Dry gritty eyes due to
keratoconjunctivitis sicca, usually seen in AL or hereditary amyloid may be relieved by
artificial tears and should also be regularly examined for infection and corneal abrasions
or ulcers.
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However, as with many diseases, prevention may be possible, is cost effective,
and remains the ultimate goal of primary care. The success of preventive strategies is
probably best illustrated by the changing pattern ofAA amyloidosis which followed the
introduction of antibiotics such that chronic inflammatory diseases have replaced
chronic infectious diseases as the most common cause of AA amyloidosis, at least, in
the developed world [219], This was followed by the demonstration that development
ofAA amyloid due to FMF may be prevented altogether if colchicine is given early and
in adequate doses [220], DRA, now a major cause of morbidity in long term dialysis
populations, may be prevented, most effectively, by an early renal transplant [13, 26],
Preventive measures, however, can be implemented only if patients at risk can
be identified. Hence in AA amyloid, patients who might be at risk should have their
CRP and SAA proteins measured regularly so that appropriate treatment can be
instituted early and its effectiveness monitored. The risk of developing DRA may be
reduced by identifying those most at risk so that limited resources with expensive but
more efficient dialysis modalities can be offered to those most likely to benefit.
Similarly in hereditary transthyretin amyloidosis, optimal timing of liver transplantation
may prevent disease progression and irreversible organ damage in carefully selected
patients.
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Treatment of the amyloidosis syndromes
Primary (AL) amyloid
Primary AL amyloid is a progressive systemic disease with a poor prognosis. In
three series [16, 53, 221] comprising almost 500 cases of AL amyloidosis, the median
survival was 14.7 months or less, and may, [53, 221] or may not [222] be worse, if
associated with multiple myeloma. Most deaths are cardiac-related and if CCF is a
feature of the disease, median survival is reduced to 6.5 months.[16, 53, 223]
The precursor protein of AL amyloid is derived from monoclonal
immunoglobulin light chains synthesised by plasma cells. Treatment of AL amyloid is
therefore aimed at suppression of the abnormal clone of plasma cells, usually with
melphalan, an alkylating agent often used in the treatment of myeloma, in the
expectation that supply of precursor light chains will be reduced or stopped, enabling
disease progression to be halted. Until recently, the beneficial effect of such treatment
which have included histological [46, 207] or scintigraphic [47, 185] evidence for
regression of the disease, was confined to isolated but numerous case reports [46, 224-
240], These reports have also included the use of colchicine [225, 241-243] which
have been used advantageously in other types of amyloidosis.
Several clinical trials have now been published (Table 8.3), comparing the use of
melphalan, prednisolone and colchicine [223, 244-247], Initial trials with melphalan
and prednisolone reported that although there may be an improvement especially with
resolution of proteinuria or nephrotic syndrome, there was no beneficial effect on
survival [223, 244], However patient numbers were small and treatment duration
shorter than subsequent studies reporting more encouraging results [246, 247],
Improved survival in patients treated with colchicine alone reported by another study
used untreated historical controls for comparison [245], However, poor survival in the
control group in this study was probably due to a significantly larger proportion of
patients with CCF, and subsequent studies have failed to demonstrate a clear benefit in
patients treated with colchicine alone [244, 247], In fact, in a large crossover study in
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1985 [244], there was no beneficial effect on survival in patients treated with colchicine
despite the use ofmaximum doses that could be symptomatically tolerated (median 1.5
mg/d). In this study, patients treated with melphalan and prednisolone survived
significantly longer, but only in the subgroup of patients who remained on one
treatment alone without crossing over, which was allowed after 6 months if there was
evidence for progression of the disease. More patients in the colchicine group crossed
over to have melphalan and prednisolone added to the treatment and when compared in
aggregate, the melphalan and prednisolone group survived longer (25.2 months vs 18
months), but the difference was not significant (p=0.23). Treatment regimes used in
this and other studies are summarised in Table 8.4.
Since then, a further study from the same group but involving larger numbers of
patients and longer duration of therapy with melphalan and prednisolone have identified
a subset of patients who derived substantial survival benefit related to response [246],
As with the previous studies, patients were divided into 4 smaller groups according to
the main organ system clinically affected (nephrotic syndrome, CCF, hepatomegaly or
neuropathy). Response to treatment was most likely in patients with nephrotic
syndrome and least likely in patients with neuropathy. Median time to response was
11.7months. Survival which was shortest in patients with CCF, was substantially
prolonged at 89.4 months in the 18% of patients who responded to treatment compared
to 14.7 months for the non-responders.
There are several features common to all these studies. The most common
presenting manifestation of AL amyloid was nephrotic syndrome, a cardiac event was
the main cause of death, and the most important predictors of a poor prognosis was
presence of CCF, multiple organ involvement, renal failure and weight loss [223, 244-
247], The prognosis of AL amyloid remains poor although encouraging results have
now been achieved following treatment with melphalan and steroids. There is evidence
to suggest that poor response to therapy may be related to inadequate dose and
duration of treatment [246], Due to variations in gastric absorption with melphalan,
adequate absorption and delivery should be confirmed by increasing the dosage of
melphalan given in 6 weekly cycles until mid-cycle leukopaenia is achieved. Longest
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survivals have been achieved so far with therapy continued for between 18 to 36
months and this has to be balanced against the risk of dymyeloplasia especially with
acute leukaemia which increases with increasing duration of therapy. However, the
poor prognosis but substantially prolonged survival in patients who respond to
treatment suggest that a trial of therapy with melphalan and prednisolone should be
given for at least 12 months or longer as some patients take more than a year to
respond. Current evidence suggests that no additional benefit is gained by adding
colchicine to melphalan and prednisolone [247], There is also no evidence that
melphalan and prednisolone is superior to melphalan alone [246],
Results of chemotherapy may be further improved by early diagnosis and rapid
institution of treatment [245], In this study, mean interval between symptoms and
diagnosis, and between diagnosis and treatment, was 15 months and 2.7 months
respectively. A shorter diagnosis-treatment interval correlated with significantly
improved survival [245], In the past, many physicians have been reluctant to
recommend therapy in AL amyloid because of poor results [235] causing further delay
in instituting treatment which will only add to the diminishing chances of survival .
In addition to melphalan, other alkylating agents such as cyclophosphamide may
be used, but in patients who fail to respond, vincristine, adriamycin and dexamethasone
as recently proposed for resistant myeloma have been used and it is also possible that
this more aggressive regime is more likely to induce a quicker response to treatment
[248], This may be important especially in patients who present with CCF and have a
median prognosis of 6.5 months and are therefore unlikely to survive long enough to
see the benefit of therapy with melphalan and steroids which has a median response
time of 11.7 months. In such patients, life saving heart transplantation followed by
chemotherapy may be appropriate [47], Systemic AL amyloid is not necessarily a
contraindication to organ transplantation especially in patients with small total body
amyloid load and in fact heart [47, 218] and renal [214, 249, 250] transplantation for
patients with AL amyloid have been successfully performed with good results. In
patients with renal failure, replacement of renal function by dialysis may prolong
survival substantially, especially if there is no echocardiographic evidence for cardiac
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amyloid [210, 211, 213, 250], Recently, autologous bone marrow transplantation
followed by chemotherapy was described in a patient with AL amyloid associated with
a monoclonal gammopathy but the patient unfortunately died 10 weeks post-transplant
from CMV pneumonitis [251],
Systemic AL amyloidosis involving the spleen may rarely be accompanied by
clotting factor deficiency leading to catastrophic haemorrhage [252], When this
happens, splenectomy may be the only effective way of correcting the clotting defect
[253, 254] although there are case reports of improvement in clotting time following
chemotherapy with melphalan and steroids [237], Treatment with alfa-tocopherol
(vitamin E) [255] in 16 patients and interferon alfa-2 [256] in 15 patients failed to
demonstrate any beneficial effect with no objective evidence for regression of the
disease. Median survival which was 19.4 months and 26.3 months respectively was not
superior to that reported with other agents used for this disease.
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Table 8.4 Treatment regimes for AL amyloid
Melphalan/prednisolone
6 weekly cycles ofmelphalan 0.15 mg/kg/day in 2 divided doses for 7 days and
prednisolone 0.8 mg/kg/day for 7 days
Leucocyte and platelet counts checked every 3 weeks
Increase daily dosage ofmelphalan by 2 mg for each 6 week cycle until mid-cycle
leucopaenia or thrombocytopaenia occurs
Reduce dose if there is severe leucopaenia or thrombocytopaenia and in renal failure
Minimum duration of therapy should be 12 months
Colchicine
Commence at 0.6 mg twice a day
Dosage then increased by 0.6 mg daily each week until abdominal cramps or diarrhoea
occurs
Colchicine then discontinued and resumed at highest dosage that did not produce side
effects
Reactive systemic (AA) amyloid
In reactive systemic AA amyloidosis the acute phase protein, serum amyloid A
(SAA) is laid down as amyloid. Any visceral organ may be affected but most cases
become clinically evident only when the kidneys are involved. Subsequent progression
of the disease with declining renal function determines prognosis and indeed, renal
failure is the major cause of death in AA amyloidosis [219, 257, 258], The importance
of recognising complications with AA amyloidosis is underlined by the poor prognosis
associated with it in diseases such as JRA which otherwise has a good prognosis [259]
More importantly, it may be preventable as clearly illustrated by the changing pattern of
AA amyloidosis which, following the introduction and widespread use of antibiotics,
have resulted in a diminishing incidence of amyloidosis secondary to chronic infectious
diseases such that it has now been replaced by chronic rheumatic diseases as the major
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cause ofAA amyloidosis in the developed world [219],
Attention has therefore focused on treatment of chronic rheumatic diseases
especially with the discovery in the 1960's of alkylating cytotoxic drugs such as
chlorambucil that act by suppressing underlying disease activity resulting in most cases
to suppression of the associated acute phase response (APR). Reduction of precursor
SAA levels achieved may reduce the risk of development of AA amyloidosis, and in
patients who already have AA amyloidosis, may lead to mobilisation and regression of
amyloid. Several clinical trials have been conducted in an attempt to determine the
effect of such treatment on progression of the disease in patients with chronic rheumatic
diseases complicated by AA amyloidosis (Table 8.5) [260-264], All patients in these
trials had proteinuria which was the earliest indicator of complications with amyloidosis
and also the commonest mode of presentation, whilst most patients had histological
confirmation of the diagnosis. The mean interval between presentation with underlying
disease and diagnosis of amyloid was 10-16 years. Response to treatment was
documented in most cases, the most obvious feature of which was reduction in or even
complete resolution of proteinuria/nephrotic syndrome, which may or may not be
accompanied by histological [206] or scintigraphic [12, 49] evidence for regression of
the disease. However, the most notable and indeed dramatic finding was significantly
and in some cases considerably improved survival compared to untreated groups.
The first and most notable of these studies involving 51 patients with juvenile
chronic arthritis (JCA) was published in 1977 [260], Proteinuria was present in all
patients at diagnosis but in only 36% after > 3 years of continuous treatment with
chlorambucil. Survival was 100% at 5 years and at follow up after 15 years [263], 68%
of the treatment group was still alive compared to 100% mortality in the untreated
group. Other studies have all also reported a major impact on survival in treated
patients. The drugs most commonly used was chlorambucil, followed by
cyclophosphamide and podophyllotoxin derivatives.
However, there are at least 2 major factors that may contribute to the vastly
improved survival seen with treatment. Firstly, treatment and control groups may not
be comparable. Patient numbers were much smaller [260] in the treatment groups
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whilst historical controls were sometimes used [261], More importantly, information
on renal function, the most important prognostic indicator, was provided and
comparable between the study groups in only one trial [262] which was also the only
prospective randomised trial so far. The poorer than expected survival in most of the
control groups suggest that proportionally, they may have more patients with renal
failure and this was confirmed in at least one study [263],
Secondly, alkylating treatment with chlorambucil was introduced in the 1960's
at the same time that HD became increasingly available. It is well recognised that
availability of dialysis and latterly, renal transplantation, has improved considerably the
prognosis of AA amyloidosis [211, 213, 265], a not unexpected finding since renal
failure was and remains the major cause of death. The improved survival in treated
patients may therefore be partly attributable to the replacement of renal function by
dialysis or renal transplantation. The proportion of patients in both groups that was
offered renal replacement therapy is not known and it is also possible that patient
selection for treatment and subsequently, dialysis or transplantation, may be biased
especially in the non-randomised trials. Indeed, in one trial [266], renal function was
normal in all patients in the much smaller treatment group. Finally, the favourable
influence of renal replacement therapy on survival is supported by the observation that
in patients treated with chlorambucil, survival was superior in those treated after 1980
compared to those treated before 1969 [263] when renal dialysis was only becoming
available and renal transplantation was uncommon. The impact of treatment with
alkylating cytotoxic drugs on prognosis in AA amyloidosis associated with rheumatic
disease can therefore only be accurately assessed by renal survival rather than patient
survival.
However, the effect of treatment with alkylating agents on the underlying
disease is unequivocal. Control of inflammatory activity may be achieved within 1 year
[260], is often accompanied by reduction or resolution of proteinuria, and significantly,
may lead to slowing down of the decline in renal function [262, 264], Apparently
improved renal survival compared to untreated controls has in fact been suggested in
one study [262], Progression of amyloid in the kidneys and elsewhere may be halted
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and regression may even occur but the effect on renal survival without need for renal
replacement therapy remains to be determined.
There have been at least 8 case reports [267-272] on the beneficial use of
colchicine on AA amyloidosis due to chronic inflammatory diseases. All but one [269]
was manifested by nephrotic syndrome which resolved on treatment with colchicine.
Reduction of proteinuria may be achieved within 2 to 3 months of treatment and in 3
cases [267-269] this was accompanied by improvement in underlying disease activity.
Although evaluation of anecdotal case reports of response to treatment is hampered by
spontaneous fluctuations in the clinical expression of amyloidosis [273], such
spontaneous and complete resolution of nephrotic syndrome rarely occurs [274], These
observations strongly suggest a beneficial effect of colchicine in AA amyloidosis and
stress the need for controlled trials.
The beneficial effect of colchicine therapy in preventing febrile attacks [275-
277] and AA amyloidosis [220, 274, 278] in FMF patients is unequivocal. This effect is
dose dependent and if given before there is renal disease, may prevent the development
of proteinuria and complications with AA amyloidosis [220, 274, 278], Colchicine may
also be effective in inducing clinical remission of the disease in patients who have
proteinuria and even nephrotic syndrome but well preserved renal function [219, 241,
279-283],
Experimental evidence that vitamin C dietary supplements in mice with
experimentally induced AA amyloidosis produces resolution of amyloid [284] have not
been confirmed [285], However, amyloidotic mice receiving vitamin C supplements
benefited from a highly significant prolongation of survival compared to untreated
controls [286], The mechanism is unknown but these results suggest that oral vitamin
C supplements of 200 mg/day which is safe and inexpensive may be useful in the
treatment ofAA amyloid.
In some cases, the pathology and stimulus for the acute phase response is clearly
localised to one site and in such instances, surgical excision of such a localised source
of inflammatory stimuli usually lead to a complete and gratifying resolution of clinical
symptoms, followed by substantial regression of amyloid deposits. This has been
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achieved by tumour resection in renal carcinoma [287], hepatic adenomas [288] and
Castleman's disease [289], bowel resection in ulcerative colitis and Crohn's disease
[267, 290] and amputations of affected limbs in chronic osteomyelitis [291] that have
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Dialysis-related ((32-M) amyloid
(32-M, the precursor protein ofDRA is a LMW protein that forms part of the MHC
Class I antigen complex expressed by all nucleated cells. Daily production is
estimated at ~ 3 mg/kg [292], almost all ofwhich are filtered and metabolised by the
kidneys. It therefore accumulates in renal failure with levels rising 30 to 50 fold in
patients on dialysis [156, 293-297], Although the pathogenesis is unknown,
cumulative exposure to high levels of (32-M is clearly an important factor, as [32-M
associated systemic amyloidosis have not been described in patients with normal
[32-M levels. The biological properties of (32-M as a growth factor capable of
remodelling bone [171, 298, 299], its ability to stimulate release of fibroblast
collagenase [300] and its affinity for collagen [172] with which it binds in a dose-
dependent manner may be important. The process of dialysis which may itself
contribute to the daily synthesis of [32-M [295, 301, 302] and may be important in
determining clinical expression of the disease [65, 165] is not essential as DRA have
been described in a patient with CRF but not yet on dialysis [303],
Prevalence ofDRA increases with increasing duration of dialysis and affects
virtually everyone who have been dialysed > 20 years [65, 176], Most patients with
DRA present with carpal tunnel syndrome followed by arthralgias of the large and
medium sized joints [294], Joint pains may be symptomatically treated with NSAID
but long term efficacy is poor [304], In contrast to AA amyloidosis, disappointing
results have been obtained with the use of colchicine in isolated cases [305], Low
dose oral steroids have given promising results [166] although this will have to be
balanced against the potential side effects on an already immuno-compromised
dialysis population. The process of HD itself may be a determinant of disease
symptomatology [65, 165] but it remains to be seen if conversion from HD to
CAPD in patients with DRA may be accompanied by an improvement in symptoms
although progression of DRA following conversion to CAPD have already been
documented in one such patient [306],
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Symptoms associated with carpal tunnel syndrome can be transiently
relieved by local steroid infiltration or more definitively by surgical release of the
median nerve, which may have to be repeated and cannot be delayed because of the
irreversibility of the neurological lesion. Successful relief of shoulder pain after
endoscopic resection of the coracoacromial ligament [307] could constitute a major
breakthrough in the symptomatic treatment of dialysis arthropathy as the shoulders
are one of the most frequently affected joints in this disease. Prosthetic
replacement, especially of the hips and knees, may be necessary in patients with
pathological fractures as they are unlikely to heal. Destructive spondyloarthropathy,
another joint disease frequently associated with P2-M amyloidosis, may lead to
severe spondylisthesis with the risk of spinal cord or nerve root compression.
Orthopaedic consolidation including osteosynthetic grafts may be a lifesaving
procedure in such cases [304],
Specific treatment of DRA as with other types of amyloidosis is aimed at
reduction of precursor protein levels which, however, unlike other types of
amyloidosis cannot be safely achieved by suppression of synthesis of P2-M. At least
75% of the daily production of (32-M comes from normal cell turnover [65] and
suppression of synthesis cannot therefore be achieved without affecting normal
cellular function especially of the immune system, the function of which is already
undesirably compromised in patients with CRF. Treatment aimed at reduction of
P2-M levels is therefore directed towards modifications of dialysis modalities to
improve clearance of P2-M, a tubular function of normal kidneys which until
recently has been poorly replaced by dialysis. Another goal sought in treatment is
the improvement of biocompatibility of membranes as there is in vitro evidence that
cellulose but not the newer synthetic membranes may stimulate synthesis of P2-M
[302, 308] although this has not been confirmed in other studies [309, 310],
However, blood-membrane interaction is not the only source of bioincompatibility
because backflow of acetate and endotoxin from dialysis fluid may also contribute to
the inflammatory reaction [65, 304, 311, 312], a problem that may be avoided by
haemofiltration or reduced by use of ultrapure dialysis fluid [313],
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Standard cellulosic membranes used in conventional HD is impermeable to
(32-M and bioincompatible. Subsequent development of synthetic membranes such
as polyacrylonitrile AN69, PMMA and polysulfone used in high flux dialysis are
more biocompatible and more permeable, capable of clearing [32-M by a
combination of adsorption (especially with PMMA [314] and AN69 [315]
membranes), diffusion transfer, but predominantly, convective transport especially
with polysulfone membranes and particularly if used in haemofiltration [316],
Although these dialysis modalities are able to reduce but not normalise P2-M levels
and DRA symptomatology does not correlate with P2-M levels [317], a reduction
of total body P2-M load could conceivably delay development of the disease in the
individual patient. In fact the beneficial effect of high flux dialysis on the
development of DRA have been demonstrated but only if such dialysis was
employed exclusively or for at least 90% of the total dialysis time [161], The
reasons for this have not been determined but are likely to involve lower P2-M
levels and differences in biocompatibility of the different membranes. Prevalence of
the disease is significantly reduced in all [161, 173, 174, 318] but one [195] of the
studies conducted so far. In patients who already have the disease, high flux dialysis
may lead to symptomatic improvement [175, 176] although whether this is
accompanied by slowing down of the progression of disease remains to be
confirmed. Prevalence of the disease may also be reduced by use of ultrapure
dialysis fluid [313] and the theoretical superiority of haemofiltration have not been
assessed in trials because of the few numbers of patients on long term
haemofiltration.
Intensive removal of P2-M by the combination of high flux dialysis and a
haemoperfusion column containing adsorbents with hydrophobic ligands specific for
[32-M may be accompanied by improvement in symptoms and even radiological
evidence for regression of bone cysts in one case [157], Confirmation with larger
controlled studies are needed but this treatment is likely to prove expensive and with
(32-M clearance ~ 300 mg per session is no more efficient than haemofiltration.
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Peritoneal dialysis, despite the perfect biocompatibility of the peritoneal
membrane that is also highly permeable for small proteins does not protect patients
against the risk of DRA [186-188, 319, 320] although disease prevalence may be
lower compared to HD populations [173], It is now one of the most common
modes of dialysis and is also capable of clearing [32-M, but at a rate that is
dependent on the serum concentration [155], However, recurrent peritonitis, an
important and common complication of CAPD may itself result in AA amyloidosis
[321],
Renal transplantation is the most effective method of reducing [32-M levels
which fall rapidly to normal limits following a successful transplant [65, 165, 294,
304] and if performed sufficiently early may prevent the development of this disease.
In patients with DRA, renal transplantation is effective in providing rapid
symptomatic relief of dialysis arthropathy [65, 165, 294, 304] although this is could
at least in the short term, be due to a combination of the anti-inflammatory effects of
steroids and a consequence of stopping HD [65, 165], Symptomatic relief achieved
with steroids have already been demonstrated in one study [166] and also suggested
in 2 patients primed with intravenous steroids for transplantation but not grafted
[167], Prospective evaluation with 123I-SAP scans following transplantation have
provided scintigraphic evidence that progression of disease in these patients is halted
and may even regress in some cases [165], This finding is supported by a
radiological survey [159] which demonstrated that in contrast to the pre-transplant
period, amyloid bone cysts ceased to grow following a successful renal transplant,
but neither do they regress although this could simply be a reflection of the failure of
bone to heal.
As more patients are being put on dialysis and survive longer, DRA is now a
major cause of morbidity in dialysis populations. Early renal transplantation is
essential in preventing this otherwise inevitable complication of dialysis, and in
patients who are unsuitable for or are unlikely to have a renal transplant but also
most at risk of developing DRA such as the elderly [161, 195, 322, 323], alternative
dialysis strategies aimed at reduction of [32-M load should be employed early so as
to delay the onset of the development of this crippling and potentially fatal
complication of dialysis that may in fact limit the duration of long term dialysis.
200
Hereditary (TTR) amyloid
FAP, an autosomal dominant disorder, is the commonest hereditary form of
systemic amyloidosis [17, 40], Patients characteristically present with mixed
sensorimotor peripheral neuropathy that is relentlessly progressive and frequently
involve the autonomic nervous system resulting in impaired bladder and bowel
function. Crippling disability from neurological disease, weight loss, malnutrition
and cardiomyopathy dominate the clinical picture in the latter stages of the disease,
resulting in death usually within 10 years of presentation [324], In all but one [18]
of the families studied so far, the disease have been due to point mutations in the
transthyretin gene, ofwhich more than 40 mutations have been described.
Until recently, treatment of FAP was limited to supportive measures.
Parenteral nutrition may be critical especially in malnourished patients susceptible to
pressure sores and infection because of immobility and bladder dysfunction. Unlike
other types of systemic amyloidosis, renal involvement is not prominent but may be
severe enough to require dialysis. The heart is the main visceral organ that is
frequently and fatally involved and indeed in some forms of FAP, cardiomyopathy
may be the sole or predominant feature of the disease [113, 149], Sudden death due
to conduction defects may be prevented by prophylactic pacemakers and heart
failure due to restrictive cardiomyopathy should be treated although care must be
taken to avoid vasodilators. As with most types of systemic amyloidosis, DMSO
have been tried but without much success.
Transthyretin is involved in the transport of Vitamin A and thyroid
hormones, functions that do not appear to be affected by the mutations. More than
90% [116] of circulating TTR comes from the liver which suggests that replacement
of the otherwise functionally normal liver should correct the metabolic defect as
have been described for familial hypercholesterolaemia [325] and primary
hyperoxaluria [326], However, amyloid in FAP are derived from both variant and
normal TTR [40], It could not, therefore be assumed that amyloidosis would be
halted.
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The first liver transplant that was performed for FAP was reported in 1991
[116] and was successful as anticipated in replacing variant TTR with normal TTR
in the plasma. At follow up 2 years later [50], disease progression was halted in all
4 patients transplanted. Symptomatic and clinical improvement in 3 of the patients
were accompanied by scintigraphic evidence for disease regression in 2 patients who
were scanned in contrast to progression of amyloid load and neuropathy in 1 patient
who was not transplanted. Successful liver transplantation for FAP have since been
reported by other centres [327-329], Patient and graft survival are similar to those
after transplantation for non-malignant liver disorders and there may in fact be less
perioperative morbidity with shorter operative time, less blood use and significantly
shorter stay in intensive care compared with transplantation for patients with
chronic liver failure [327],
Cardiac involvement which may be clinically silent will necessitate
prophylactic pacing, at least, perioperatively. In one patient with terminal heart
failure, double transplant of heart and liver, the first time this was performed for
FAP was undertaken in July 1992 (unpublished observations). Two years after his
double transplant, serial autonomic function and nerve conduction studies
demonstrated progressive improvement, providing unique evidence for regression of
neuropathy that have not previously been demonstrated in other patients despite the
halt in disease progression.
The successful treatment, at least in the short term, of FAP by liver
transplantation should be confirmed in longer term studies. In addition, patient
selection and timing of the operation must be established. Patient selection is
complicated by variations in disease expression; TTR mutation are not always
penetrant, and even within the same family phenotypic expression may vary
considerably [330], Individuals with late-onset and slowly progressive disease are
least likely to benefit as are those who are already severely affected and likely to
suffer perioperative morbidity or mortality. Timing is therefore crucial for liver
transplantation to be optimally effective. Individuals known to have the mutation
must be monitored closely for neurological and cardiac involvement. Clinical
evidence for disease must be confirmed histologically so that early liver
transplantation can be considered especially in a young patient with rapid disease
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progression. Genetic counselling is mandatory and of particular significance in
younger members of the family who are at risk of having inherited and therefore
transmitting the mutation. Gene therapy which will have to be aimed at selective
elimination of expression of variant TTR is unlikely to be developed before
conditions where therapy is aimed at replacing a deficient but not defective product.
In summary, liver transplantation offers the only effective treatment for FAP.
Disease progression is halted and may even be reversed. Patient selection and
timing needs to be established and optimised to provide maximal benefit especially
in areas where the disease is endemic and organ demand will considerably exceed
organ supply. Finally, liver transplantation may have a role in the treatment of
hereditary amyloidosis due to variant apolipoprotein AI which is partly produced by
the liver and partly by the small intestine. Reduction in supply of precursor variant
apoAI following a liver transplant may slow down progression of the disease in
which the amyloid consists exclusively of fragments of variant apoAI [19],
Localised amyloid
Localised amyloid may affect virtually any organ systems. It occurs in the
absence of primary disease of the affected organ and also in the absence of systemic
diseases. The fibril precursor protein of localised amyloid deposits are usually
derived from locally produced proteins or from immunoglobulin products of a
localised clone of plasma cells (Table 1.1). Clinically significant deposits result in
impaired organ function or more commonly, cause mechanical problems such as
hoarseness in laryngeal amyloid, obstruction or haematuria in urinary tract amyloid,
restricted eye movements and proptosis in orbital amyloid (see Chapter 7). More
importantly, localised amyloid often resembles a tumour and is misdiagnosed as a
malignancy leading to unnecessary surgery such as ureteronephrectomy [331, 332],
A high index of suspicion and good quality histology including Congo red staining is
therefore critical for an accurate diagnosis.
Treatment of localised amyloid is largely symptomatic and usually achieved
by local excision. Recurrence necessitating repeat surgery may occur and long term
follow up is therefore recommended. With laryngeal amyloid, local endoscopic
resection is usually successful [333] although reconstructive surgery may be
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necessary [334], Laser therapy [335] may have a role especially with large deposits
in the trachea or bronchi causing airways obstruction.
The most common procedure described for treatment of amyloid of the
upper urinary tract was resection and reanastomosis of the ureter [332], Successful
treatment with renal autotransplantation [336], ileal conduit surgery and ileal ureter
[332] have also been reported. Ureteronephrectomy is usually unnecessary and
almost always performed because of a diagnosis of transitional cell carcinoma which
has similar radiographic findings [331, 332], Amyloid of the lower urinary tract
may be treated with transurethral resection and electrocoagulation [337, 338] whilst
extensive lesions may require segmental resection of the urethra and end-to-end
anastomosis or perineal urethrotomy [339], Radical treatment with total cystectomy
and urinary diversion may be necessary in extensive amyloid of the bladder [340],
Primary localised cutaneous amyloid often causes hyperpigmentation and
pruritus which may follow a chronic intractable course. There have been isolated
reports of the beneficial effect of therapy with the aromatic retinoid, etretinate,
dermabrasion, topical DMSO [341], ultraviolet B (UVB) [342] and even carbon
dioxide laser therapy [343], Other reports however, described poor results with
strong topical corticosteroids and keratolytic agents such as salicylic acid ointment
[344],
Role of dimethyl sulphoxide
DMSO is a highly hygroscopic solvent with minimal toxicity. It has an anti¬
inflammatory action and may reversibly block the thermoprecipitation reaction of
Bence-Jones proteins and dissolve amyloid fibrils in vitro [345], Reports that
DMSO may be used advantageously in AA [346], AL [205] and hereditary systemic
amyloidosis [347] have yet to be confirmed. A considerable social disadvantage of
the drug which is also likely to limit treatment compliance is the odour it produces
on the breath because a small percentage of the drug is excreted as dimethysulphide.




Colchicine is an antimitotic agent that works by interfering with cell division.
Its effectiveness as an anti-inflammatory agent in suppressing acute attacks of FMF
was first demonstrated in 1972 [277], Since then colchicine have been used in the
treatment ofAA [220, 267-272, 274, 278] AL [223, 225, 241-247] and even (32-M
[305] amyloidosis. However, its beneficial effect have so far been demonstrated
unequivocally only in the prevention of amyloidosis of FMF [220, 274, 278], This
effect is dose dependent and achieved only with a daily dosage of at least 1.5 mg.
Interestingly, this protective effect of colchicine is seen even if it fails to prevent
attacks of FMF [274, 278, 348], supporting the hypothesis that amyloidosis due to
FMF is a phenotypically independent trait of the disease [348, 349], Colchicine also
prevents recurrence of amyloidosis in FMF patients who have received a kidney
transplant [278], Since prolonged spontaneous remissions of FMF rarely occurs
[278, 350], it is likely that colchicine will have to be continued indefinitely to remain
effective. The long term outcome of colchicine treatment remains unknown
although colchicine have been given to children [351] and pregnant mothers [352]
without adverse effects. In FMF patients who are already affected by amyloidosis,
colchicine may be able to reduce proteinuria and even promote resolution of
nephrotic syndrome [241, 279-283], Response may be rapid although it is usually
seen after 6 to 12 months of treatment [278],
Isolated but numerous case reports [267-272] suggest that colchicine may
also be beneficial in the treatment of AA amyloidosis secondary to other chronic
inflammatory conditions, resulting in reduction of proteinuria and even improvement
in renal function. These encouraging findings will however need to be confirmed by
controlled clinical trials.
The suggestion that colchicine on its own may be useful in the treatment of
AL amyloid [245] especially if kidneys are the main organ system affected, and even
improve survival have not been confirmed [244, 247], Furthermore, recent evidence
suggests that prolonged survival achieved with melphalan and prednisolone is not
improved further by adding colchicine to the regime [247], Finally, in dialysis-
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related amyloid, results of treatment with colchicine have proved disappointing
[305],
Role of renal replacement therapy
Renal failure is a major cause of morbidity and mortality in AA, AL and
some forms of hereditary systemic amyloidosis. The availability of renal
replacement therapy (RRT) with HD from the 1960's and CAPD from the 1980's
have considerably improved the prognosis [210-212] in what was otherwise an
invariably fatal complication of amyloidosis. Survival of AL patients requiring
dialysis compares favourably with those not requiring dialysis [213] and it is likely
that the much improved survival reported in AA patients given alkylating cytotoxic
treatment [260-264] is partly attributable to replacement of renal function by
dialysis. However, the benefits of dialysis is limited by the progressive and systemic
nature of the disease. Survival on dialysis is therefore significantly poorer than in
patients with renal failure due to nonsystemic diseases but comparable to patients
with renal failure due to a multisystem disease such as diabetes [210, 211], Fistula
failure, gastrointestinal complications and especially intradialytic hypotension are
problems encountered more frequently in amyloidosis patients [210], However,
other indices ofmorbidity such as infection rate including peritonitis rates in CAPD
patients and number of hospital admissions per patient are similar to that seen in the
general dialysis population [210],
Survival in dialysis patients with AL amyloidosis may be shorter than that of
patients with AA amyloidosis [213] although in a study involving 48 patients [210]
most of whom had AA amyloidosis, median survival on dialysis of 52 months was
comparable between the two sub-groups but better than the median survival of 8.2
months of 37 AL patients in another study [213], Cardiovascular and circulatory
complications associated with amyloidosis are the main causes of death for both AA
and AL patients [210, 211, 213], Clinically silent but echocardiographically evident
cardiac amyloid is the most important predictor of poor survival in dialysis patients
with AL amyloidosis [213] whilst acute deterioration of renal function, short disease
duration, age and evidence for extra-renal amyloid predicts poor survival in both
206
AA and AL amyloid patients [210, 211], The adverse effect of multisystem
involvement is best illustrated by long term survivors, most of whom have no
evidence for extra-renal amyloidosis [210, 211, 213],
There have been no prospective studies comparing HD with CAPD which
have several theoretical advantages. It is not associated with the circulatory stress
of intermittent HD, and haemoglobin levels are better preserved on CAPD. Both
these factors may be important in the presence of cardiomyopathy and coronary
artery disease, especially since intradialytic hypotension is the commonest
complication in these patients. In addition, vascular access required for HD in a
vessel potentially infiltrated with amyloid may be a problem, although fistula failure
may [210], or may not [211] be more common in amyloidosis. Finally,
immunoglobulin light chains which are not cleared by HD may be cleared by CAPD
[212, 353] and can therefore potentially slow down progression ofAL amyloid. On
the other hand, attacks ofFMF may curiously be reduced following commencement
ofHD [354], In published studies, all retrospective [210, 211, 213], HD was more
commonly employed than CAPD and survival for both modalities of dialysis were
similar despite a significantly higher proportion of patients with cardiac amyloid in
the CAPD group in one study [211], Such indirect evidence that dialysis survival
may be superior in CAPD is supported by the observation that circulatory stress of
intermittent HD may contribute to the death of amyloidotic patients with cardiac
involvement, an important cause of death in these patients. Despite concerns raised
regarding the efficacy of peritoneal membranes potentially infiltrated with amyloid
[355], both dialysis and ultrafiltration appears adequate in these patients [211-213],
However, although peritonitis rates may be comparable to the general CAPD
population [212, 355], temporary conversion to HD should be considered during
chemotherapy for AL amyloid although this may not always be necessary [356],
Amyloidosis continue to progress on dialysis and is responsible for much of
the morbidity seen in these patients. Gastrointestinal involvement may cause pseudo
obstruction, anorexia or nausea and vomiting [357] which may be readily but
wrongly attributed to uraemia. Much of the circulatory failure seen in systemic
amyloidosis especially in AA patients could be due to previously unrecognised
adrenal dysfunction due to amyloid [358] and a clinically silent but functionally
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important hypoadrenal state should therefore be sought by appropriate stimulation
with synacthen. Hypotension, in addition, could also be due to autonomic
neuropathy or cardiomyopathy even in AA patients. Clinically significant cardiac
involvement in AA amyloid may be more common than previously suspected
especially when amyloidosis is allowed to progress in patients maintained on dialysis
[359] and is suggested by the observation that cardiomyopathy and circulatory
failure are also the most common causes of death on dialysis even in AA patients
[210, 211], Finally, most patients die of progressive systemic amyloid disease rather
than complications of dialysis, suggesting that survival on dialysis may be improved
further if progression of amyloid can be halted.
Role of organ transplantation
Since it was first performed in 1968 [360], renal transplantation have been
established as an effective treatment of renal failure due to AA and AL amyloidosis
[214-217, 249, 265], Five year patient and graft survival at 65% and 62%
respectively [214] compares favourably with survival in other groups of patients
including those with nonsystemic causes of renal failure. In 2 large studies [214,
215], survival was similar between AL and the larger group of AA patients. Age
was found to have a major influence, with survival significantly higher in those aged
< 45 years [214, 216], There was evidence that survival may be improved further
by early transplantation [215] although this was not confirmed in another study
[214] which demonstrated no difference between those transplanted before and
those transplanted after dialysis-dependent renal failure although the mean time
spent on dialysis was short at 9.6 months.
A striking finding is the very high early post-operative mortality due to
infection [214, 215, 217, 249], The need for anti-rejection therapy in addition to
standard immunosuppressive treatment especially during the first 3 months
following transplantation is the period in which amyloidotic patients are most
vulnerable, with most succumbing with fatal consequences to overwhelming
pneumonia and septicaemia. Such critical susceptibility to infection could be due to
their already immunocompromised status which may in part be related to splenic
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involvement in AL and particularly AA amyloidosis in which it is universally
affected [58], No information was provided as to the organisms involved but
morbidity and mortality can clearly be potentially reduced in these patients with
appropriate precautions. Prophylactic antibiotics at least in the first 3 post¬
operative months should be considered together with appropriate isolation to
minimise exposure during rejection episodes. Modifications of anti-rejection
therapy currently employed may be necessary but the most effective precaution
would be to reduce the risk of rejection and therefore the frequently fatal
consequences of anti-rejection therapy. Careful selection of patients and matching
of donor organs are therefore of paramount importance. The development and use
of newer immunosuppressive treatment such as cyclosporine have led to improved
graft survival [214, 217] but whether the number of rejection episodes are reduced
was not confirmed.
In contrast, outcome improves considerably after 1 year. Mortality is
markedly reduced and the number of anti-rejection episodes overall may in fact be
lower and graft survival better than that of non-amyloidotic patients [215],
Recurrence of amyloid in the transplanted kidney is an obvious concern, but this
affects only up to 26% [361] of patients surviving > 1 year and very rarely causes
graft failure even after 15 years of follow-up [214], This observation contrasts
sharply with the relentless progression of amyloidosis seen in dialysis patients. Most
patients in the dialysis and transplant studies published so far have AA amyloidosis
due to chronic inflammatory diseases and it is likely that post-transplant
immunosuppressive treatment have a beneficial effect on the underlying disease
process in these patients. Amyloidosis on the other hand may be accelerated in
dialysis patients because of the associated acute phase response that may occur in
bioincompatibility reactions during HD and peritonitis in CAPD. These
observations which will need to be confirmed, provide further evidence that
effective management of dialysis and transplant patients must include monitoring
and treatment of the underlying disease process, successful control of which can
reduce patient morbidity and mortality.
The role of organ transplantation in the treatment of terminal organ damage
caused by amyloidosis was recently extended to include heart transplantation [47,
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218], In the only published study so far which involved 10 patients [218] survival
was not significantly worse than patients transplanted for other cardiac diseases.
This encouraging finding is made all the more remarkable by the fact that all 10
patients had AL amyloid and many had evidence for multisystem disease. In
addition, chemotherapy for AL amyloid pre or post-transplant may not have been
given although this important information was not provided in the report. All 4
patients known to have died after 50 months of follow-up succumbed to systemic
progression of amyloidosis, a process that may be halted by appropriate post-
transplant chemotherapy [47], Cardiac AL amyloidosis carries a poor prognosis
with median survival of 6 months [16, 53, 223], Such patients are therefore unlikely
to see the benefits of chemotherapy which have a median response time of 11.7
months [246], Heart transplantation will therefore not only be life saving and
improve the prognosis considerably, but will also allow time for chemotherapy to
take effect. Chronic shortage of donor organs [218] should not be used as an
excuse to deny the opportunity of life saving heart transplantation in this small but
select group of patients in whom survival may be substantially prolonged with
effective post-transplant chemotherapy. Young patients with minimal multisystem
involvement are most likely to benefit. Patient assessment and selection is therefore
important. Pre-operatively, quantification and distribution of total body amyloid
must be determined and this at the moment can only be achieved in vivo by a radio-
labelled SAP scan [58, 59], Post-operatively, chemotherapy aimed at preventing
systemic progression of amyloidosis must be given as this may further improve
survival which is already substantially prolonged by the life saving transplant.
Until recently, the role of organ transplantation in amyloidosis was limited to
replacement of target organs terminally damaged by the disease. This palliative role
of organ transplantation is well established and considerably improves prognosis
although the underlying disease process may continue and necessitate specific
treatment. Recently, a potentially curative role of organ transplantation have been
established in the treatment of hereditary systemic TTR amyloidosis [50, 116], The
liver accounts for > 90% [116] of total body TTR production and replacement of
the functionally normal but metabolically defective liver in hereditary systemic
amyloidosis due to variant TTR results in replacement of variant TTR from the
210
plasma, halt in disease progression and may even be accompanied by disease
regression [50], Such a curative role for transplantation have also been attempted
by bone marrow transplantation in the treatment of systemic AL amyloidosis in one
patient [251], However, such a radical approach is unlikely, at least in the near
future, to replace the combined use of chemotherapy and solid organ transplantation
in treatment ofAL amyloid.
Future Developments
Treatment aimed at reducing supply of precursor proteins are not always
successful or may be too late in patients who already suffer severe target organ
damage. However, the demonstration that SAP is a universal constituent of all
amyloid deposits, its inherent resistance against digestion in the presence of calcium,
and in vitro evidence that it protects fibrils against degradation [362] may provide
the basis for future treatment directed specifically towards degradation and
mobilisation of amyloid. The specific binding of SAP to amyloid fibrils, a property
utilised with considerable success in SAP scintigraphy suggests that SAP may also
be used as a targeting molecule or 'magic bullet' to deliver pro-inflammatory agents.
The mobilisation of macrophages and release of proteinases would therefore be
maximal at sites of specific SAP localisation, thereby encouraging local amyloid
reabsorption. However, this scenario may already be superseded by the recent
identification to atomic resolution of the three dimensional structure of SAP [36],
Availability of the complete structure to 2A resolution of SAP and determination of
its ligand binding sites now offer the opportunity of direct modelling of competitive
inhibitors of SAP binding and for producing binding site homologues, either of
which could be used as drugs to displace SAP from amyloid deposits in vivo. This
would open up new avenues for treatment of amyloidosis, enabling the body to
mobilise and degrade the fibrils which may otherwise be inappropriately protected
by SAP. Finally, the advent of genetic therapy means that expression of precursor
proteins especially variant proteins of hereditary systemic amyloidosis may be
selectively eliminated but this is unlikely to be developed before conditions where
therapy is aimed at replacing a deficient but not defective product.
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General Conclusions
The solubility of amyloid fibrils in water but not salt forms the basis of the
standard amyloid fibril extraction technique [8], enabling fibrils to be separated from
tissue proteins which are soluble in both salt and water. However, such isolation of
amyloid fibrils have until recently been possible only from gram quantities of tissue
obtained at post-mortem or during an operation. A novel method of "mini-fibril"
extraction which for the first time has enabled amyloid fibrils to be isolated and
characterised from tiny milligram quantities of biopsy tissue is described [10],
The studies on families with hereditary systemic amyloidosis [111, 113, 130,
363] illustrates the potential application of combined laboratory and clinical
investigative techniques in characterising the molecular and genetic basis of the
disease, in relation to the clinico-pathological features of the disease. The
investigations of these families are entirely dependent initially on the
immunohistochemical identification of the precursor protein which then allows the
appropriate gene to be identified, extracted and amplified by PCR for DNA
sequencing. This routine and most basic of molecular biological investigative
techniques was sufficient for identification of these mutations. However, not all
mutations are pathogenic or amyloidogenic as clearly illustrated for example by the
demonstration of more than 20 electrophoretic (non-amyloidogenic) variants of
apoAI following the screening of 32,000 blood samples [86], Concordance between
mutation and disease will therefore have to be established by the demonstration of
variant sequence in isolated amyloid fibrils.
In the two families where elaborate characterisation of fibril proteins by
amino acid sequencing and electrospray mass spectrometry was made possible by
the development of the "mini-fibril" extraction technique, the fibrils were found to
be derived exclusively from variant proteins [111, 363], Such precise
characterisation provided novel information on the heterogeneity of the cleavage
sites of the precursor proteins with C-terminal raggedness in the amyloidogenic
apoAI fragments. These fragments are however, electrophoretically homogeneous
in having an extra positive charge despite being derived from different apoAI
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variants. This suggests that the acquisition of an extra positive charge in the N-
terminal amyloidogenic fragments of apoAI rather than substitution by any specific
residue is the key amyloidogenic event. It is possible that the extra positive charge
mediates a pro-amyloidogenic destabilisation of protein structure, promoting
fibrillogenic aggregation with proteolytic cleavage as a secondary phenomenon, or
they may facilitate proteolytic cleavage of the native molecule to yield fibrillogenic
fragments. With the hereditary transthyretin amyloidoses, the inherent
amyloidogenic potential of wild-type transthyretin was increased for the variants,
resulting in disease of a different phenotype. These inherited amyloidogenic variants
therefore provide valuable models for analysing the pathogenesis of amyloidosis,
and in addition, their identification allows genetic counselling and informed testing
to be conducted in the affected families.
Phenotype in these families were extensively studied clinically,
biochemically, histologically and scintigraphically, providing unique information on
the pattern of distribution of amyloid with invariable involvement of the kidneys in
families with hereditary renal amyloidosis. A prodromal phase of sub-clinical
amyloid deposition together with poor correlation between amyloid load and organ
dysfunction was demonstrated. The observation that the natural history of the
disease may vary even amongst families with the same mutation, suggests that
factors other than the mutation are important in determining clinical expression of
the disease. The autosomal dominant pattern of inheritance, concordance between
mutation and disease, and the virtually complete penetrance of these mutations were
also demonstrated.
Studies on acquired forms of amyloidosis were focused on the effect of renal
transplantation [191] and CAPD [177] on DRA, an invariable complication of long
term dialysis. In addition to confirming the rapid resolution of symptoms of DRA
following a successful transplant, the long term preservation of such symptomatic
improvement despite withdrawal of steroids were reported for the first time.
Unique radiological and scintigraphic regression of DRA deposits post-transplant
were also demonstrated, in contrast to progression of the disease in patients
maintained on haemodialysis. Amongst long term CAPD patients, scintigraphic
evidence for the disease appears to be comparable to histological evidence for the
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disease in HD patients [183], However, CAPD patients were less symptomatic,
suggesting that clinical expression of the disease may be modulated by dialysis
modality.
In both HD and CAPD patients, CTS was the commonest presenting feature
of DRA and scintigraphically, the wrists were always affected in patients with a
positive scan. Age and duration of dialysis were confirmed as the most important
risk factors for the development of DRA. Histological and scintigraphic studies
demonstrated that in both the hereditary and acquired forms of amyloidosis, there
was an asymptomatic prodromal phase, which may last for several years, and in the
case of DRA, the disease was frequently underestimated clinically and
radiologically.
Finally, the first case of primary localised orbital amyloidosis [10] was fully
characterised and the CH3 domain of y heavy chains was identified as the precursor
protein. This is the third case of heavy chain-related (AH) amyloid but the first case
of immunoglobulin-related (both AL and AH) amyloid where the fibril precursor
protein is derived exclusively from a constant domain with apparently no
contribution from the variable domains. The inherent amyloidogenic potential of
heavy chains demonstrated by these three cases of heavy chain amyloid, two of
whom had phenotype similar to AL amyloidosis [203, 204], suggests that some
cases of monoclonal immunoglobulin-related amyloid (usually clinically designated
as AL amyloid), may be AH amyloid derived from heavy chain components of these
monoclonal proteins.
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Amyloid andAmyloidosis 1993. Park Ridge, New Jersey: The Parthenon Publishing
Group; 1994:682-684).
2. Tan SY, Madhoo S, Brown E, Clutterbuck EJ, Lavender JP, Pepys MB,
Hawkins PN. Continuous ambulatory peritoneal dialysis and dialysis-related
amyloid: Clinical, radiological and 123I-SAP scan findings in 7 patients. The Renal
Association (UK) Autumn Meeting, University College, London; 17-18 October
1994.
(Nephrol. Dial. Transplant. 1995:10;741-742)
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3. Tan SY, Madhoo S, Brown E, Clutterbuck EJ, Lavender JP, Pepys MB,
Hawkins PN. Continuous ambulatory peritoneal dialysis and dialysis-related
amyloid: Clinical, radiological and 123I-SAP scan findings in 7 patients. The
American Society of Nephrology 27th Annual Meeting, Orlando, Florida, 26-29
October 1994.
(J. Am. Soc. Nephrol. 1994:5;479)
4. Booth DR, Booth SE, Persey MR, Tan SY, Madhoo S, Pepys MB, Hawkins
PN 3 new amyloidogenic TTR mutations: Prol2, Glul8, and Val33 The 3rd
International Symposium on Familial Amyloidotic Polyneuropathy and other
Transthyretin RelatedDisorders, Lisbon, Portugal, 27-29 October 1995.
5. Tan SY, Booth DR, Debusmann ER, Pepys MB, Hawkins PN
Characterisation and therapy of hereditary renal amyloidosis in a German family.
The American Society ofNephrology 28th Annual Meeting, San Diego, California,
5-8 November 1995.
(J. Am. Soc. Nephrol. 1995:6;728)
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Appendix II - Publications Arising From Thesis Work
1. Tan SY, Pepys MB. Amyloidosis. Histopathology. 1994;25:403-414.
2. Tan SY, Murdoch IE, Sullivan TJ, Wright JE, Truong O, Hsuan JJ, Hawkins
PN, Pepys MB. Primary localised orbital amyloidosis composed of the
immunoglobulin y heavy chain CH3 domain. Clinical Science. 1994;87:487-491.
3. Tan SY. Amyloidosis. ContinuingMedical Education (CME) Review. 1994: 4;
61-70.
4. Booth DR, Tan SY, Hawkins PN, Pepys MB, Frustaci A. A novel variant of
transthyretin, 59Thr->Lys, associated with autosomal dominant cardiac amyloidosis
in an Italian family. Circulation. 1995;91:962-967.
5. Tan SY, Pepys MB, Hawkins PN. Treatment of Amyloidosis: An In-Depth
Review American Journal ofKidney Diseases. 1995:26;267-285.
6. Booth DR, Tan SY, Booth SE, Hsuan JJ, Totty NF, Nguyen O, Hutton T,
Hutchinson WL, Thomson N, Soutar AK, Hawkins PN, Pepys MB. A new
apolipoprotein AI variant, Trp50Arg, causes hereditary amyloidosis. Quarterly
Journal ofMedicine. 1995:88;695-702.
7. Hawkins PN, Tan SY, Pepys MB. General aspects of amyloidosis In: Oxford
Monographs on Clinical Nephrology: Dialysis Amyloidosis (van Ypersele C,
Drueke T, eds.), Oxford University Press, Oxford 1996; 34-68.
8. Tan SY, Irish A, Winearls C, Brown E, Gower P, Clutterbuck EJ, Madhoo S,
Lavender JP, Pepys MB, Hawkins PN. Long term outcome of dialysis-related
amyloid deposits and disease symptomatology in patients undergoing renal
transplantation: A prospective 5 year study. Kidney International 1996 (in press).
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9. Hawkins PN, Tan SY, Pepys MB. The patient with amyloidosis. In: Oxford
Textbook of Clinical Nephrology, 2nd Edition (Davison, AM, Cameron, JS,
Grunfeld, JP, Kerr, DNS, Ritz, E, eds.), Oxford University Press, Oxford, (in press).
10. Tan SY, Booth DR, Booth SE, Tennent GA, Hutchinson WL, Hsuan JJ, Totty
NF, Nguyen O, Soutar AK, Hawkins PN, Bruguera M, Caballeria J, Sole M,
Campistol JM, Pepys MB. Hereditary hepatic and systemic amyloidosis caused by a
new deletion/insertion mutation in the apolipoprotein AI gene. Journal ofClinical
Investigation 1996 (in press).
11. Murdoch, IE, Sullivan TJ, Moseley I, Hawkins PN, Pepys PN, Tan SY, Garner
A, Wright JE. Primary localised amyloidosis of the orbit. British Journal of
Opthalmology 1996 (in press).
12. Pepys MB, Tennent GA, Booth DR, Bellotti V, Lovat LB, Tan SY, Persey
MR, Hutchinson WL, Booth SE, Madhoo S, Soutar AK, Hawkins PN, Van Zyl-
Smit R, Campistol JM, Fraser PE, Radford SE, Robinson CV, Sunde M, Serpell
LC, Blake CCF. Molecular mechanisms of fibrillogenesis and the protective role of
amyloid P component: two possible avenues for therapy. In The nature and origin
ofamyloidfibrils. Wiley, Chichester, Ciba Foundation Symposium 1996; 73-89.
13. Tan SY, Hawkins PN, Pepys MB. The hereditary renal amyloidoses: Report of
a family and review of the literature, (submitted to Kidney International).
14. Tan SY, Baillod R, Brown E, Farrington K, Soper C, Clutterbuck EJ, Percy
M, Madhoo S, Pepys MB, Hawkins PN. Continuous ambulatory peritoneal dialysis
and dialysis-related amyloid: A clinical, radiological and scintigraphic study.
(submitted to Nephrology Dialysis Transplantation 1996).
15. Familial amyloid polyneuropathy due to a novel transthyretin mutation in a
Colombian family. (Tan SY, et. alfor submission to Human Genetics).
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16. Hereditary renal amyloidosis associated with a mutant fibrinogen a-chain.
(Hawkins PN et. alfor submission to Kidney International).
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Appendix III - Proposals For Future Research Work
Characterisation of amyloid proteins
Primary cutaneous (lichen) [364] and intra-tumour amyloidosis [27] are rarely seen in
the West, but common in South America and the Far East. The precursor proteins for
these well recognised forms of amyloidosis have not yet been identified and attempts will
therefore be directed towards the characterisation of these precursor proteins, suspected
to be keratin [365] in primary cutaneous amyloidosis. However, the deposits in intra-
tumour amyloid do not react immunohistochemically with antibodies directed against
known amyloid proteins [27], suggesting that the fibrils may be derived from a novel
amyloidogenic protein. Amyloid fibrils will therefore be isolated and purified as previously
described [10], and analysed by Congo red staining, electron microscopy, SDS-PAGE,
and immunoblotting. Precise characterisation of fibril protein by amino acid sequencing
and determination of molecular masses of extracted fibrils by electrospray mass
spectrometry will be performed in collaboration with Dr Justin Hsuan's laboratory at the
Ludwig Institute for Cancer Research, London, and with Therese Hutton of Fisons VG
Biotech, Altrincham, Cheshire. Scintigraphic studies of affected cases by 123I-SAP scans,
an in vivo technique for the diagnosis of systemic amyloidosis [58, 59], will be conducted
in collaboration with Professor M B Pepys and Dr P N Hawkins of The Royal
Postgraduate Medical School, London.
In addition to contributing to the understanding of the pathogenesis of amyloidosis,
the identification of the precursor protein of intra-tumour amyloid which is classically
associated with nasopharyngeal carcinoma (NPC) [14, 27], has potentially important
clinical applications. This precursor protein may be used as a marker for NPC, the
commonest gastrointestinal malignancy to affect the Oriental population, and may
therefore be used as a screening test for the tumour and for following clinical progress
following treatment. With primary cutaneous amyloidosis, the characterisation of the
precursor protein will be followed by genetic studies to identify the mutation(s) involved
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in hereditary forms of the disease which has an autosomal dominant pattern of inheritance
[366],
Role of advanced glycation end-products (AGE) in amyloidogenesis
The role of AGE modified forms of precursor proteins have been established in the
deposition of (32-M amyloid of dialysis arthropathy [367] and P-amyloid of Alzheimer's
Disease [368], The role of AGE modified precursor proteins in AA, AL, transthyretin,
primary cutaneous and intra-tumour amyloid will therefore be studied by
immunohistochemical staining of paraffin-fixed biopsies by the peroxidase-anti-peroxidase
method, using mouse monoclonal anti-AGE antibodies [369] to be supplied by Dr
Toshimitsu Niwa of Nagoya University Branch Hospital, Japan. Immunohistochemical
evidence for the presence of AGE modified proteins will then be confirmed by
immunoblotting of extracted fibrils using the same monoclonal antibodies.
Role of advanced glycation end-products (AGE) in the pathogenesis of
ultrafiltration failure in peritoneal dialysis
It has been suggested that diabetics may have poorer ultrafiltration on CAPD due to
increased capillary permeability caused by diabetic microvascular disease, a process
mediated at least in part, by advanced glycosylation [370, 371], Similarly, prolonged
exposure of peritoneal membrane to concentrated glucose solutions used in peritoneal
dialysis may eventually lead to ultrafiltration failure via a similar mechanism which
involves AGE modification of structural membrane proteins [372], The peritoneal
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membrane transport characteristics of diabetics with renal failure will therefore be studied
using the peritoneal equilibration test (PET) [373], and compared with patients with renal
failure due to systemic amyloidosis, a disease which may also affect peritoneal membrane
structure and function. The control group will consist of patients with renal failure due to
non-systemic diseases such as the primary glomerulonephritides. Correlation between
ultrafiltration characteristics and presence ofAGE modified proteins in the circulation and
peritoneal membrane will be established. AGE-modified haemoglobin [374] and plasma
pentosidine [375] will be used as circulating markers of advanced glycosylation whilst
tissue glycosylation will be determined by quantifying accumulation of peritoneal
membrane pentosidine [375] using biopsies taken at the time of catheter insertion, renal
transplantation or at post-mortem. This cross-sectional study will be followed by a
longitudinal study to determine the changes, if any, in peritoneal membrane structure and
transport characteristics in all 3 groups of patients.
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